Computational and in vitro study of isolated domains from fungal polyketide synthases by Piech, Oliver
  
 
 
 
 
Computational and In Vitro Study of Isolated 
Domains from Fungal Polyketide Synthases 
 
 
Von der Naturwissenschaftlichen Fakultät  
der Gottfried Wilhelm Leibniz Universität Hannover  
 
zur Erlangung des Grades 
Doktor der Naturwissenschaften (Dr. rer. nat.) 
genehmigte Dissertation 
 
 
 
 
von 
Oliver Piech, M.Sc. 
 
 
2020 
  
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referent:   Prof. Dr. Russell Cox 
Korreferent:   Prof Dr. Plettenburg 
Tag der Promotion: 29.05.2020 
  
 iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vi veri universum vivus vici 
  
 iv 
Abstract 
Keywords: Polyketides, Enzyme engineering, Squalestatin tetrakeitde Synthase, Tenellin 
Diverse approaches have been explored to generate new polyketides by engineering 
polyketide synthases (PKS). Although it has been proven possible to produce new 
compounds by designed PKS, engineering strategies failed to make polyketides available 
via widely applicable rules and protocols. 
 The aim of this work was the first rational engineering of an iterative highly-
reducing polyketide synthase (HR-PKS). This approach was performed on the 
Squalestatin Tetraketide Synthase (SQTKS), which catalyses the biosynthesis of the 
tetraketide side chain of squalestatin-S1 53, which is a potent squalene synthase inhibitor 
and can be potentially used to treat serum cholesterol related diseases. Second, tenellin 
62 was investigated, which is the product of the iterative Type I polyketide synthase non 
ribosomal peptide synthetase (PKS-NRPS) TENS. 
 Using a combination of different in silico methods, structural models of the enoyl 
reductase (ER) domain of SQTKS were obtained and validated. With the generated 
protein models different rational engineering experiments in silico were performed, in 
which amino acids for the mutagenesis approach in vitro were identified.  
The subsequent in vitro experiments revealed that it was possible to rationally 
engineer the ER domain of SQTKS. In addition, the different integrated mutations 
showed different effects on the intrinsic programming of the ER domain. Further, the 
chemical selectivity and kinetic parameters of the tested di-, tri-, tetra- and heptaketide 
substrate were influenced in a specific way through the different mutated ER domains.  
 In addition, the structural-biological foundations and analysis for the domain 
swaps between Pretenellin A Synthetase (TENS), Predesmethylbassianin A Synthetase 
(DMBS) and Premilitarinone C Synthetase (MILS) were investigated and validated. 
Through different in silico structural analyses it was possible to consider the effects of 
swaps on protein structure and to understand the effect of the swaps at the structural level. 
Additionally, the in silico analysis helped to clarify the influence of extrinsic and intrinsic 
programming factors. 
   
 v 
Kurzzusammenfassung 
Schlagwörter: Polyketide, Enzym engineering, Squalestatin tetrakeitde Synthase, Tenellin 
Verschiedene Ansätze wurden erforscht, um neue Polyketide durch engeeniering von Polyketide 
Synthasen (PKS) zu erzeugen. Obwohl es sich als möglich erwiesen hat neue Verbindungen durch 
künsltiche PKS herzustellen, erwieß es sich trotzdem nicht als möglich über allgemein 
anwendbare Regeln und Protokolle neue Polyketide herzustellen. 
 Ziel dieser Arbeit war das erste rationale Engineering einer iterativen, 
hochreduzierenden Polyketid Synthase (HR-PKS). Dieser Ansatz wurde an der Squalestatin-
Tetraketid-Synthase (SQTKS) durchgeführt, die die Biosynthese der Tetraketid-Seitenkette von 
Squalestatin-S1 53 katalysiert, einem wirksamen Inhibitor der Squalen-Synthase, der 
möglicherweise zur Behandlung von Erkrankungen im Zusammenhang mit Serumcholesterin 
eingesetzt werden kann. Desweiteren wurde Tenellin 62 untersucht, welches das Produkt der 
iterativen nicht-ribosomalen Peptid Synthetase (PKS-NRPS) TENS des Typ I ist. 
 Unter Verwendung einer Kombination verschiedener in silico Methoden wurde ein 
Strukturmodell der Enoylreduktase (ER) Domäne von SQTKS erzeugt und validiert. Mit den 
generierten Proteinmodellen wurden verschiedene rationale Engineering Experimente in silico 
durchgeführt, wobei unteranderem Aminosäuren für den in vitro Mutageneseansatz identifiziert 
wurden.  
Die anschließenden in-vitro Experimente zeigten, dass es möglich war, die ER-Domäne von 
SQTKS rational zu engeenieren. Darüber hinaus zeigten die verschiedenen generierten 
Mutationen unterschiedliche Auswirkungen auf die intrinsische Programmierung der ER-
Domäne. Darüber hinaus wurden die chemische Selektivität und die kinetischen Parameter des 
getesteten Di-, Tri-, Tetra- und Heptaketisubstrate auf spezifische Weise durch die verschiedenen 
mutierten ER-Domänen beeinflusst. 
 
Darüber hinaus wurden die strukturbiologischen Grundlagen und Analysen für die Domain-
Swaps zwischen Pretenellin-A-Synthetase (TENS), Predesmethylbassianin-A-Synthetase 
(DMBS) und Premilitarinon-C-Synthetase (MILS) untersucht und validierd  
 Durch verschiedene in silico Strukturanalysen konnten die Auswirkungen von Swaps 
auf die Proteinstruktur berücksichtigt und die Auswirkungen der Swaps auf die Strukturebene 
verstanden werden. Darüber hinaus hat die in silico-Analyse dazu beigetragen, den Einfluss 
extrinsischer und intrinsischer Faktoren der Programmierung zu klären.  
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1 Introduction 
 
1.1 Natural Products 
 
In general, a natural product is a chemical compound or substance produced by a living 
organism.1 In the organism the production of these natural products is accomplished by 
enzymes. Hence, the repertoire of secondary metabolites is evolved, like the proteome in 
the organisms is evolved to its specific physical and biological environmental 
requirements.2 Natural products can be classified according to their biological function, 
biosynthetic pathway or source. 
 
 
Figure 1: Examples of some natural products: A, Examples of natural products of the primary metabolite 
classes; B, Examples of natural products of different secondary metabolite classes. 
 
The simplest classification of natural products is based on the biological source from 
which the naturally derived metabolites were isolated. For example prokaryotes like 
bacteria or archaea or eukaryotes like plants, animals and fungi.3 
In addition, natural products are classified in two major classes, the primary and 
secondary metabolites (Figure 1). Primary metabolites, like 1-4, have an intrinsic function 
that is essential to the survival of the organism that produces them. For example palmitic 
acid 4 (Figure 1), which is the most common saturated fatty acid in animals, plants and 
microorganism.4 In contrast, secondary metabolites, like 5-8, have a function that mainly 
affects other organisms. These compounds are not essential for survival but may give an 
organism an evolutionary advantage. Secondary metabolites are often useful to humans 
because of these effects. For example, callystatin A 8 has potent antitumor properties.5 
Secondary metabolites are further sub-classified according to their biosynthesis. Major 
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families include polyketides and fatty acids, peptides, terpenes, alkaloids and hybrid 
metabolites. The focus of this thesis is on polyketide and fatty acid metabolites. 
 
1.2 Fatty Acid Biosynthesis  
 
Fatty acids like palmitic acid 4, are made using highly conserved enzymatic reactions.6 
The enzymes which catalyzes fatty acid synthesis are called fatty acid synthases (FAS).6–
8 FAS are multi-enzyme proteins. Hence, it is not a single enzyme but a multifunctional 
enzymatic system, in which substrates are passed from one functional domain to the 
next.6–8 FAS proteins differ in structure and are divided into Type I and II systems 
(Section 1.4).6 
 The overall reaction sequence of the biosynthesis of fatty acids is the sequential 
extension of an acyl chain by two carbons in each elongation cycle, by a series of 
decarboxylative condensation reactions that are summarized in Scheme 1.8 
 
 
Scheme 1: Overall reactions sequence of the biosynthesis of palmitic acid 4.8 
 
The biosynthesis is initiated by the transfer of a starter unit, normally an acetyl moiety 9, 
from CoA thiolester to the nucleophilic serine residue of an acyl transferase (AT). The 
AT then transfers the acyl group to the thiol of an acyl carrier protein (ACP) domain and 
finally to the active site cysteine residue of the β-ketoacyl synthase (KS, Scheme 2).8 
 Acetyl-CoA 9 is converted to malonyl-CoA 10 by carboxylation catalysed by the 
enzyme acetyl-CoA carboxylase (ACC).8,9 The malonyl group is then transferred from its 
CoA thiolester to the FAS-ACP domain to form malonyl-ACP 18. The new fatty acid C–
C bond is formed by condensation of the acetyl-KS 17 and malonyl-ACP 18 moieties to 
form acetoacetyl ACP 19. The driving force of the reaction is an energetically and 
entropically favorable decarboxylation. From this point forward, in each round of 
elongation the beta keto group is reduced to the fully saturated carbon chain by the 
sequential action of a ketoreductase (KR), to form a β-alcohol 20, dehydratase (DH) to 
form an αβ-unsaturated thiolester 21 and enoyl reductase (ER) to form a fully saturated 
chain 22. At this stage, short chains are passed back to the KS and extended again. At the 
end of chain-building, when the chain has reached its required length, the product is 
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released by the action of a thiolesterase (TE) upon reaching a carbon chain length of 16 
(palmitic acid 4, Scheme 2).8 
 
 
Scheme. 2: Example of the reaction sequence for de novo biosynthesis of fatty acids by the animal FAS. 
After each round of elongation, the beta keto group is reduced to the fully saturated carbon chain by the 
sequential action of a ketoreductase (KR), dehydratase (DH), and enoyl reductase (ER). The chain is 
released by the action of a thiolesterase (TE) upon reaching a carbon chain length of 16 (palmitic acid 4) 
 
1.3 Enzymes of Fatty Acid Biosynthesis 
 
The starting point of the series of condensation reactions leading to the production of 
palmitic acid 4 is the translocation of one acetyl 9 and malonyl 10 moieties, from CoA 
thiolester to the phosphopantetheine thiol of the ACP domain.8 ACP is a universal and 
highly conserved carrier of acyl intermediates. In yeast and mammals, ACP exists as a 
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domain within a large multifunctional fatty acid synthase polyprotein (type I FAS), 
whereas it is a small monomeric protein in bacteria and the plastids of plants (type II 
FAS).10 
 The next step that follows is the chain elongation. Type I FAS contains only one 
type of KS domain, whereas two or three KSs with different chain-length selectivity, are 
found in type II FAS.6 The overall condensation reaction in KS domains can be further 
divided into three discrete steps: (1) transfer of saturated acyl moieties from acyl-ACP 
thiolester form to the active-site cysteine residue, (2) binding and decarboxylation of a 
malonyl-ACP thiolester moiety to yield a reactive carbanion and (3) formation of a new 
carbon–carbon bond.8 
KS domains have been shown to have invariant hydrophobic residues that line 
their active site pockets to facilitate binding of the acyl chain. A catalytic triad lies at the 
bottom of the pocket and the acyl chain folds into an extended U-shaped conformation. 
KS domains usually have a Cys-His-His active site triad (Scheme 3), although other 
variants with a catalytic triad that consists of Cys-His-Asn are known.11,12 
In the Cys-His-His active site triad, one histidine is proposed to abstract a proton 
from the carboxylic acid of the malonyl 10 residue, while the other histidine accepts a 
hydrogen bond and then makes contact with the thiolester oxo group of the malonyl 
residue inducing a partial positive charge on that group (Scheme 3). These two processes 
prompt the decarboxylation reaction, which is followed by condensation.11,13 
 
 
Scheme 3 Mechanism, with the Cys-His-His triad, of the ketosynthase domain. 
 
The carbon-carbon bond-formation is followed by ß-processing steps during which the 
beta keto group is converted to the fully saturated carbon. The ß-processing starts with 
the KR domain, which belongs to the short chain dehydrogenase/reductase (SDR) 
superfamily. KRs reduces a β-ketone into an alcohol of S- or R-stereochemistry using 
NADPH 11 (Scheme.4).14 
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Scheme 4: Mechanism of the reduction of the keto reductase domain. 
 
The next chemical step after the KR is catalysed by the DH domain (Scheme 5). The DH 
domain catalyzes the elimination of water from the β-alcohol product 19 of the KR 
domain.15 This reaction is independent of the presence of an alkyl substituent at the alpha 
position. The syn-elimination process eliminates the alpha hydrogen atom (Scheme 5, red 
hydrogen atom) and the beta hydroxy group (Scheme 5, red marked) as water. 
The catalysing process works by a His-Asp dyad mechanism in which a hydroxyl 
in the β-position is eliminated through an E1cb mechanism.15–17 At the same time, aspartic 
acid protonates the β-hydroxyl group and forms water as a good leaving group. 
 
 
Scheme 5: Mechanism of the dehydratase domain. 
 
The ER domain belongs to the medium chain NADPH-dependent dehydrogenase/ 
reductase family (MDR). ER domains reduce αβ-unsaturated thiolester 21 by an addition 
of the hydride from NADPH 11 or NADH to the C-3 position and protonation at C-2, 
which determines the stereochemistry at the β-position (Scheme 6). 
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The ER of animal FAS, catalyses attack by the 4′-pro-R hydride of NADPH 11 at the 3-
Re face of 21, with subsequent protonation at the 2-Si face of 21, giving an overall syn of 
H2 addition (Scheme 6). The ER of yeast FAS catalyses attack by the 4′-pro-S hydride of 
NADPH 11 at the 3-Si face, with protonation occurring at the 2-Si face, an overall anti 
addition. In the type II FAS of E. coli, the ER catalyses attack by the 4′-pro-S hydride of 
NADH 11 at the 3-Si face of the enoyl intermediate with protonation at the 2-Re face to 
give an overall syn addition.18,19 
 
 
Scheme 6: Mechanism of the enoyl reductase domain. 
 
After the iterative chain elongation cycle, fatty acid biosynthesis is terminated either by 
offloading the fatty acid from the ACP by an acyl-ACP thiolesterase releasing a free fatty 
acid or by transesterification onto a suitable nucleophile by an acyltransferase. Most 
often, prokaryotes utilize acyltransferases and eukaryotes utilize thiolesterases.20 
The α/β hydrolase thiolesterases have a conserved catalytic triad: a nucleophile-
histidine-acid triad, with the nucleophile commonly being a serine residue (Scheme 7). 
The acid stabilizes the basic histidine, which accepts a proton from the nucleophile. The 
nucleophilic serine forms a tetrahedral intermediate 23 with the substrate before it is 
attacked by water resulting in product 22.20,21 The active site residues in TEs are on the 
surface of the protein, rather than buried in an acyl-binding pocket as seen with other FAS 
domains. The hotdog-fold TEs lack defined non-solvated binding pockets and conserved 
catalytic residues, and therefore a variety of catalytic residues and mechanisms exist.20,22 
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Scheme 7: Mechanism of the thiolesterase domain. 
 
1.4 Architecture of Fatty Acid Synthases 
 
All known FAS produce fatty acids, like palmitic acid 4, in an iterative process. This 
means the individual C-C bond forming and β-processing domains are reused in each 
elongation step until the full length fatty acid is produced.23 Hence, the fatty acid synthase 
is a key paradigm for carrier protein-dependent multi enzymes.24 As mentioned before 
(section 1.2) FAS proteins can differ in structure and organization and are thus divided 
into type I and II systems (Figure 2). 
Type I FAS are large multifunctional proteins containing all domain activities for 
fatty acid biosynthesis in one mega synthase protein (Figure 2A).23/25 All of the enzyme 
activities are covalently linked to form a large multifunctional protein. They are found in 
animals and fungi. Even so, the structural arrangement of fungal and animal synthases 
differ.  
In contrast, Type II systems are found in archaea, bacteria and the plastids of 
plants and are characterized by the use of discrete, monofunctional enzymes, which most 
likely form a non-covalent complex (Figure 2C). 
 
 
Figure 2: A, Homodimer crystal structure of mammalian FAS. PDB entry 2VZ8.23 In purple the AT domain, 
In red the KS domain, in blue the DH domain, in violet the ER domain, in yellow the KR domain, in orange 
the ψKR and ψC-MeT domain; B, Crystal structure of the yeast fatty acid synthase. PDB entry 2UV8;26 C, 
Crystal structure of KR domain (yellow), ER domain (violet), KS domain (red) and DH domain (blue) from E-
coli of the Type II FAS system. PDB entry’s: 1Q7B, 1MKB, 1DFI and 2VB9).27–30 
 
The mammalian FAS (mFAS, Figure 2A) structurally consists of a homodimer of two 
identical protein subunits, in which the catalytic domains in the N-terminal section, the 
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keto synthase (KS) and malonyl/acetyltransferase (AT), are separated by a linker region 
from the C-terminal domains. There are the dehydratase (DH), enoyl reductase (ER), 
ketoacyl reductase (KR), acyl carrier protein (ACP) and thiolesterase (TE, Figure 2A). 
The FAS I structure also includes a ψC-MeT domain and a ψKR domain. The ψC-MeT 
is an inactive (and mostly degraded) methyltransferase domain. The ψKR domain is a 
structural (supporting) domain of the KR. In contrast, the yeast FAS (yFAS) assembles 
into a barrel-shaped structure (Figure 2B).24 Catalytic domains of yFAS are embedded in 
an extensive scaffolding matrix and arranged around two enclosed reaction chambers.24 
Architecturally yFAS and mFAS are unrelated. 
 
1.5 From Fatty Acid Synthases (FAS) to Polyketide Synthases (PKS) 
 
While fatty acid synthases are optimized molecular machines specially for the production 
of fatty acids, like palmitic acid 4, many multienzymes with an overlapping set of 
functional domains and a related synthetic scheme are known which are not involved in 
primary fatty acid metabolism.24 In contrast, they are involved in secondary metabolism.  
These secondary metabolism machines do not necessarily produce fully reduced 
products. They can possess modifications at the C-α as well as C-β positions, which 
originate from incomplete reduction cycles caused by the absence of specific modifying 
domains, by catalytically inactive domains, or by programmed domain skipping. Because 
of their chemically diverse products, these synthases are named according to their primary 
condensation product: polyketide synthases (PKS).24 
The catalytic domains of PKS are closely related to those of mFAS. The enzymes 
are also independently folding protein domains, which like the FAS, construct polymeric 
chains and tailor their functionalities.31 They include KS, DH, ER, KR as well as active 
C-methyl transferase (C-MeT) domains. Substrate loading is catalyzed by 
acyltransferases, which are specific for the particular substrate of the PKS and are 
commonly abbreviated as AT.24  
PKS are found in bacteria, fungi and plants. PKS produce a highly diverse group 
of natural products. This includes aliphatic, cyclic, acyclic and aromatic components and 
macrocyclic lactones. The activities of the polyketides reach from antibacterial and 
immunosuppressive to anticancer to just name a few.32 Examples of microbial polyketides 
include erythromycin 25 from the bacterium Saccaropolyspora erythraea and 
tetracycline 26 from Streptomyces rimosus, which are used as antibiotics (Figure 3).33  
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Figure 3: Some examples for natural products of the PKS produced by fungi and bacteria. 
 
1.6 Biosynthesis of Polyketides 
 
Polyketide synthases (PKS), like the FAS, are responsible for forming a backbone of 
carbon atoms out of different carbon units. The biosynthesis usually starts with a simple 
starter unit such as acetyl-CoA 9. There is also the possibility to use other more unusual 
starter units for example propionyl-CoA.34 Furthermore, a PKS consists of several 
catalytic domains. However, for each PKS the acyl transferase (AT), a ketosynthase (KS) 
and the acyl carrier protein (ACP) are obligatory. Other domains like keto reductase (KR), 
dehydratase (DH), enoyl reductases (ER), methylation domains, oxidase domains and 
more are all facultative and are not found or active in every PKS. 
The first step, the AT domain “selects” the starting unit, which is normally an acyl 
CoA 9 and transfers this through a nucleophilic attack of the sulfur of the KS to the carbon 
on the acetyl-CoA to the KS 28 (Scheme 8). 
 
 
Scheme 8: Loading of the KS domain with the starter unit. 
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A typical extender unit for a PKS is malonyl CoA 10, but many bacterial systems can use 
methylmalonyl CoA.35 The ACP domain carries the polyketide chain, which is transferred 
through auto acylation to the KS domain. The malonyl-building block will bind to the 
ACP domain and will be decarboxylated. The generated enolate reacts similar to a Claisen 
condensation with the molecule on the KS. Now on the ACP domain is the elongated 
polyketide chain 30 with four C-atoms (Scheme. 9). 
 
 
Scheme 9: Elongation of the polyketide chain without any modifications. 
 
After the chain extension, further modifications of the developing polyketide chains are 
possible (Scheme. 10A-C). A different catalytic domain is responsible for each so-called 
β-processing step. The modifying domains are the ketoreductase (KR), resulting in β-
alcohol 32 (Scheme. 10A), dehydratase (DH) resulting in alkene 33 (Scheme 10B) and 
the enoyl reductase (ER) resulting in alkane 34 (Scheme 10C). Each domain can be either 
active or inactive in each round of chain extension, so that a following modification might 
or might not take place. Fungal PKS can also include a functional C-MeT domain. 
The end of the polyketide synthase process is generally determined through the 
thiolesterase (TE). They release the polyketide chain from the PKS complex. Often, a 
macrcolactonisation can happen. In addition to that, after release, other post modifications 
through tailoring enzyme can take place. 
 
Scheme 10: Elongation of the polyketide chain with different β-processing steps: A, Only the KR domain is 
active in the β-processing; B, The KR and DH domain are active in the β-processing; C, the KR, DH and ER 
domain are all active in the β-processing. 
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1.6.1 Mechanism of the C-MeT domain in PKS 
 
In contrast to FAS, PKS can possess an active C-methyl transferase domain (C-MeT). 
The C-MeT can transfer a methyl group to the α-position of the polyketide 36 
(Scheme.11). The cofactor for this reaction is S-adenosyl methionine (SAM) 35. The S-
methyl group of 35 is a potent electrophile.15 The hypothesized mechanism is through an 
attack by a nucleophilic carbon of 37 on the electrophilic SAM 35 methyl group resulting 
in product 38 (Scheme 11). Fingerprint residues (D/E) xGxGxG and neighbouring D/E) 
can be found in many C-MeT domains. 
 
 
Scheme 11: Mechanism of the methyl transfer of the C-Methyl transferase domain. 
 
1.7 Polyketide Synthases 
 
PKS can be divided in three different groups. Based on the architecture of the protein that 
is responsible for the final compound.  
 
Type I PKS 
Type I PKS are found in bacteria and fungi. They are like Type I FAS and consist of 
covalently linked enzymes. These PKS are further divided in modular (section 1.8) and 
iterative (section 1.9) types. Subclasses of the iterative Type I PKS are non-reducing (NR-
PKS), partially reducing (PR-PKS, section 1.9) and highly reducing PKS (HR-PKS, 
section 1.10).36 
 
Type II PKS 
Type II PKS are mono domain enzymes that come together for several catalyzing 
processes and form a complex. This complex consists of five to ten individual enzymes. 
 12 
The synthesized polyketides normally have a chain length of 16 to 24 carbons. Type II 
PKS systems are typically found in bacteria.37 
 
Type III PKS 
Type III PKS are found in plants, bacteria and fungi. They are simple homodimers of keto 
synthases. These systems do not use an ACP and they have no β-processing domains. 
They react directly with the extender substrates in a decarboxylative Claisen 
condensation. Type III PKS are iterative and produce small mono- and bicyclical 
aromatic metabolites like such as flavonoids 27.  
 
1.8 Modular Type I Polyketide Synthases 
 
Modular type I PKS occur in bacteria and consist of ordered assembly lines of multi-
domain modules. Examples of polyketides, which are synthesised by modular type I PKS, 
are shown in Figure 4. One module consists of KS, AT and ACP and optional KR, DH 
and ER domains. The PKS consist of two or more modules each extending and modifying 
a specific chain-elongation intermediate before transfer to the next module for further 
processing. Each module typically acts only once in the synthesis of a polyketide. The 
structure of the product can often be predicted by the domain sequence of the enzyme.38,39 
 
 
Figure 4: Examples of polyketides synthesised by modular type I PKS40 
 
One of the most investigated modular PKS is that which synthesizes Curacin A 52. This 
system is a hybrid between a PKS and non-ribosomal peptide synthetase (NRPS) 
components from the cyanobacterium Lyngbya majuscula.41 Curacin A 52 contains 
several interesting structural features. These includes the terminal alkene, a thiazoline 
ring and a unique cyclopropyl moiety, which is essential to the compound's biological 
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activity.41,42 A gene cluster encoding 14 open reading frames (ORF) encodes the enzymes, 
which are responsible for the synthesis of Curacin A 52 (Scheme 12). 
 
 
Scheme 12: Biosynthesis of Curacin A 52 of Lyngbya majuscula.41 40 
 
The biosynthesis includes different unique features. This includes an HMG-CoA synthase 
cassette (HCS) located on CurD (Scheme 12). Further, CurA contains a unique GCN5-
related N-acetyltransferase (GNAT) loading domain and an associated ACP.42 The 
loading module passes an acetyl group 16 to the ACP that then condenses with one of 
three tandem ACP present in the module of CurA (Scheme 12).41–43 A 
hydroxymethylglutaryl-CoA synthase cassette (mevalonate pathway) catalyses the 
formation of hydroxymethylglutaryl acid 42 by the addition of a malonyl-CoA unit to the 
terminal ketide 19 of the aceto-acetyl-ACP moiety of ACP1, ACP2, or ACP3.42,43 
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Subsequent enzymes, including a unique heme independent halogenase (Hal) catalyses 
the formation of a cyclopropyl ring 42.3,42,43 A cysteine specific NRPS module located on 
CurF follows after cyclopropyl ring formation, and due to the activity of a cyclizing 
condensation domain, forms a thiazole ring attached to the cylcopropyl moiety, resulting 
in thiazoline 44. 41–43 Seven PKS (curG-CurM) modules follow to extend the growing 
polyketide chain. The final curacin synthase module, with intermediate 51, employs a 
rare offloading strategy involving a sulfotransferase. The sulfotransferase sulfates the 
hydroxyl group of carbon 15, which activates the molecule for decarboxylation and 
terminal alkene formation, resulting in Curacin A 52 (Scheme 12).  
 
1.9 Iterative Type I Polyketide Synthases 
 
Most fungal PKS are iterative type I synthases consisting of one single module. Examples 
of polyketides, which are synthesised by iterative type I PKS, are shown in Figure 5. 
These enzymes repetitively use a single set of catalytic domains to assemble complex 
metabolites. The growing polyketide is cycled in each round of elongation. The most 
complex and interesting fact is that the extent of β-processing can have a large variation 
between the different extensions.   
 
 
Figure 5: Example for products of type I iterative PKS systems39 
 
Fungal iterative type I PKS are further divided into three functional classes based on the 
presence or absence of particular catalytic domains. These sub-classes are highly reducing 
(HR-PKS), partial reducing (PR-PKS) and non-reducing polyketide synthases (NR-PKS).  
HR-PKS possess the full set of modifying domains (KR, ER, and DH) and usually 
a C-MeT. NR-PKS lack the whole set of β-processing domains (KR, ER, DH) but can 
possess a C-MeT. In contrast, they possess some unique domains. For example the N-
terminal starter unit acyl-carrier transacylase (SAT).14,44 Furthermore, another unique 
domain, which controls the cyclisation of the backbone and in addition the chain length 
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of the product. This domain is known as a product template (PT) domain. PT domains 
are required because poly- β-keto intermediates have acidic protons and keto functions 
that make the polyketide intermediate very unstable.14,44 Hence, spontaneous cyclisation 
would be possible and the PT domain controls reactions.45 
 PR-PKS possess an incomplete set of modifying domains and often no known off-
loading domain.46/45 The PKS also consists of a KS, AT, DH, so called core domain, KR 
and ACP domain.47 In PR-PKS the most important domain is the ketoreductase (KR) 
domain. Here, the KR domain selects which intermediate will be reduced and controls, 
through the size of substrate binding pocket, the chain length. However, how the KR 
domain achieves the selective keto-reduction is not yet fully understood.45 
 HR-PKS will be discussed in detail because the focus in this work is on HR-PKS. 
 
1.10 Highly Reducing Iterative Polyketide Synthase (HR-PKS) 
 
HR-PKS are a group of multi domain enzymes which act in an iterative way.48,49 They 
also have a high sequence (and probable high structural similarity) to mammalian FAS. 
The strongest evidence for a common PKS-FAS architecture comes from their 
homologous domain organization (Figure 7) and sequence homology.40 In addition, 
another evidence for a common architecture is the crystal structures of KS-AT di-domains 
excised from HR-PKS modules, which are strikingly similar to the KS-AT of Type I 
FAS.50 
 
Figure 6: Homodimer crystal structure of mammalian FAS. PDB entry 2VZ8. Displayed in violet the AT 
domain, in green linker regions, in red the KS domain, in blue the DH domain, in pink the ER domain and in 
orange the KR, ψKR and ψC-MeT domain. 
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Based on the mFAS structure it is thought that HR-PKS structurally consists of a 
homodimer of two identical protein subunits, in which the catalytic domains in the N-
terminal section (KS) and malonyl/acetyltransferase (AT) are separated by a short linker 
of extended polypeptides from the C-terminal domains. These are the dehydratase (DH), 
enoyl reductase (ER), -ketoacyl reductase (KR) and acyl carrier protein (ACP, Figure 6). 
In contrast to mFAS, may HR-PKS also have a full and active C-MeT domain (Figure 
7).51/52 
The KS, AT and ACP are active in each extension cycle, but the other domains can 
be active or inactive during β-processing cycle and this gives rise to the observed 
programming of the HR-PKS. Hence, the difference in the programming of the HR-PKS 
results in structurally complex compounds, such as Lovastatin 54 or Squalestatin S1 53.53  
 
 
Figure 7: General domain architecture of the HR-PKS in comparison with the mFAS: KS and AT domains 
are responsible for the chain elongation while DH, C-MeT, ER and KR domains are β-processing domains. 
HR-PKS do not always possess an active ER domain that is why it is in brackets. HR-PKS often terminates 
with an ACP domain.39 
 
One example for such a product of an iterative PKS is Lovastatin 54. Lovastatin 54 is a 
polyketide metabolite produced by the filamentous fungus Aspergillus terreus. Among 
the enzymes that biosynthesize lovastatin are two polyketide synthases (PKS) and 
numerous accessory enzymes (Scheme 13).54,55 The two-mega synthases are the 
lovastatin nonaketide synthase (LovB), which catalyses the assembly of the decalin core 
(Scheme 13, marked in blue) and lovastatin diketide synthase (LovF), which catalyses the 
assembly of the 2-methylbutyrate side chain (Scheme 13, marked in red), respectively. 
LovB possess an inactive enoyl reductase (ER0). A trans-acting enoyl reductases, 
LovC, is encoded in the biosynthesis cluster. This trans-acting ER catalyses some 
reduction during the biosynthesis of Lovastatin (Scheme 13, marked in violet). LovC 
specifically interacts with only LovB, but not LovF, and accepts only three out of eight 
possible LovB intermediates as its substrates (tetra-, penta-, and heptaketides). Similar 
trans-acting ER have also been reported in other fungi and in particular the Tenellin PKS-
NRPS (section 1.13). 
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When LovC and LovB are coupled, they iteratively catalyses more than 30 precisely 
synchronized reactions to yield a 19-carbon intermediate dihydromonacolin L 59 
(Scheme 13). In comparison, LovF only catalyses one round of Claisen condensation to 
produce a 2-methylbutyryl intermediate, which is attached to the C-8 hydroxyl of 
monacolin J 60 to produce lovastatin 54 (Scheme 13).54,55 
 
 
Scheme 13: The biosynthesis of Lovastatin 54 as an example of an iterative PKS.54,55 
 
1.11 Stereochemical course in HR-PKS 
 
The biosynthesis of polyketides proceeds under a very high level of stereocontrol.56 As 
the stereochemistry of various functional groups affects the bioactivity of polyketides, the 
origins of stereochemical control are of significant interest for creating derivatives of 
these compounds by various methods such as genetic engineering.56 Different in vitro 
studies have been able to provide a near complete stereochemical description of the first 
cycle of beta-modification reactions of a fungal highly reducing polyketide synthase (HR-
PKS).56–58 The following section describes the current state of knowledge in the 
stereochemical course of HR-PKS. As an example, for the stereochemical course of HR-
PKS, the stereochemical course of the HR-PKS SQTKS is displayed in Scheme 14. 
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Scheme 14: Stereochemical course of KR, DH and ER domain of SQTKS. Experimental evidence supports 
the pathway shown with bold arrows. 
 
The starting point is the ACP bound diketide 61, which in the first step is methylated by 
the C-MeT domain to give the C-2 methylated 3-oxo diketide 2R-62a (Scheme14). 
Afterwards, the 2R, 3R -diketide is created by reduction of the 3-oxo group by the KR 
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domain using NADPH as the cofactor (Scheme 14). Studies in the Cox group showed that 
the SQTKS KR releases a 3R substrate, and thus it must reduce the 3-oxo group of its 
substrate 62a by 3-Si addition of the hydride. Isotopic labelling studies have shown that 
the 4´-pro-S hydride of NADPH is transferred in this step.56–58 Since racemization at the 
2-position of the diketide is strongly disfavored after reduction of the 3-oxo group, this 
observation also suggests that the KR accepts and releases 2R-methylated diketides (e.g. 
2R-63a, Scheme 14).56–58 Subsequently the DH domain dehydrates 2R, 3R substrate 63a 
to give E-products 65 by syn elimination. Cox. et. al. showed that the SQTKS DH has 
exactly the same stereochemical selectivity as the mFAS DH.57 Even though the SQTKS 
substrate is methylated at the 2-position, the 2R stereochemistry ensures that the 2-pro-S 
proton is removed during DH reaction.56–58 In addition, Cox et. al elucidated the 
stereoselectivity of the ER domain.58 They showed that the stereochemical preferences at 
the β-carbon are identical for SQTKS ER and mFAS ER, in terms of both the cofactor 
itself (transfer of 4´-pro- R hydrogen) and the substrate (addition of hydride to the 3- Re 
face, Scheme 14). 56–58 
 Overall, the in vitro studies concerning the stereochemical course show that 
SQTKS shares not only the sequence homology and domain organization with mFAS 
(Chapter 1.10) but also that its fundamental mechanisms for substrate reaction and 
stereoselectivity are preserved.56–58 Furthermore, other HR-PKS, for example such as 
TENS, DMBS and MILS should have the some stereochemical course, since they show 
significant sequence homology. 
 
1.11.1 Excursus into KR domains 
 
The KR domain determines the stereochemistry of the processed alcohol 63a and the 
stereochemistry of substituents at the β-position. KR domains are classified into different 
stereochemical types (Scheme 15), often distinguishable through fingerprints in their 
amino acid sequence.59 There is a distinction between A1-Type, A2-Type, B1-Type, B2 
type and C-types (Latter will be not explained in detail). The residues, which are unique 
to each type of KR were identified through multiple sequence alignments.59 A leucine-
aspartate-aspartate (LDD) motif is consistently present in the B-Type KRs, whereas a 
conserved tryptophan is present in A-type KR domians.59 A2-Type KR domains can often 
be distinguished from A1-Type KR domains through the presence of a histidine three 
residues N-terminal to the catalytic tyrosine B2-Type KR domains can often be 
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distinguished from B1-type KR domains through the presence of a proline two residues 
C-terminal to the catalytic tyrosine.59 
 
Scheme 15: KR stereocontrol on natural substrate. 
 
The KR domains can stereoselectily generate either an 3S-hydroxyl group (A-type KR 
domains, Scheme 14 63b and 63d) or a 3R-hydroxyl group (B-type KR domains, Scheme 
14 63a and 63c). Furthermore, they can also be stereoselective in reducing a substrate 
with either a 2R-substituent (A1- or B1-type KRs) or a 2S-substituent (A2- or B2-type 
KRs).15,60–62 
 The crystal structures of the EryKR1 and TylKR1 domains have revealed that the 
conserved catalytic residues of KR domains cooperate as observed in other short-chain 
dehydrogenase/reductase (SDR) enzymes.15,60–62 The substrate β-carbonyl is positioned 
adjacent to the nicotinamide ring by a tyrosine and a serine so that the 4-pro-S hydride 
can attack the β-carbonyl (Scheme 16). As anticipated, the A- and B-type sequence motifs 
reside on opposite sides of the catalytic groove. Keatinge-Clay and Raid et. al. hypotised 
that the LDD motif (The leucine in this motif can be occasionally replaced by valine or 
isoleucine; several residues can replace the first aspartate; the second aspartate is strictly 
conserved) mediate the entrance of the phosphopantetheinyl-bound β-ketoacyl thiolester 
substrate from the right side of the catalytic groove (the side closer to the NADPH binding 
site), resulting in formation of a 3-R hydroxyl group (Scheme 16). The conserved 
tryptophan is hypothesized to guide the substrate into the groove from the left side, 
thereby presenting the opposite face of the β-keto group to NADPH to produce a 3-S 
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hydroxyl group.15,60–62 However, the orientations of the catalytic residues change little 
between KR-types (Scheme 16).59 
 In addition, the nicotinamide coenzyme binds to both A- and B-type KRs in the 
same location and conformation. NADPH occupies a characteristic groove in the 
Rossmann fold of KR and presents its pro-4-S hydride to the active site, consistent with 
the observation that both A- and B-type KRs transfer the NADPH pro-4 S hydride to 
substrates (Scheme 16).59 By this analysis the KRs of mFAS and HR-PKS are B1-types. 
 
Scheme 16: Display of the active pocket with the bound cofactor 11 and different catalytic and structural 
amino acids.  
 
1.12 Biosynthesis of Squalestatin Tetraketide Synthase 
 
Squalestatins, also known as zaragozic acids, are polyketides isolated from the fungus 
Phoma sp. C2932, among others.59 They were identified by research groups of Glaxo and 
Merck.63 They are potent inhibitors of cholesterol biosynthesis and act by inhibiting 
squalene synthase probably by mimicking the natural substrate, presqualene 
pyrophosphate. All squalestatins contain the common 4,6,7-trihydroxy-2,8-
dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid core and hydrophobic side chains.39 
The side chains have a high diversity in the chain length, methylation pattern and 
methylation positions. In addition, the reduction pattern of the side chains can differ. 
 
Figure8: Structure of Squalestatin S1 53. 
 
The biosynthesis of squalestatin S1 53 (Figure 8) has been observed by several feeding 
experiments using isotopes. Chain A is a tetraketide with acetate as starter and extender 
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units. The genes which encoded the enzymes responsible for the tetraketide chain were 
identified by Cox et al.64 Chain A is produced by a single PKS known as squalestatin 
tetraketide synthase (SQTKS).63 SQTKS consists of KS, AT, DH, C-MeT, ER, KR and 
ACP domains (Scheme 17). The biosynthesis comprises three rounds and starts with the 
binding of acetyl-CoA 9 to the AT. The AT then transfers the acetate to the KS and binds 
malonyl-CoA 10. After that, the ACP takes the malonyl group from the AT via trans-
esterification. After decarboxylation of the bound malonyl group, the chain at the ACP is 
extended by the addition of the acetate from the KS (Scheme 17A). The ACP carries the 
β-keto compound and the C-MeT adds a methyl group at the α-position (Scheme 17B).39 
Then the remaining β-processing steps follow (Scheme 17 A-E). 
SQTKS, like other characterised fungal HR-PKS, lacks a TE or any other obvious 
releasing domain. Most characterised highly reduced polyketides do not exist as free 
polyketide chains but are extensively modified by post-PKS enzymes and linked to other 
moieties. During the synthesis of SqualestatinS1 53 the tetraketide 68 becomes linked to 
the squalestatin core. 
 
Scheme 17: Biosynthesis of the side chain of Squalestatin S1 through the iterative working of SQTKS. 
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1.13 Biosynthesis of Tenellin  
 
 
Figure9: Structure of Tenellin 69 
 
A hybrid PKS-NRPS system biosynthesizes the fungal metabolite Tenellin 69.65 The PKS 
which builds the polyketide part of tenellin, is an HR-PKS. The special thing about this 
PKS is that the ER domain is inactive and a trans-acting ER domain catalyses the 
reaction. 
 The biosynthesis of pretenellin A 73 starts with the building block acetyl CoA 9, 
which is elongated four times with malonyl CoA 10 (Scheme 18). After the first 
elongation, all β-processing enzymes including the C-MeT are active and the enoyl 
reduction is performed by the TenC trans-ER. This trans-ER is only active in the first 
elongation round so an unsaturated carbon chain is formed in the next elongations steps 
(Scheme 18). In the first two rounds of the programming, the methylation (Scheme 18B) 
takes place, similarly to other PKS systems like Squalestatin. The KR (Scheme 18C) is 
functional after the first three rounds of extension, but inactive after the final elongation 
step. 
 Afterwards the NRPS adds a tyrosine to the resultant polyketide chain and 
catalyses a Dieckmann cyclisation (Scheme 19), which acts as the release step. After 
release, two cytochrome P450 enzymes oxidize pretenellin A 73. TenA catalyses an 
oxidative ring expansion to form the pyridone. Finally TenB hydroxylates the pyridone 
nitrogen.48,65 
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Scheme 18: Biosynthesis of the PKS part of Tenellin through the iterative working of TenS. 
 
 
Scheme 19: Part of the biosynthesis of Tenellin 69. 
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1.14 Engineering of Polyketide Synthases 
 
The practical usefulness and chemical diversity of natural products stands against some 
difficulties, such as limited accessibility through total synthesis, structural complexity, 
solubility, bioavailability, exposure, stability, and metabolism.66 This explains the long 
standing interest in engineering PKS enzymes to produce novel polyketides in a 
predictable manner. There is a vast potential for producing pharmaceutically relevant 
compounds and in addition, it would be a simple way to get these products. 
Theoretically, different changes to HR-PKS or the tailoring enzymes should be 
possible (Figure 10). Focused on the PKS, the most obvious starting point is manipulating 
individual HR-PKS domains. For example, by specific modification of active site 
residues, the domains could be inactivated or their substrate or stereochemical specificity 
could be adjusted.67 Also, there is the possibility to switch one domain for another from 
the same or a different HR-PKS in order to alter these same properties. This is a reason 
why they are attractive targets for genetic engineering. Modifications also include the 
removal or addition of specific tailoring steps or changes in the regiospecifity or 
stereospecifity of the reactions.68 
 
To date, different engineering approaches have been undertaken in modular PKS systems, 
from which a few examples will be described in the following.  
 The AT domain has been a key target for polyketide engineering in modular PKS, 
and a number of studies focus on understanding and engineering building block selection 
by this domain.69 Mainly, typical starter units, substrates different to malonyl-CoA 10 or 
methylmalonyl-CoA are used. For example, an AT domain from the modular monensin 
PKS4 and the loading AT from the avermectin PKS5, both with relaxed substrate 
specificities, were subjected to computational modelling and structural analysis, 
respectively, to enable the identification of residues responsible for substrate binding and 
specificity.69 
In addition, the KR domain of modular PKS has also been a target for engineering. 
The specificity can be modified through site-directed mutagenesis. As an example, the 
mutation of the catalytic tyrosine of the DEBS module 6 KR. The residue was identified 
through homology modeling of KR domains to the SDR superfamily of enzymes. 
Afterwards, this was tested in vitro through the point mutation of this residue. The in vivo 
production resulted in the expected ketone, illustrating that even through deactivating of 
domain it is still possible to generate new polyketides.60 In addition to site-directed 
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methods for engineering KR domains, numerous experiments have illustrated the 
viability of full KR domain swaps to modulate the stereochemistry and oxidation state of 
a given polyketide in modular systems.70 
Engineering the DH domain has not been as extensively pursued as the 
engineering of other PKS domains, but even so several examples of both site-directed and 
swap-based engineering exist. For example a DH domain from the modular DEBS was 
inserted into a module of the avermectin synthase in S. avermitilis, resulting in the 
exclusive production of C22,23-unsaturated avermectins.71 
One of the earliest examples of mutasynthesis targeted the avermectin PKS. A 
strain of Streptomyces avermitilis was generated wherein the enzymes required for 
generating the precursors 2-methylbutyryl-CoA and isobutyryl-CoA were inactivated. 
Out of 800 potential precursors, which were tested, over 40 starter unit analogs were 
tolerated by the avermectin PKS.72 Through this method, a cyclohexyl-containing 
avermectin derivative (Doramectin) was generated that exhibited increased anti parasitic 
activity against veterinary pathogens.73 
 Another approach to understand and engineer PKS is through iterative type I PKS. 
However, due to the complexity of programming of Type I PKS, very few reports of 
rational engineering exist. Numerous bioactive polyketides are synthesized by iterative 
type I PKS. These fungal PKS have only one module that is used iteratively. The related 
programming rules regarding substrate selection, catalytic domain utilization in each 
elongation cycle, regiospecifc modification, polyketide chain length, control, chain 
release and transfer, etc. are only just beginning to be understood.69 A more simple 
approach is through non-reducing iterative type I PKS (NR-PKS) that are involved in 
aromatic polyketide synthesis. The starter unit ACP transacylase (SAT) domain has been 
the focus of several recent studies including domain swapping to generate new aromatic 
polyketides69 and structural analysis to identify the basis for acyl unit selection, since 
unnatural starter units often are processed properly by the rest of the catalytic domains of 
NR-PKS.69 
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Figure 10: Schematic overview over different possibilities for rational changes of the programming of PKS. 
 
1.15 Engineering of C-MeT and ER domain from fungal HR-PKS 
 
Very few engineering approaches have been reported with iterative C-MeT domains from 
PKS. One rare example is the approach from Cox et.al. were the C-MeT domain of the 
SQTKS S1 was engineered in vivo in order to investigate the programme of SQTKS.74 
Their aim was to disable the methylation of the tetraketide by blocking the co-factor SAM 
binding to alter the methylation pattern. This was done through site-directed mutations of 
potential residues involved in SAM binding.74 However, the results of LCMS analysis of 
the mutant protein showed that mutations of the C-MeT domain from SQTKS did not 
give the desired effect with certainty. The mutations overall might prevent the SAM 
binding, but the linear alkene product was rapidly metabolised by growing A. oryzae M-
2-3. From these results they could only propose that the methylation of the tetraketide 
prevents β-oxidation.74 Furthermore, they suggested that the inhibition of the methylation 
in the early steps of the elongation cycle may prevent further processing and during the 
later steps, it might possibly block the PKS. Overall the programming of HR-PKS was 
not able to be revealed or changed though these in vivo expression and mutagenesis 
experiments.74  
Even less engineering has been done with ER domains. Some early mutagenesis 
studies of ER domains in DEBS module 4 targeted the conserved “HAAAGGVGMA” 
NADPH binding motif for engineering.70 Changing this sequence to “HAAASPVGMA”, 
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based on the NADPH binding motif of the inactive KR domain from the same module, 
resulted in production of primarily D-6,7-anhydroerythromycin C.70 
A different approach of PKS engineering, which is not at the amino acid, domain, and 
module level, is the precursor-directed biosynthesis (PDB). By feeding analogues of their 
natural building blocks that are likely tolerated by the native biosynthetic PKS in the 
producing host. The efficiency of this technique can be enhanced with the previously 
mentioned mutasynthesis, wherein the naturally occurring precursor pathways are 
inactivated, thus removing competition from natural precursors.70 In addition to precursor 
supplementation through feeding experiments, metabolic pathways that produce 
precursor analogs can be introduced heterologously to replace the deleted pathways.66 
As polyketide, engineering continues to progress, the development of tools and 
strategies, to understand the underlying PKS programming rules and exploit them for the 
diversification and overproduction of new polyketide compounds is of importance. 
Thereby, in vitro biochemical analysis using purified enzymes continues to serve as the 
most important method for studying PKS enzymology, particularly in understanding the 
precise function and substrate specificity of catalytic domains, reaction mechanisms, and 
the internal kinetics of the catalytic program. 
 
1.16 Rational Domain Swaps between the HR-PKS TENS and DMBS 
 
One of the very rare examples of engineering of HR-PKS is through domain swaps. In 
previous studies, Cox et. al could successfully swap different domains of the HR-PKS 
TENS with the corresponding sequence from the HR-PKS DMBS.48,75–77 The TENS and 
DMBS polyketide synthases are 86% identical, but produce polyketides which differ in 
chain-length and methylation pattern.76 The product of TENS is pretenellin A 73 and of 
DMBS predesmethylbassianin A 74 (Figure 11). 
 It was shown that the exchange of entire functional domains between these closely 
related (but differently programmed) HR-PKS, could lead to the creation of new 
polyketides (Figure 13).76  
 
 
Figure11: Structure of pretenellin 73 and predesmethlybassianin A 74. 
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The first domain swaps between TENS and DMBS included the KS, AT and DH of TENS 
with the ones of DMBS (Fig 12). This resulted in no change in the polyketide chain. The 
product was still pretenellin A 73. 
 
 
Figure12: Example of a swap experiment. The DH, KS and AT domain from TENS (green) was swapped 
with the KS AT and DH domain from DMBS (red). 
 
However, if the C-MeT and KR domain from DMBS were swapped into TENS, this 
reprogrammed the PKS and resulted in two new products. Desmethyl-pretenellin A 75 
and prebassianin A 76 were isolated as the major and minor product (Figure 13).  
 
 
Figure13: Structure of desmehtly-pretenllin A 75 and prebassianin A 76. 
 
Overall, the domain swap experiments are, on the one hand, another example for the 
engineering approach of HR-PKS and on the other hand give a first insight into the 
programming of HR-PKS (section 1.17). 
 
1.17 Programming in Iterative Type I HR-PKS 
 
HR-PKS synthesize complex products using a single set of domains in a highly 
programmed, iterative fashion. Although many examples of type I HR-PKS are known in 
the literature, the mechanism that controls the iteration processes in these PKS has not 
been clearly understood.78 This stands in contrast to modular Type I PKS. In modular 
PKS the programming is simply controlled through the assembly of the modules and the 
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availability of the specific domains in each respective module (for example see Curacin 
A 52, section 1.8). However, a limited number of in vitro and in vivo investigations of 
HR-PKS catalytic domains have been discussed in the literature, which gives first 
evidence for a possible programming mechanism.  
 The catalytic domains of HR-PKS have two types of selectivity. First, they have 
a chemical selectivity, whereby they only act on substrates, which are chemically 
competent. For example, the DH domain can only act on ACP-bound β-alcohols and the 
AT can only supply malonyl extender units.79 
 The second level of selectivity is the structural selectivity of each domain. For 
example, Cox et. al. recently showed in vitro that the ER domain from Squalestatin 
Tetraketide Synthase has low substrate selectivity and is able to effectively reduce a wide 
range of enoyl-pantetheines, even including unnatural isomers such as 83 and 
stereoisomers such as 78 (Figure 14).58  
 
 
Figure 14: Synthesized pantetheine substrates for SQTKS ER assays from the previous studies. 
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Furthermore, Vederas et. al. could show in vitro that the C-MeT domain from the 
lovastatin nonaketide synthase displays tight selectivity for its substrate, while the KR in 
the same system is less selective.80  
For the clarification, comparisons between individual rates of isolated C-MeT and KR 
domains toward the different substrates were investigated. For the subsequent 
quantification, and to prevent further tailoring reactions of the KR products in the assay, 
a point mutation was introduced in the active site of the DH domain to yield LNKS-DH0.80 
 By expressing LovB with an inactive DH domain and assaying these synthetic 
substrates, they recorded the Michaelis-Menten saturation kinetics (comparing kcat/KM) 
and found that the C-MeT domain activity to substrate 99 is more than 2000 times higher 
than substrate 96 (Scheme 20). However, the KR domain exhibits far less selectivity in 
reactivity to these substrates. This may suggest an important role of the C-MeT domain 
as a gatekeeper domain in the programming of LNKS. 56,80 
 To determine if there is indeed competitive catalysis between the KR and C-MeT 
domains towards the 3-ketoacyl substrates, Tang and co-workers performed a combined 
C-MeT/KR assay (Scheme 20). Both the natural substrates 96 and 99 were added to 
LNKS-DH0 with the same equivalent of SAM and NADPH, and the yields of the 
methylation product and the ketoreduction product were compared (Scheme 20). 
Thereby, Tang and Vederas could observe for substrate 96 a 10:1 ratio of KR-catalysed 
product 98 to C-MeT-catalysed product 97. However, for substrate 99, only the 
methylated product 100 was observed and no reduced product 101 could be detected, 
thereby confirming the much higher catalytic efficiency of C-MeT domain toward 
substrate 93 compared to that of the KR domain. These experiments verified the 
assumption that the outcome of the modifying steps is determined by the relative activity 
of each domain towards specific substrates. However, one unexpected result is that the 
KR domain cannot reduce compound 99, although it is the natural substrate for the KR 
domain in this biosynthesis. One possible explanation is that the recognition of this 
substrate needs interactions with the ACP domain.56,80 
 
 
Scheme 20: Kinetic analysis of the LNKS CMeT domain towards different ketoacyl-SNAC substrates. 
Compounds 90 and 93 are both natural product analogues. 
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In addition, the stereoselectivity of each domain is fixed. For example, in the KR domain 
the stereochemical course of each β-ketoacyl-ACP reduction is programmed and is 
independent of either modular context or substrate structure, including chain length and 
substitution pattern.81 
 Overall, Vederas and Tang hypothesised that the programming mechanism of HR-
PKS is kinetically controlled. In the modification stage, HR-PKS may adopt an assembly 
line-like model in which each substrate is passed through the catalytic domains 
sequentially in the order of C-MeT → KR → DH → ER. In the case of the HR-PKS, 
LNKS encoded by lovB, which partners with a trans-acting ER encoded by lovC, the C-
MeT only recognizes substrate 99 while excluding all of the other substrates completely 
(Scheme 20). They suggested that the outcome of the modifying steps is determined by 
the relative activity of each domain towards specific substrates.56,80 
 
These in vitro experiments are supplemented through the in vivo swap experiments with 
the HR-PKS of TENS and DMBS of Cox et. al (section 1.16). The swap experiments 
could successfully elucidate a part of the programming mechanism in the HR-PKS 
TENS.48,75–77  
 In different swap experiments with different domains such as KS, AT and DH of 
TENS with the ones of DMBS, no change in the polyketide chain was observed (Figure 
15A-C), hence, the product was still pretenellin 67. Therefore, it was concluded that the 
chain length seems not to be programmed by these three domains (Figure 15A-C). 
 In addition, in the case of both TENS and DMBS the PKS proteins are terminated 
with a non-ribosomal peptide synthetase (NRPS) module which catalyzes the transfer of 
the polyketide via an amide linkage to tyrosine. A Dieckmann cyclisation domain (DKC) 
then effects chain-release by intramolecular cyclisation - the NRPS also does not 
influence the programming of the PKS.79 Further the trans-acting enoyl reductase 
proteins can also be exchanged without affecting programming.79 However, 
programming and fidelity changes are observed in these systems when the KR and C-
MeT domains are swapped, and when the trans-acting ER is absent (Figure 15D-J). This 
swap reprogrammed the PKS and resulted in two new products with different chain length 
and methylation pattern (Figure 15D-J). 
 In combination with other results, it can be suggested that the methylation pattern 
is controlled by the C-MeT-ψKR. Hence, the C-MeT domain is programmed on its own. 
Whereas the DMBS C-MeT seems only to recognize diketides, the TENS C-MeT can 
recognise both diketides and triketides. 
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Overall, the results hypothesize that the programming mechanism of HR-PKS is 
kinetically controlled. Therefore, the next level of programming is on the level of the 
single domains. They have on the one hand chemical selectivity, whereby they only act 
on substrates which are chemically competent and on the other hand a structural 
selectivity. The single domains can also be further dived into domains which play a part 
in the programming mechanism of the chain length or methylation pattern (e.g. KR, C-
Met and ψKR) or don’t play a part in the programming mechanism of the chain length 
and methylation pattern (e.g. KS, AT, DH). The last effect on the programming is not on 
the single domains, but on the interaction of the different domains with each other. In 
other words: Domain-domain interactions. 
 
 
 
Figure 15: Rational domain swapping between TENS and DMBS. The trans-acting ER (not shown in the 
figure) and the NPRS are interchangeable with no programming effect.  
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1.18  Overall Project Aims 
 
Diverse approaches have been explored to generate new polyketides by engineering 
polyketide synthases (PKS). Although it has proven possible to produce new compounds 
by designed PKS, engineering strategies have so-far failed to make polyketides available 
via widely applicable rules and protocols and engineering of HR-PKS is barely 
described.82 
In this study, the aim is to engineer the ER domain of the HR-PKS Squalestatin 
tetraketide synthase (SQTKS) in a rational approach. SQTKS is one of the simplest 
iterative type I HR-PKS that has all the iterative β-modification domains present in an 
active state and in which a degree of programming occurs.  
There is no existing structural information, for complete fungal iterative HR-PKS, 
such as SQTKS. However, if site-directed mutagenesis of these systems is to be attempted 
it will be necessary in a first step to obtain useful structural models of the specific catalytic 
domains. 
With the generated protein models, different docking studies with modern 
modelling procedures will be used. The best-generated homology models will then be 
used as the basis for the design of different rational engineering experiments in silico. 
Afterwards, the applied in silico modifications shall be applied on the ER domain of 
SQTKS and effects of the mutagenesis verified through suitable in vitro assays.  
Overall, the experiments should reveal if it is possible to engineer an HR-PKS. In 
addition, the effect of the different mutations on the intrinsic programming of the 
respective domain shall be investigated, especially how the chemical selectivity and 
kinetics of the different substrates are influenced by the changes introduced into the 
respective domain.  
 
In the second project, the aim is to provide in parallel to the molecular-biological work, 
the structural-biological foundations and analysis for the domain swaps between TENS, 
DMBS and MILS. Sen Yin, Dr. Katherine Willams, Dr. Xiao-Long Yang and Dr. Steffen 
Friedrich performed the actual domain swaps and the molecular-biological work. 
 The purpose of the in silico structural analyses is to consider the effects of swaps 
on protein structure and to understand the effect of the swaps on the structural level. 
Additionally, the in silico analysis helps to clarify the influence of extrinsic and intrinsic 
programming factors. Subsequently, this analysis should provide the knowledge for 
targeted mutations and rational enzyme engineering.   
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2 Modelling Studies of the SQTKS ER Domain 
 
2.1 Introduction  
 
Protein structures provide valuable information which is important for understanding the 
molecular basis of their function and reengineering.83 Currently, more than 130 000 
experimental protein structures are deposited in the Protein Data Bank (PDB: Status 
2019). Even so, the number of structurally characterized proteins are low compared to the 
number of known protein sequences. Hence, no structural information is available for the 
majority of protein sequences.83 Methods such as X-ray crystallography, nuclear 
magnetic resonance spectroscopy (NMR) or cryo-electron microscopy (cryo-EM) are 
available to determine the structure of proteins and their complexes. However, all these 
techniques have the drawback that they are time-consuming processes without guaranteed 
success.40,83 
Other techniques for the quick calculation of protein structures are therefore 
necessary. In order to solve the problem, it is understood that proteins are subjected to the 
process of evolution. Different results indicate that three-dimensional protein structure is 
evolutionarily more conserved than expected due to sequence conservation. Hence 
evolutionarily related proteins have similar sequences and naturally occurring 
homologous proteins have similar protein structures.84,85 So-called homology modeling, 
or comparative modeling, is currently the only method that can reliably generate a 3D 
model of a protein (target) from its amino acid sequence.83,86,87 Successful model building 
requires that at least one experimentally solved 3D structure (template), which has a 
significant amino acid sequence similarity to the target sequence, is available. In general 
homology modeling consist of five main steps:88–90  
 
1. Identification of evolutionarily related proteins with experimentally solved 
structures that can be used as template(s) for modeling the target protein of 
interest; 
2. Mapping corresponding residues of the target sequence and the template 
structure(s) by means of sequence alignment methods and manual adjustment; 
3. Building a three-dimensional model on the basis of the alignment; 
4. Evaluation of the quality of the resulting model; 
5. Repetition of this procedure until a satisfactory model is obtained. 
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Potential structural templates are identified using a search for homologous proteins in 
available databases, for example the PDB databank. From the resulting list of possible 
candidate structures, a template structure is chosen based on its suitability according to 
various criteria such as the level of similarity between the query and template sequences, 
the experimental quality of the solved structures, the presence of ligands or cofactors, etc. 
In the best case, a wide range of the protein sequence should be matched by a single high-
quality template.90 
Estimating the accuracy of a protein structural model is an important step in the 
modelling process. The quality of the homology model is dependent on the quality of the 
sequence alignment and template structure. For example, the modelling could be 
complicated through the presence of alignment gaps, indicating a structural region, which 
is present in the target but not in the template. On the other side, this structure gap could 
be present in the template. Finally, the model quality can also decline with decreasing 
sequence identity.83,90 
The three-dimensional models, which are built on possible templates, can then be 
further investigated on their quality. Differences in protein backbone structures are 
quantified by the root mean square deviation (RMSD) of the positions of alpha carbons 
(Cα). A model can be considered 'accurate” when its RMSD is within the spread of 
deviations observed for experimental structures displaying a similar sequence identity 
level as the target and template sequences.91–95 
As a general rule, the core Cα atoms of protein models sharing 50% sequence 
identity with their templates will deviate by ∼1.0 Å RMSD from experimentally 
elucidated structures. Although the atomic coordinates of the three-dimensional model, 
for regions of the target protein aligned to the template, can be modeled on the basis of 
the information provided by template structure,62,96 regions that are not aligned with a 
template (insertions/deletions) require specialized approaches.90,97–99 Unaligned regions 
of the target such as loops that are modeled using de novo techniques will on average be 
less accurate than structurally conserved regions of the model on the basis of information 
derived directly from the template.90 
If the percentage identity falls below ∼30% (so-called 'twilight zone'), the model 
quality estimation on the basis of sequence identity can become unreliable, as the 
relationship between sequence and structure similarity gets increasingly dispersed.90,100 
With decreasing sequence identity, alignment errors and the incorrect modeling of large 
insertions become the major source of inaccuracies.90 
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Overall, the two most common and large-scale sources of error in homology modeling 
arise from poor template selection and inaccuracies in target-template sequence 
alignment.101 These problems can be minimized by the use of multiple templates, but the 
method is complicated by both the templates differing local structures around the gap and 
by the likelihood that a missing region in one experimental structure is also missing in 
other structures of the same protein family. Missing regions are most common in loops 
where high local flexibility increases the difficulty of resolving the region by structure-
determination methods.87 
Even bearing these problems in mind, homology modelling is a good method to 
determine possible structure of a protein of unknown structure. The only requirement for 
this method is the availability of adequate templates. Currently, completely automated 
methods for homology modelling and assessment are available online. These methods 
have been extensively validated and are being increasingly used to build useful protein 
models, which allow deeper understanding and engineering protein structures in cases 
where X-ray and NMR structures are not easily available. Such methods include, Swiss-
Model, Modeller and ROSETTA.83 102 103 
 
2.1.1 Swiss-Model 
 
Swiss-Model is an automated system for modelling the 3D structure of a protein from its 
amino acid sequence using homology modelling techniques.83,92,95 Since its original 
development it has been continuously improved.90,104 Today, Swiss-Model is one of the 
most widely used structure modelling web servers worldwide, with more than 0.9 million 
requests for protein models annually. 
Like most modelling programs, the Swiss-Model workflow consist of four main 
steps that are involved in building a homology model of a given protein structure. First, 
identification of structural template(s) is performed. Therefore, BLAST and HHblits are 
used to identify templates.105,106 In the second step, templates are stored in the Swiss-
Model Template Library (SMTL), which is derived from the PDB (Protein Data Bank).105 
Afterwards the alignment of target sequence and template structure(s) is performed.105 
The GMQE score (Global Model Quality Estimation) is a quality estimation, which 
combines properties from the target–template alignment and the template search 
method.105 The resulting GMQE score is expressed as a number between 0 and 1, 
reflecting the expected accuracy of a model built with that alignment and template and 
the coverage of the target. Numbers closer to 1.0 indicate higher reliability. The GMQE 
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score gives a first impression of the overall the quality of the model.105 The last two steps 
consist of energy minimization and assessment of the overall quality of the generated 
model.83,92,95 
 Model quality estimation is an essential component of protein structure 
predictions, as the accuracy of a model determines its usefulness for practical 
applications. Swiss-Model provides model quality estimates based on a QMEAN 
potential, specifically re-parameterized for models built by Swiss-Model.83,92,95 In 
addition, the accuracy of the Swiss-Model server is independently evaluated in 
comparison with other state-of-the-art methods by the CAMEO project. It is based on 
target sequences weekly pre-released by the Protein Data Bank (PDB).83,92,95 
QMEAN is a composite estimator based on different geometrical properties and 
provides both global (i.e. for the entire structure) and local (i.e. per residue) absolute 
quality estimates based on one single model.107 The QMEAN Z-score provides an 
estimate of the ‘degree of nativeness’ of the structural features observed in the model on 
a global scale. It indicates whether the QMEAN score of the model is comparable to what 
one would expect from experimental structures of similar size. QMEAN Z-scores around 
zero indicate good agreement between the model structure and experimental structures of 
similar size. Scores below -4.0 are an indication of models with low quality.90,104 
The reason why Swiss-Model was used in these studies is the advantage that the 
template search and the validation of the model are already integrated in the software and 
therefore did not have to be done separately.  
 
2.1.2 Molecular Docking (AutoDock Vina) 
 
Molecular docking is a method to predict the structure of intermolecular complexes 
formed between two or more constituent molecules.108 In particular, the complex formed 
between a protein and a ligand such as a cofactor or substrate.  
Many methods for molecular docking and virtual screening have been developed 
to date, such as AutoDock, AutoDock Vina, DOCK, Flex, Glide, GOLD, RosettaDock, 
SLIDE and Surflex.109–118 Docking protocols can be described as a combination of a 
search algorithm and a scoring function (Scheme 21).108 However, these methods 
introduce various approximations to simplify the problem; otherwise the calculation 
would include too many variables and would be nearly impossible to solve.  
 The search algorithm should allow several degrees of freedom of the protein–
ligand system to be sampled sufficiently to include the true binding modes. Thereby, the 
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success of a docking algorithm in predicting a ligand binding pose is normally measured 
in terms of RMSD between the experimentally observed heavy-atom positions of the 
ligands and the one(s) predicted by the algorithm.119 
 
 
Scheme 21: Overview over the docking process and available methods. 
 
Different levels of approximation can be performed in the search algorithm. The earliest 
and most basic one is the rigid-body approximation.119,120 This is valid for rigid ligands 
in which one or a limited set of ligand conformations is possible. However, most ligands 
are highly flexible. A more common approach nowadays is to model the ligand flexibility 
while assuming a rigid protein receptor.119,121 Three general categories of algorithms are 
devised to treat ligand flexibility: systematic methods; random or stochastic methods; and 
simulation methods. Furthermore, three basic types of methods are based on random 
algorithms: Monte Carlo methods (MC); Genetic Algorithm methods (GA); and Tabu 
Search methods. Of these, the genetic algorithms apply ideas derived from genetics and 
the theory of biological evolution to docking.119 
 GA methods start from an initial population of different conformations of the 
ligand with respect to the protein. Each conformation is defined by a set of state variables 
(defined as genes) that describe aspects like the translation, orientation, and conformation 
of the ligand in relation to the protein receptor. The full set of the ligand´s state variables 
is defined as the genotype, whereas the atomic coordinates refer to the phenotype. Genetic 
operators (mutations, crossovers, and migrations) are applied to the population to sample 
the conformational space, until a final population that optimizes a predefined fitness 
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function is reached.119 AutoDock and AutoDock Vina include this type of search 
algorithm, for example.110,122,123  
 The scoring function should represent the thermodynamics of interaction of the 
protein–ligand system adequately so as to distinguish the true binding modes from all the 
others explored, and to rank them accordingly.119 Different assumptions must be made 
for the searching algorithms and the scoring function to minimize the computational 
intensity. However, these assumptions result in less accuracy concerning the docking 
procedure. For this reason, the lack of a suitable scoring function both in terms of speed 
and accuracy is the major bottleneck in docking.119,124 
 Scoring functions can be divided into three major classes: force field-based, 
empirical, and knowledge- based scoring functions.119 Standard force fields generally 
quantify the sum of two energies: the interaction energy between the receptor and the 
ligand, as well as the internal energy of the ligand.119 The energies are normally accounted 
through a combination of van der Waals with an electrostatic energy terms. A Lennard-
Jones potential is used to describe the van der Waals energy term, whereas the 
electrostatic term is given by a Coulombic formulation with a distance-dependent 
dielectric function that lessens the contribution from charge–charge interactions.119 The 
limitations of force field scoring functions include the absence of solvation and entropic 
terms, and the inaccurate treatment of the long-range effects involved in binding. Several 
force field scoring functions such as D-Score, G-Score, Gold-Score or AMBER are 
known.115,125–127 
As mentioned previously, AutoDock is one of the many protein−ligand docking 
programs available. The first version was described in 1990 and has been improved 
during the following years.109,128 The AutoDock scoring function is based on the 
molecular mechanics force field AMBER with two additional terms: one to model the 
desolvation free energy change on binding, which is based on atomic solvation 
parameters and one empirical term to model the loss of conformational entropy on 
binding.122,129,130 Furthermore AutoDock has been used in the discovery of several 
drugs.131,132 In addition, it is the most cited docking program in previous studies.119,128,133  
 AutoDock Vina was developed in 2010 by the same group as AutoDock, 
intending to improve accuracy and performance.128 AutoDock Vina achieves an 
approximately two orders of magnitude increase in speed compared to the molecular 
docking software previously developed in AutoDock 4, while also significantly 
improving the accuracy of the binding mode predictions. Furthermore, multi-core 
processors are now common on desktop PCs which also accelerates the process. 
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AutoDock Vina automatically calculates the grid maps and clusters the results in a way 
transparent to the user.110 
 
Two main criteria are considered during the evaluation of the results of docking 
experiments: First, how well does the postulated binding mode agree with known 
structural data; and second, how well did the docking rank the ligands or rather, if the 
method's scoring function is designed to predict binding affinities, how high is the 
agreement.122 
 The first evaluation method is usually the RMSD between the docked position and 
the crystallographically observed binding position of the ligand, where success is 
typically regarded as being less than 2 Å.119,122 
In addition, if stochastic methods are performed, the experiment could be run 
several times with different initial conditions. The similarity of the predicted binding 
modes can be assessed by computing a matrix of pairwise RMSD values, and clustering 
docked conformations according to an RMSD threshold, typically 2 Å. If all of the 
docking-clusters fall into one family, this indicates that the search parameters were 
sufficient for each docking to converge.119,122 
 Further, if the docked conformation with the lowest energy would always 
correspond to the crystallographically observed binding mode, it would be concluded that 
there are no bad contacts in the crystal structure. This is not always the case, and 
sometimes a different binding mode is observed significantly more often than the lowest 
energy-binding mode. Furthermore, current docking methods will tend to find the binding 
mode with the lowest possible interaction energy for a given ligand: this score does not 
necessarily indicate whether the ligand even binds.119,122 
 
2.1.3 YASARA 
 
Molecular dynamics (MD) is a computer simulation method for studying the physical 
movements of atoms and molecules. It is widely used as a powerful simulation method 
in many fields of molecular modelling. In the context of docking, by moving each atom 
separately in the field of the rest of the atoms, MD simulation represents the flexibility of 
both the ligand and protein more effectively than other algorithms.134 However, the 
disadvantage of MD simulations is that they progress in very small steps and thus have 
difficulties in stepping over high energy conformational barriers, which may lead to 
inadequate sampling. On the other hand, MD simulations are often efficient at local 
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optimization (Figure 16). Thus, the most common strategy for simulated ligand docking 
involves docking experiments with another software (such as AutoDock Vina), followed 
by MD simulations for further refinement after docking (Figure 16).134 Different software 
packages are available for this approach, such as ORCAR, Lee-Server, ROSETTA, 
Undertaker or YASARA.135 
YASARA, is a software package that runs molecular dynamics simulations of 
models in explicit solvent, using a new partly knowledge-based all-atom force field 
derived from AMBER, the parameters of which have been optimized to minimize the 
damage done to protein crystal structures. The YASARA force field addresses these 
issues by combining the AMBER all-atom force field equation with multi-dimensional 
knowledge-based torsional potentials and with a consistent set of force field parameters 
to maximize the accuracy.135,136 This is achieved by making a random change to one or 
more parameters (e.g. a certain van der Waals radius, a charge, or the weight of a 
knowledge-based potential). To ensure that all forces responsible for the experimentally 
observed structure are considered, minimizations are done in crystal space, using 
complete unit cells. As a result, one obtains a force field that has stable energy minima as 
close as possible to native structures. This is essentially equivalent to a force field that 
moves models closer to native structures during a simulation.135,136 
 
 
 
Figure 16: Schematic example for the applications of YASARA. A; Native protein in the inactive state, hence 
without a substrate. Positioned in the local minimum A. B; Protein obtained a higher energy level, after the 
substrate was docked inside through a molecular docking software package (still located in the local 
minimum A). Indicated with the red arrow: YASARA would refine the model and “move” the protein with the 
substrate into the local minimum B. Which also represents a native state, but an active conformation. 
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2.2 Previous Studies 
 
Iterative highly reducing PKS (HR-PKS) show distinct and often complex programming. 
The level of complexity of fungal polyketides synthesized by HR-PKS, like SQTKS, is 
on a similar level of structural complexity as polyketides which are synthesized by 
bacterial modular PKS. However, through the use of a single iterative PKS module, such 
fungal PKS systems are highly efficient and the programming is much more complicated 
(Chapter 1, section 1.17). Furthermore, through a variety of variables (amino acid 
sequence, structure of the modules, module-module interactions, structure of the 
substrate, etc.) the mechanisms of programming of these types of PKS are cryptic. For 
modular systems, the number of modules, and the content of -processing domains in 
each module, controls the program. Hence the presence or absence of β-processing 
domains within modules (i.e. extent of functionalization at each β-position); and 
individual domain selectivity, for example by the AT domains, which controls the 
selection of extender units (i.e. the methylation pattern). Furthermore, modular PKS can 
control the stereochemistry of each α- and β-position, and this is usually controlled by the 
selectivity of the KR domain (β-hydroxyl positions) and the ER domain (α-alkyl 
positions). 
In the previous studies of Cox et. al. the fundamental work for the programming 
of SQTKS could be laid and serves here as the fundamental basis for enzyme engineering 
(Chapter 1, section 1.12).58,137  In addition, the expression and analysis of the ER domain 
is based on primary works of Cox et. al.58 
 
ER Domain of SQTKS 
 
The biosynthesis and programming of SQTKS was elucidated before (Chapter 1, Section 
1.12, 1.17), hence will here not further be discussed. In previous studies, it was shown 
that the isolated ER domain of SQTKS possesses a broad substrate selectivity in vitro. It 
accepts both natural and unnatural enoyl species as substrates. The substrates included 
likely intermediates as well as others which are improbable intermediates (including Z-
isomers) and those which cannot be intermediates (e.g. ethyl-substituted, incorrectly 
methylated, and compounds with odd carbon chain-lengths, Figure 14, Section 1.17)58,137  
 Further, Cox et. al. could show in in vitro assays that the isolated SQTKS ER 
domain is not able to control the stereochemistry at the α-position. Hence, all substrates 
were produced as -racemates.58 Neither possible product enantiomer was preferred 
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because reprotonation of an enol(ate) intermediate could occur from either face (Scheme 
6). In contrast, the stereochemical outcome at the β-position could be predicted and the 
transfer of hydride from NADPH was shown to be highly stereoselective, indicating a 
rigid arrangement of the cofactor and substrate in the ER active site. Other studies showed 
that multi-domain fragments of SQTKS, in which specific fragments from the DH-KR 
domains are included, are better able to control the stereochemistry of the α-position 
compared to isolated domains, suggesting that reprotaonation of the α-position is 
probably achieved by a water molecule rather than a specifically located amino acid 
resiude.56  
 In addition, a first model structure of the ER domain was obtained using the crystal 
structure of mammalian fatty acid synthase (mFAS, 2vz9) as the template. The 3D model 
of SQTKS ER was consistent with numerous experimental observations. For example, 
the structural domain organization is consistent with that observed for other PKS and FAS 
ER proteins and docking of NADPH showed interactions with known cofactor binding 
residues and the correct 4´-hydrogen of the cofactor was exposed for reaction. Likewise, 
docking of substrate pantetheines gave structures consistent with the observed 
stereochemistry of reduction at the substrate -carbon. Finally, it was shown that the ER 
may sequester its final substrate to prevent further chain extension.58 
 
2.3 Aims of the Project 
 
There is no existing structural information, for complete fungal iterative HR-PKS, such 
as SQTKS. However, if site-directed mutagenesis of these systems is to be attempted it 
will be necessary to obtain useful structural model of the specific catalytic domain. The 
enzyme domain, which is of interest for engineering and thus modelling, is the ER domain 
of SQTKS. Information on isolated proteins would be useful, but it would also be useful 
to generate multi-domain models, which could help show how the domains interact. The 
modeling should be done through homology modeling.  
As mentioned before, a critical requirement for homology modeling is the 
availability of a suitable template. Sequence alignments show that the mammalian fatty 
acid synthase (mFAS) has an appropriate similarity and the domains are arranged in the 
same order (Chapter 1.10). However, the mFAS crystal structure was obtained at 
relatively low resolution (3.2 Å) and parts of the structure are missing.25 In addition, 
mFAS has no functional C-MeT domain. Hence, the first steps will be to find appropriate 
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templates for the specific domains and use these for homology modelling. After the 
modeling the quality of the modelled structure should validated.  
With the generated protein model in hand, different docking studies with AutoDock 
Vina will be performed. On the one hand, this will be done to obtain a substrate and 
cofactor docked model of the ER domain, which could be used as a template for the 
mutagenesis in silico. On the other hand, this will be done in order to determine the range 
of values for different parameters, such as C-H distances and carbonyl position, etc. which 
could result in productive or non-productive conversion of the substrate by the ER 
domain. The best-generated homology model will then be used as the basis for the design 
and validation of different rational engineering experiments in silico (Chapter 3). 
 
2.4 In Silico Studies of the SQTKS ER Domain 
 
The first domain to be modelled was the enoyl reductase from SQTKS. However, before 
homology modelling could be done the domain boundaries of the ER domain of SQTKS 
should be determined. Therefore, the sequence of SQTKS was examined with BLAST 
(basic local alignment search tool).138 Subsequently, a conserved domain search (CD-
Search) was performed to determine the domain boundaries.139–142 The search determined 
the boundaries for the ER domain from L1908 as start point and P2208 as an end point of 
the ER domain.  
 Afterwards, homology modeling was done using Swiss-Model.83,92,95,105 This 
selected 50 possible templates including Mycocerosic acid synthase (PDB 5bp4),24,143 
CurK (PDB 5dp1),144 JamJ (PDB 5doz1),144 mFAS (PDB 2vz9)25 and CurF (PDB 
5dp2).144 For the selection as template the GMQE score (section 2.1.1), sequence identity 
and the resolution of the templates were considered and compared. A low GMQE score, 
level of sequence identity or resolution of the template, would result in a low quality 
model. From the proposed templates, the CurF ER from the curacin A biosynthetic 
pathway (PDB 5dp2) was selected as the most suitable template for the modelling.144 The 
CurF PKS module is an unusual modular cyanobacterial PKS, which contains functional 
β-processing domains (Chapter 1, section 1.8).145 
 The CurF ER was chosen for various reasons. On the one hand, the structures 
have high sequence identity of 37 %, which is also displayed in the sequence alignment 
of the template with the SQTKS ER domain (Figure 17). Further, the template had a high 
GMQE score of 0.71. The final reason, which was important difference to the other 
possible templates, was the X-Ray resolution. The other templates were obtained at lower 
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X-ray resolutions between 1.8 - 3.8 Å. In contrast, the X-Ray resolution of CurF was 1.0 
Å. In addition, the PKS CurJ might be closer to the actual structure of SQTKS, than 
mFAS. 
Overall, a structure model of the ER of SQTKS with a QMEAN (Chapter 2.1.1) 
value of -2.37 was obtained after the modeling (Figure 19), which indicates, that the 
quality of the generated structure model was good enough to proceed. 91–95  
 
 
Figure 17: Sequence alignment of the ER sequence of SQTKS with the CurF ER template sequence 
(5dp2). 
 
In the next step, the homology model and the template were alignet in PyMOL (Figure 
18). The alignment resulted in Cα- RMSD value of 1.34 Å. This Cα- RMSD value is 
good. Even so, some structural differences in the loops of both structures were observed. 
The core α-helices and β-sheets overlay very well (Figure 18); the crystallization of loop 
regions is not always very accurate, because of their high flexibility. 
 
 
Figure 18: Alignment of the SQTKS ER model (red) with the template CurF (PDB: 5dp2; blue) displayed in 
PyMOL. A, Front view; B, Back view. 
 
The generated model itself consists of three main structural features (Figure 19).58 The 
N-terminus (L1908-I2001, blue in Figure 19) forms a globular domain, which is involved 
in contacting the acyl-pantetheine substrate. The central sequence V2002-V2144 
(red/green, Figure 19) forms the cofactor-binding domain and includes a Rossmann-fold 
(green, Figure19). Finally, the C-terminal sequence (D2145-P2208 grey, Figure 19) forms 
 47 
a link between the cofactor and substrate binding domains as well as a part of a capping 
region above the active site.  
 
 
Figure 19: Model of the ER domain of the SQTKS displayed in PyMOL. Shown are the structural features: 
Red, cofactor binding domain; blue, substrate binding domain; green, Rossmann fold; grey, C-terminal 
sequence. 
 
2.5 Integration of the cofactor into the modelled ER domain of SQTKS 
 
The next step was to add the cofactor NADPH 11 into the active side of the ER domain 
(Figure 21). This was done through the alignment of the homology model with the 
template in PyMOL (Figure 18).146,147 The cofactor was extracted from the template and 
then manually integrated into the structural model of the SQTKS ER. Afterwards, the 
generated ER domain plus cofactor was minimized in YASARA, to refine the protein-
cofactor interaction (section 2.1.3, Figure 16).135 Then the extracted and refined cofactor 
11 was aligned with the cofactor 11 from the template (Figure 20). The alignment resulted 
in a RMSD of 2.01 Å. The highest variability in the alignment is at the purine moiety. 
However, the nicotinamide moiety and the diphosphate “bridge” overlay well. Hence, the 
cofactor in the ER SQTKS model should have the correct position and orientation. 
Further, the nicotinamide 4´-pro-R hydrogen is exposed for reaction in agreement with 
experimental results.58 
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Figure 20: Alignment of the cofactor 11 from the SQTKS ER model (green) with the cofactor from the CurF 
(blue) 
Furthermore, NADPH 11 contacts one side of the tunnel made up from the N-terminal 
domain of the ER, making specific contacts with residues S2072 and K2055, G2029 
(diphosphate), I2119 and V2144 (nicotinamide). All these residues are conserved in other 
PKS and mFAS ER domains (Sequence alignment of the ER, Table 4). In addition, the 
interaction of the conserved binding NADPH binding motif “HAASGGVGQA” with the 
NADPH cofactor 11 was observed. Overall, the QMEAN and the structural features of 
the model generated for the SQTKS ER indicate that the quality should be suitable for 
further in silico studies. 
 
 
Figure 21: Model of the SQTKS ER domain displayed in PyMOL. Shown are the structural features: red, 
cofactor binding domain; blue, substrate binding domain; green, Rossmann fold; grey, C-terminal sequence. 
The cofactor 11 as sticks with the nicotinamide near the top of the image. 
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2.6 Development of a Substrate and Cofactor Docked Model for the ER of 
SQTKS 
 
In the next step, different substrates were docked into the active pocket of the ER SQTKS 
(table 1). On the one hand, this was done to obtain a substrate and cofactor docked model 
of the ER domain, which could be used as a template for the mutagenesis in silico. On 
the other hand this was done in order to determine the range of values for different 
parameters, such as C-H distances and carbonyl position, etc. which could be correlated 
with productive or non-productive conversion of the substrate by the ER domain. Hence, 
in the following in silico experiments we aimed to correlate results from in vitro kinetic 
experiments with the in silico docking results to attempt to determine a range of 
productive and non-productive geometric substrate poses from which predictive 
geometric parameters could be extracted.58,137 Therefore data was generated which 
included three-dimensional parameters of the substrates known to be active or inactive 
with the SQTKS ER.58 
 
Table 1: Model substrates for the determination of the validation parameters (ER SQTKS). 
 Substrate 
Observed Substrate 
Specificity (kcat/KM)58
 
A 
 
Okay 
(12.0) 
B 
 
Good 
(119.0) 
C 
 
Okay 
(23.6) 
C 
 
Bad 
(0.0) 
 
The docking was performed by manually overlaying the substrate in the SQTKS ER 
active site using PyMOL. This was done to simplify the docking in the next step. This 
method minimized the so-called Grid Box, which has a critical role in the speed of the 
docking calculations. Molecular docking was done using AutoDock Vina (Chapter 2, 
section 2.1.2).110,147,148 The model was then refined by YASARA. The visualization of 
the different models, after the refinement step was always done in PyMOL. An example 
is shown with squalestatin triketide pantetheine 85 (E-4S-2,4-dimethylhex-2-enoyl-
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pantetheine, Figure 22 and Figure 23) which is known to be both a natural substrate and 
a good substrate in vitro. 
 
 
 
Figure 22: Active site of the ER domain with a mesh surface. In green the cofactor NADPH 11 and in white 
the modeled substrate squalestatin triketide pantetheine (E-4S-2,4-dimethylhex-2-enoyl-pantetheine) 85. 
 
 
 
Figure 23: Active site of the ER domain. In green the Cofactor NADPH 11 and in white the modeled substrate 
squalestatin triketide pantetheine (E-4S-2,4-dimethylhex-2-enoyl-pantetheine) 85. 
 
Since no structural data for the SQTKS ER domain was available, it was not possible to 
perform a direct validation of the molecular docking of the substrates. For example, the 
RMSD between the docked substrate and the structural available substrate could not be 
compared. In addition, validation of the docked substrates according to the lowest energy 
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conformation is not very reliable (section 2.1.2). The last validation option that could be 
used would be a cluster of RMSD analysis. Even so, this method is very time consuming.  
 Hence, a visual validation of the docking was performed based on different 
criteria, before the values for the different parameters were determined. The criteria of 
the visual validation included amongst other things the orientation of the substrate 
towards the cofactor 11. 
 
In the following, the determination of the values for the C-H bond, distance to the active 
hydride, etc. are shown for squalestatin triketide pantetheine 85 (E-4S-2,4-dimethylhex-
2-enoyl-pantetheine, Fig 24 and 25) and 93a squalestatin tetraketide (6S,4S-2E-
dimethyloct-2-enoylpantetheine, Fig 26 and 27) which is known not to be a substrate. The 
best docking result, which could be obtained with optimization of different parameters of 
the Grid Box in the docking procedure with AutoDock Vina (section 2.1.2), are shown in 
Figures 24-27. 
 
In the model of the squalestatin triketide pantetheine 85, the catalytic nicotinamide moiety 
of the NADPH cofactor 11 is located inside the ER-domain. NADPH 11 is in contact with 
its binding site, consisting of highly conserved residues (Sequence alignment of the ER, 
Table 2). The squalestatin triketide pantetheine 85 extends into the protein. The 
pantetheine part of the substrate extends parallel to the adenine diphosphate locating the 
thiolester and the β-carbon adjacent to the nicotinamide. The α/β-unsaturated carbonyl of 
the substrate adopts an s-cis conformation (Figure 25), which places the reactive β-carbon 
3.4 Å away from the cofactor's correct/observed reactive 4´-pro-R hydrogen (Fig 24). The 
Burgi-Dunitz angle substrate-cofactor complex is 61.7° and the dihedral angle 46.6° 
(table 2). The Burgi-Dunitz angle and the dihedral angle might differ from the optimal 
angles from literature (e.g. Burgi-Dunitz angle: 107°),149,150 however, enzymes are 
flexible systems and in crystals and the generated model only snapshot of a certain state 
is displayed. Hence, in nature the enzyme might change is structural conformation until 
the right pose with the necessary angle is occupied. In addition, other angles than the 
optimal angle of 107° have been observed in enzymatic reactions, since the angle in the 
enzymatic conversion in the SQTKS ER might be also different.151 
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Table 2: Sequence alignment of the ER (wild type) domain from SQTKS with other fungal ER domains.  
                      SSS     S S      S  S                          . 
Fumonisin   (1809) NFRDVLLAMGIVEANNLGIGLEGSGVITDVGAGV----TDLQVGDRVF 
Zearalenone  (1688) NFRDVMASMALVPVK--GLGQEASGIVLRTGRDA----THLKPGDRVS 
Alternapyrone (1185) NFKDVLVALGNLAEN-K-LGVDASGIVTRVGSAV----TNVQVGDRVM 
Squalestatin (1923) NFRDVMVAMGQLEES--IMGFEC-GVVRRVGPSS--AGHNIKVGDRVC 
Asperfuranone (1853) NFRDVMVAMGQLKER-V-MGLECAGVITRVGAEA-A-AQGFAVGDRVM 
 
                                                       CSC CC        . 
Fumonisin   (1853) YLDDNCFSTRITMSAMRCAKIPSFLSYEEAATMPCVYATVIHSLVDIG 
Zearalenone  (1706) TLDMGTHATVMRADHRVTVKIPDAMSFEEAAAVPVVHTTAYYALVRLA 
Alternapyrone (1927) TASCDTFATYVRFPAKGAIGVPTGMSFEEAASMPLIFLTAYYALVTAG 
Squalestatin (1966) ALLGGQWTNTVRVHWHSVAPIPQAMDWETAASIPIVFVTAYISLVKIA 
Asperfuranone (1897) ALLLGPFSSRARVSWHGVASMPAGMGFADAASIPMIFTTAYVALVQAA 
 
                                CCCCCCCCCC               CCCC  C     . 
Fumonisin   (1901) GLQSGQSVLIHSACGGIGIAAINVCQSIGGVQVYVTVGNQDKVRYLME 
Zearalenone  (1758) KLQRGQSVLIHAAAGGVGQAALQLAN-HLGLVVYATVGSDDKRKLLTD 
Alternapyrone (1975) GIVAGEKVLIHAAAGGVGQAAIMIAQ-AKGAEIFATVGADTKKQLLIE 
Squalestatin (2015) RMQAGETVLIHAASGGVGQAAIILAK-HVGAEIFATVGTDEKRDLLIK 
Asperfuranone (1945) RLSQGQTVLIHAAAGGVGQAAVILAKEYLGAEVFATVGSQEKRDLLIK 
 
                             CC                     C  S             . 
Fumonisin   (1954) TFNIPRASIFNSRDTSFREDVLAHTNGRGVDLVLNSLSGELLHASW-E 
Zearalenone  (1810) TYQVSEDHIFNSRDASFAKGIMRVTGGRGVDCVLNSLSGELLRVSW-S 
Alternapyrone (2027) QYGIPEDHIFSSRDTSFVKGVLRATDGQGVDLVLNSLAGEALRLSWTD 
Squalestatin (2067) EYKIPDDHIFSSRNALFAKSIRQRTNGKGVDVVLNCLAGGLLQESF-D 
Asperfuranone (1998) EYGIPDDHIFNSRDSSFAPAALAATAGRGVDCLI-------------E 
 
                               CCSSS                     CSSS        . 
Fumonisin   (2006) CVAPYGKMLEIGKRDFIGKAKLSMDIFEANRSFIGIDL---ARFDAAR 
Zearalenone  (1862) CLATFGTFVEIGLRDITNNMLLDMRPFSKSTTFSFINMYTLFEEDPSA 
Alternapyrone (2080) CLAKFGRFLEIGKADLFANTGLDMKPLLDNKSYIGVNLLDFENNPTPR 
Squalestatin (2119) CLADFGRFIEIGKRDIELNHCLNMGMFARSATFTAVDLIAIGRDRSYM 
Asperfuranone (2038) VLAPFGHFVEIGKRDLEQNSLLEMATFTRAVSFTSLDMMTLLRQRGDE 
 
                      S                                   . 
Fumonisin   (2056) CHPLLTRTVQMLEAGHIKPIAPRTTFSAGHIEDSFR 
Zearalenone  (1915) LGDILEEVFKLLGGGILQTPSPMTVYPINQVEDAFR 
Alternapyrone (2133) AVALWHDTAKMIHDGAIKPIAPLQVFTMAEVEKAFR 
Squalestatin (2157) FAEALPKIMTLLQEKAIRPVTPISIYKIGDIETAFR 
Asperfuranone (2091) AHRVLSELARLAGQGIVKPVHPVSVYPMRQVDKAFR 
 
Legend: 
      . Identical within HR-PKS ER domains         . Highly conserved within HR-PKS ER 
domains 
      . Mutagenesis resiude                         C = Cofactor binding; S = Substrate binding 
 
In addition, in Scheme 20 the stereochemical course for the reduction of 79 catalyzed by 
the isolated SQTKS ER domain is shown (Chapter 1.11).58 Previous studies demonstrated 
that for the highly stereoselective transfer of the 4´-pro-R hydrogen of NADPH 11, the 
cofactor must be rigidly located in the active site. Furthermore, the transfer of the hydride 
to the 3-carbon of the substrate is also highly stereoselective, indicating that the substrate 
must take a single conformation relative to NADPH, which was in the previous studies 
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determined for the substrate as the s-cis conformation.58 Our calculations for the good 
substrate are similar to the results found in previous studies.58 
 
 
Scheme 22: Stereochemical course of the reduction catalyzed by the SQTKS isolated ER domain. 
 
 
 
Figure 24: Active site of the ER domain. Cofactor NADPH 11 (green) and the modeled substrate 
squalestatin tetraketide (4S-2E-dimethylhex-2-enoylpantetheine) 85 (white). The hydride at the cofactor are 
marked. A, Back view; B, Front view. 
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Figure 25: Modeled substrate squalestatin tetraketide (6S,4S-2E-dimethyloct-2-enoylpantetheine) 85 
(white). Shown in red the s-cis geometry of the α/β-unsaturated carbonyl. 
 
In the model of the squalestatin tetraketide pantetheine 93a the catalytic nicotinamide 
moiety of the NADPH cofactor 11 is also located inside the ER-domain. NADPH 11 is 
in contact with its conserved binding site, consisting of highly conserved residues (see 
Sequence alignment of the ER, Table 2). The squalestatin tetraketide pantetheine 93a 
extends with the side-chain into the protein. The pantetheine part of the substrate extends 
parallel to the adenine diphosphate locating the thiolester and the β-carbon adjacent to the 
nicotinamide. The α/β-unsaturated carbonyl of the substrate adopts a different pose to the 
triketide 85. An s-trans conformation is observed (Figure 27), which places the reactive 
β-carbon 3.2 Å away from the cofactor's reactive 4´-pro-R hydrogen (Fig 26). The Burgi-
Duniz angle substrate-cofactor complex is 100° and the dihedral angle at 72.3° is also 
higher than for the triketide 85 (table 2). 
 
Figure 26: Active site of the ER domain. Cofactor NADPH 11 (green) and the modeled inhibitor squalestatin 
tetraketide (6S,4S-2E-dimethyloct-2-enoylpantetheine) 93a (white). The hydride at the cofactor are marked. 
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Figure 27: Modeled inhibitor squalestatin tetraketide (6S,4S-2E-dimethyloct-2-enoylpantetheine) 93a 
(white). Shown in red the s-trans geometry of the α/β-unsaturated carbonyl. 
 
These parameters: distance of the C-2 position to the NADPH hydride; orientation of the 
substrate towards the NADPH; the geometry of the α/β-unsaturated carbonyl; the Burgi-
Dunitz angle and the dihedral angle were reconsidered for the determination of whether 
the substrate is, or is not, held in a productive conformation. This is summarized for all 
three substrates in Table 3. Overall, a geometry of the α/β-unsaturated carbonyl in s-cis 
conformation and a dihedral angle with <65° are the best predictors for a good substrate.  
 
Table 3: Summary of the validation parameters for the different model substrates.  
 
C-H 
distance 
Si/Re-
Face  
Geometry - α/β-
unsaturated 
carbonyl 
Burgi-
Dunitz 
angle 
Dihedral 
angle  
 
3.5 Å 
Re-
Face 
s-cis 46.6° 63.8° 
 
3.4 Å 
Re-
Face 
s-cis 61.7° 46.6° 
 
4.7 Å 
Re-
Face 
s-cis 151° 42.8° 
 
3.2 Å Si-Face s-trans 100° 72.3° 
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3 In Silico Mutagenesis Studies of the SQTKS ER Domain 
 
3.1 Introduction 
 
The generation of the model of SQTKS ER was described in chapter 2. Validation of this 
model protein by various methods suggested that the binding of cofactor and substrates 
is chemically reasonable. We therefore considered that these models could form a valid 
basis for the design of further experiments with the aim of engineering the substrate 
selectivity of the ER domain of HR-PKS. There have been almost no reports of the 
successful rational engineering of HR-PKS, but based on the results from several in vitro 
studies of isolated HR-PKS domains, combined with the modelling described in the 
previous chapter, we considered that such experiments should now be possible. 
 
3.2 Aim of the Project 
 
The best-generated homology models of the ER domain of SQTKS will be used for 
different rational engineering experiments in silico. For example, different site-directed 
mutants will be generated in silico and then docking studies with different potential 
substrates using AutoDock Vina will be performed. In combination with sequence 
alignments, these studies will be used to investigate the effect of the site-directed changes 
of the ER domain in silico. The validation of mutagenesis and the docking studies will be 
done using the parameters previously determined for the functional conversion of the 
substrate-mutant complex. Hence, we should be able to assess if the substrate is, or is not, 
held in a productive pose. Overall, the generated models should be suitable for the rational 
design of different potential site-directed mutants for later in-vitro or in-vivo studies. 
 
3.3 Identification of Residues Potentially Involved in Substrate Selectivity in the 
ER domain of SQTKS 
 
We hypothesized that the ER enacts its substrate selectivity via a fixed pocket length, 
which does not allow longer, or more methylated chains to bind productively for 
reduction (Figure 28). Therefore, increasing the length and volume of the substrate-
binding pocket could enable larger or more methylated substrates to bind productively. 
For this purpose, amino acids, which bind the thiolester or the pantetheine, should not be 
mutated, but amino acids, which line the alkyl-binding part of the pocket, could be 
considered for mutation. The selection of the amino acids was done in PyMOL after the 
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docking of the substrates 77, 85, 93a and 94 into the active pocket (Chapter 2, section 
2.6). 
In the first example squalestatin tetraketide pantetheine 93a (6S,4S-2E-
dimethyloct-2-enoyl-pantetheine, Figure 28 and 29) was used as a test-case. In particular, 
large hydrophobic residues lining the substrate-binding pocket (grey) were targeted (e.g. 
I1938, F1941, L2146, I2147 and F2157). 
Additional to the docking studies, a sequence alignment was performed in 
Geneious. Only ER domain sequences from other fungal HR-PKS were chosen for the 
alignment (table 2). Sequence alignment of the ER of SQTKS with other HR-PKS pointed 
out highly conserved residues and variable residues in the ER sequence. This information 
was considered in selecting possible mutation residues. Since highly conserved residues 
are most likely important for an intact structure and function of the protein, these residues 
were not selected for mutation. 
 
 
 
Figure 28: Active site of the ER domain with a mesh surface. In green the Cofactor NADPH 11 and in white 
the modeled substrate squalestatin tetraketide (6S,4S-2E-dimethyloct-2-enoylpantetheine) 93a. Possible 
mutation residues in dark grey for the conversion of longer substrates and for the conversion of the 
squalestatintetraketide. 
 
In addition, the structures of the longest intermediate, which is able to be reduced by the 
ER domain of each respective PKS, are shown in Table 4. However, the sequence 
alignment did not reveal any correlation between maximal chain length of the substrate 
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and the amino acid sequence of the ER-domain. As an example: the ER of FUM1 can 
reduce a C20 chain.  
 A large and hydrophobic amino acid (F2157) is positioned at the end of the closed 
cavity of the ER SQTKS active site (Figure 29). Concerning the sequence alignment, this 
position is highly variable throughout fungal PKS (table 2). Overall, it is difficult to 
reason from the sequence alignment onto the chain length of the product, without further 
information, such as a 3D structure of each individual protein. However, the combined 
model and sequence analysis suggests it would be worthwhile investigating these 
identified residues further. 
 
Table 4: Structure of the longest intermediate of the specific PKS, which still could be reduced by the 
respective ER domain 
Compound Structure Length (acelates) 
Fumonisin152 
 
8 
Zearalenone153 
 
5 
Alternapyrone154 
 
5 
Squalestatin tetraketide39 
 
3 
Asperfuranone155 
 
2 
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Figure 29: Active site of the ER domain with a mesh surface. In green the Cofactor NADPH 11 and in white 
the modeled substrate squalestatin tetraketide (6S,4S-2E-dimethyloct-2-enoylpantetheine) 93a possible 
mutation residues in grey for the conversion of longer substrates and for the conversion of the squalestatin 
tetraketide with their mesh surface. A, Back view; B, Side view. 
 
3.4 In Silico Studies Concerning the Conversion of the Squalestatin 
Tetraketide-Pantetheine Stereoisomers 93a-d (ER domain of SQTKS) 
 
3.4.1 Investigation of tetraketide stereoisomers 
 
In the previous section (section 3.3), various residues of the SQTKS ER domain were 
identified for possible mutations by docking studies. From previous studies in the Cox 
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group58,137 it was known that a racemic mixture of diastereomers of the squalestatin 
tetraketide-pantetheine 93a-d can be converted by the isolated ER domain in vitro 
although the single 4S,6S stereoisomer is not converted.58 Thus, at least one of the three 
remaining stereoisomers 93b-d should be converted by the ER domain of SQTKS. The 
conversion of any of the three diastereomers 93b-d should depend on its orientation 
towards one or more residues within the active site. It therefore might be that not all 
diastereomers will be converted.  
 Hence, all four stereoisomers of 93 were docked, one by one, into the active site 
of SQTKS to visualize their orientation (Figure 30). This was achieved by starting with 
the already docked 93a model (chapter 2.6). This was used as a template to generate the 
other stereoisomers (6R,4S)-93b (Figure 30A blue), (6S,4R)-93c (Figure 30B pink) and 
(6R,4R)-93d (Figure 30C yellow). The coordinates of the corresponding substrates were 
directly switched in the raw PDB-files. Afterwards, the identical Grid Box parameters for 
the calculations in AutoDock Vina were used. Subsequently each substrate-protein 
complex was minimized with YASARA. These calculations resulted in four different 
models, one for each diastereomer (Figure 30A-C). It was observed that the different 
backbones of the diastereomers take up similar poses in the active site of the ER domain 
(Figure 30A-C).  
Furthermore, by comparing the diastereomers (6S, 4S) 93a (Grey) with (6S, 4R, 
Pink, 93c) and (6R, 4R, Yellow, 93d) in Figure 32, it is observed that the CH3-groups at 
the 4 and 6 position of the substrates always take up the same pose in the active site and 
interact with the same amino acids (Table 5). Only the stereoisomer (6R, 4S, 93b) differs 
from the other isomers (Figure 30B, table 5). The backbone of the chain overlaps very 
well with the natural stereoisomer 93a. However, the CH3-group at position 6 has a 
different orientation in the active site of the ER domain. The CH3-group is oriented 
downwards with respect to the residue F1941 in the active site. This differs in comparison 
to the other stereoisomers 93c and 93d, where the CH3-group is orientated towards the 
residue F1941 (Table 5).  
 The α/β-unsaturated carbonyls of the stereoisomers 93a, 93c and 93d respectively 
adopt an s-trans conformation, which places the reactive β-carbon 3.2, 3.0 and 3.5 Å away 
from the cofactor's reactive 4´-pro-R hydrogen (Figure 30). In contrast, the α/β-
unsaturated carbonyl of the stereoisomer 93b adopts an s-cis conformation, which places 
the reactive β-carbon 3.4 Å away from the cofactor's reactive 4´-pro-R hydrogen (Figure 
30). As previously determined, the s-cis conformation is also observed in docked 
substrates known to be reduced by the ER. 
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Hence, the 6R,4S-stereoisomer has some parameters, such as C-H distances and carbonyl 
position, but especially the s-cis conformation which could result in productive 
conversion of the substrate by the ER domain (chapter 2, section 2.6). Overall, this 
information suggests that diastereomer 93b can take up a productive conformation in the 
active site of WT SQTKS ER and 93b may therefore be the diastereomer shown 
previously to be reduced in vitro. The residue F1941 may be the critical residue, which 
prevents conversion of diastereomers 93a, 93c and 93d by the ER domain. F1941 appears 
to induce a steric control of the substrate through the interaction with the S-orientated 
CH3-group at the 6-position. Mutation of this residue could therefore lead to a different 
conformation of 93a in the active site, which should be similar to the specific isomer 93b 
and potentially allow the reduction reaction to occur. 
Table 5: Overview of the different validation parameters for the poses of the different substrates. 
 
C-H 
distance 
Si/Re-
Face 
Geometry - 
α/β-
unsaturated 
carbonyl 
Burgi-
Dunitz 
angle 
Dihedral 
angle 
Interaction 
with other 
amino acids 
 
3.2 Å 
Si-
Face 
s-trans 100° 72.3° 
I9138(M), 
F1941 (B), 
L2146 (B), 
I2147 (B), 
F2157 (B) 
 
3.4Å 
Re-
Face 
s-cis 76.9° 75.6° 
I9138(M), 
F1941 (M), 
L2146 (B), 
I2147 (B), 
F2157 (B) 
 
3.0 Å 
Si-
Face 
s-trans 76.9° 74.3° 
I9138(M), 
F1941 (B), 
L2164 (B), 
I2146 (B), 
F2157 (B) 
 
3.5 Å 
Si-
Face 
s-trans 106.4° 44.1° 
I9138(M), 
F1941 (B), 
L2146 (B), 
I2147 (B), 
F2157 (B) 
Legend:  (M) – Interaction with methyl group of the substrate 
  (B) – Interaction with the backbone of the substrate 
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Figure 30: Display of the active site of the ER domain with the cofactor in (green). In addition to the 
squalestatin tetraketide 93a (6S,4S) are displayed the other docked diastereomers (grey). Blue (6R, 4S) 
93b, pink (6S, 4R) 93c and in yellow (6R, 4R) 93d.  
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The following docking experiments (Figure 31) should investigate if mutation of residues 
I1938 and F1941 to alanine would influence the orientation of the squalestatin tetraketide-
pantetheine 93a to a similar orientation in the active site, like the stereoisomer 93b Figure 
31.  
 
3.4.2 In silico mutation experiments 
 
Therefore, residues I1938 and F1941 were individually changed in the holo-ER (ER 
domain with cofactor 11) in PyMOL from their original amino acid to alanine in silico. 
The reason for the change to alanine was to make sure that a significant size change was 
performed. Afterwards, the mutated holo-ER model was submitted to YASARA to refine 
the respective model. Overall, two mutated holo-ER domains were obtained (I1938A and 
F1941A). The volume increase of the active sites for the different mutated ER domains 
in silico were investigated. The pocket volume calculations for the WT and mutated ER 
domains were predicted through an open software program (3V web server, Table 6).156 
 Subsequently the tetraketide 93a was docked in the two mutated holo-ER 
domains. The molecular docking was performed with AutoDock Vina, without changing 
the GridBox parameters. Validation of the docking was done visually. The best-obtained 
substrate-protein complex was then minimized with YASARA. Through this in silico 
experiment two mutated holo-ER domains, with the docked tetraketide 93a were 
obtained.  
 In the I1938A mutant it was observed that the orientation of the CH3-groups at 
positions 4 and 6 of 93a, are unchanged in comparison to the original conformations 
(Figure 31A). The α/β-unsaturated carbonyl of the I1938A mutated domains all adopt s-
trans conformations (Table 6). However, in the F1941A mutant a new pose of 
squalestatin tetraketide-pantetheine 93a in the active pocket was observed (Figure 31B). 
In this pose the α/β-unsaturated carbonyl of the docked substrate 93a adopts an s-cis 
conformation. In addition, the CH3-group at position 6 possess a different orientation in 
the active site of the ER domain (Table 6). Hence, in the F1941A mutant the tetraketide 
93a can adopt a conformation which could result in productive reduction by the ER 
domain (chapter 2, section 2.6).  
 Overall, these in silico docking experiments suggest that the residue F1941 plays 
an important role in blocking the conversion of squalestatin tetraketide-pantetheine 93a. 
Based on the analysis it was hypothesised that the mutation F1941A could possibly result 
in conversion of 93a by the ER of SQTKS. 
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Figure 31: Active site of the ER domain. In green the Cofactor NADPH 11. Displayed are the docked 
substrates 87a of the wild type (white) compared to the docked substrates after the change of a specific 
amino acid in the active side (blue) 93a.  
 
Table 6: Overview of the different validation parameters for the poses of the different mutated ER domains 
with docked 93a. 
ER 
domain 
Volume of 
active site / 
Å3 
C-H 
distance 
Si/Re-
Face 
Interaction with 
other amino acids 
Geometry - α/β-
unsaturated 
carbonyl 
WT 1383 3.2 Å 
Si-
Face 
I1938(M), F1941 (B), 
L2164 (B), I2147 
(B), F2157 (B) 
s-trans 
I1938A 1480 3.0 Å 
Si-
Face 
A1938(M), F1941 
(B), L2164 (B), 
I2147 (B), F2157 (B) 
s-trans 
F1941A 1405 2.7 Å 
Re-
Face 
I1938(M), A1941 
(M), L2164 (B), 
I2147 (B), F2157 (B) 
s-cis 
Legend:  (M) – Interaction with methyl group of the substrate (B) – Interaction with 
the backbone of the substrate 
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3.5 In Silico Studies Concerning Conversion of Longer Substrates (ER domain 
SQTKS) 
 
So far, the docking experiments only investigated which possible residues could lead to 
an engineered enzyme which might convert squalestatin tetraketide-pantetheine 93a. This 
analysis identified residue F1941 (section 3.4) as potentially blocking conversion of this 
substrate. We were also interested in engineering the ER to accept longer chains – for 
example penta- or hexa-ketides. Some HR-PKS ER domains must be able to accept longer 
chains, for example the ER involved in the biosynthesis of the nonaketide fumonisin 110 
which must accept an octaketide. 
 Therefore, the structural features between SQTKS ER and FUM1, of the fumonsin 
109 biosynthesis, were compared (Figure 33). FUM1 is a HR-PKS and the product of this 
PKS is 109 (Figure 32).80,152 109 is a highly reduced molecule, with even a longer carbon 
backbone than SQTKS. Hence, it is a perfect structure to compare the ER of SQTKS, 
which reduces a shorter carbon chain. 
 
 
Figure 32: Structures of Fumosnin 109 and the product of FUM1 of the Fumonisin biosynthesis 110.80,152 
 
The domain boundaries of the FUM1 ER domain were determined using a conserved 
domain search (CD-Search). 139–142 Homology modeling was then performed in Swiss-
Model83,92,95,105 using the same CurF ER template (PDB 5dp2) as used for the modelling 
of the SQTKS ER domain. Validation of the model was done in the same way as the 
SQTKS ER (chapter 2, section 2.4). Overall, a structure model of the ER of FUM1 with 
a QMEAN value of -1.87 and an RMSD of 1.07 Å when compared to the template 
(section 2.1.1) was obtained after the modeling (Figure 33, red), which indicates, that the 
quality of the generated structure model was good. 91–95  
 The alignment of the ER domain of SQTKS (Figure 33, blue) and with the ER 
domain of FUM1 (Figure 33, red) is displayed in Figure 33. This shows that the backbone 
overlays very well, which is also displayed in the backbone RMSD 1.37 Å. In addition, 
the surfaces of the pockets are highlighted. 
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Figure 33: A, Model of the generated FUM1 ER; B, Alignment of the FUM1 ER (red) with the template CurF 
ER (blue, PDB 5dp2). 
 
The volume of the active site pockets were estimated using the open software program 
3V web server.156. The calculations predicted that the volume of the active site channel 
of the FUM1 ER (1456 Å3) is increased compared to the active site channel of the SQTKS 
ER (1383 Å3). An increase in pocket volume of the SQTKS ER active site channel could 
facilitate conversion of longer substrates.  
 The main differences between the two structures appears to be at position F2157 
which is a large hydrophobic residue located at the end of the active pocket the SQTKS 
ER (section 3.3). This is changed to a smaller residue (cysteine) in the FUM1 structure 
(sequence alignment, table 4). This seems to open up an extra space beyond the end of 
the SQTKS ER channel. 
 
Figure 34: Overlay of ER homology models: A, in red the pocket volumne of SQTKS Er with the residue 
F2157 at the end of the pocket displayed; B, in red the pocket volume of SQTKS ER, in blue pocket volume 
of FUM1 ER. In addition are the residues F2157 of the SQTKS and C2041 of FUM1 at the end of the pocket 
displyed. Interior surfaces of the proposed substrate binding pockets are shown. 
 
For the in silico mutagenesis of the SQTKS ER, residues L2146, I2147 and F2157 were 
changed in PyMOL to alanine or valine. The mutation to alanine was done to perform a 
significant size change. On the other hand, the mutation to valine was done to perform a 
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lesser size change which might cause less structural damage to the protein. In addition, 
two mutated ER domains were generated, which also included the mutation F1941A, 
since this might be able to convert the squalestatin tetraketide 93a. Afterwards, the 
mutated holo-ER model was submitted to YASARA to refine the respective model. 
Overall, eight mutated holo-ER domains were generated (Table 7). 
 The volume increase of the active side for the different mutated SQTKS ER 
domains in silico were investigated. The calculations for the WT and mutated ER domains 
were predicted through an open software program (3V web server, Table 7).156 It was 
observed that some mutations increased the pocket volume (e.g F2157A and 
F1941A/F2157A) while other changes decreased the pocket volume (e.g. I2147A and 
I2147A/F2157V, etc.) which was rather against expectations. Even so, these amino acids 
might have a critical effect on the general scaffold of the active pocket, effectively holding 
it open. Hence, through the mutagenesis to smaller residues the active site could partially 
collapse, which decreases in the volume of the active site.  
 The next step was to perform molecular docking in AutoDock Vina with the 
triketide 85 and pentaketide 94 in the same way as previously described (Chapter 2, 
section 2.1.2).110,147,148 The models were then refined by YASARA. The visualization of 
the different models after the refinement step was always in PyMOL. As an example, the 
complex between pentaketide substrate 94 in the F2157A mutated ER domain is shown 
in Figure 35. 
 
The residue F2157 is an ideal candidate for mutation experiments because it fulfils the 
following criteria. The residue F2157 is orientated in the end of the active site pocket 
(Figure 35). In addition, the residue is a large hydrophobic amino acid. Hence, possible 
interactions, such as hydrogen bond or other polar interactions could be neglected. 
Further, its mutation in the case of F2157A (61 Å3) and less-so in the case of F2157V (49 
Å3) leads to an apparent pocket volume increase (Table 7). From these docked substrate-
protein complexes parameters, such as C-H distances and carbonyl positions were 
determined (Table 7). Subsequently, these parameters were analyzed to characterize if 
the docked substrate-protein complex could result in productive conversion of the 
substrate by the ER domain. 
 If the orientation of the docked substrate 94 in the non-mutated ER domain (Figure 
35A) is compared to the docked substrate 94 in the mutated ER (Fig 35B) it could be 
observed that the mutation elongates the active site and gives the substrate 94 more space. 
The substrate 88 can fit deeper into the active site. This correlates with the volume 
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increase of the mutant compared to the WT (Table 7). Further, the thiolester and the β-
carbon are located closer to the nicotinamide moiety of the cofactor. In the WT ER 
domain, the distance between the β-carbon and the catalytic hydrogen of the nicotinamide 
is 4.7 Å. In the mutated ER domain, the distance is reduced to 3.2 Å. For good substrates 
(Triketide 85) an average distance of 3.4 Å was observed (Table 7). Hence, the distance 
in the mutated ER domain now corresponds better to a substrate-protein complex which 
could result in a productive conversion. 
 
Table 7: Overview of the different validation parameters for the poses of the triketide 85 and pentaketide 94 
in the different mutated ER domains in silico. Green figures show an increase in pocket volume; red figures 
show a decrease in pocket volume. 
ER 
domain 
Volume 
/ Å3 
C-H 
distance 
Triketide 
85 Å 
Si/Re- 
Face 
C-H 
distance 
Pentaketide 
94 Å 
Si/Re- 
Face 
Geometry 
Triketide 
85 
Geometry 
Pentaketide 
94 
ER 
(WT) 
1383 3.4 Re 4.7 Si s-cis s-cis 
L2146A 1367 3.5 Re 4.6 Si s-cis s-cis 
L2146V 1376 3.4 Re 4.7 Re s-cis s-cis 
I2147A 1307 3.0 Re 4.8 Re s-cis s-cis 
F2157A 1444 2.8 Re 3.2 Si s-cis s-cis 
L2146A/ 
I2147A 
1269 3.0 Re 4.7 Si s-cis s-cis 
I2147A/ 
F2157V 
1317 2.4 Re 4.0 Si s-cis s-cis 
F1941A/ 
F2157A 
1467 2.8 Re 3.3 Re s-cis s-cis 
F1941A/ 
I2147A/ 
F2157V 
1392 2.5 Re 3.9 Si s-cis s-cis 
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Furthermore, when comparing the distances for the triketide, it was observed that 
mutations of F2157A in combination with a mutation of I2147A greatly reduced the 
distance between the substrate and hydride. In combination with the volume decrease of 
the active pocket, the substrate might need less time to take up the correct pose; hence, 
shorter chains might bind more productively for reduction through the volume decrease 
of the active pocket. 
 
 
 
Figure 35: Active site of the SQTKS ER domain with a mesh surface. In green the Cofactor NADPH 11 and 
in white the modeled substrate 94. Modelled are: A, the wild type and B, the mutated ER (F2157A). 
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3.6 Conclusion  
 
To date, different approaches have been explored to generate new polyketides by 
engineering HR-PKS.82 Most efforts to reprogram HR-PKS have been focussed on swaps 
of domains or other parts of the specific PKS.82 A different approach is the modification 
of active sites to induce different substrate specificity or higher substrate variabilty.82 
Such an approach could preserve the structural and conformational properties of the 
complete PKS as well as the protein-protein interactions. Hence, only the intrinsic 
programming of the protein would be influenced, whereby the extrinsic programming 
would not be changed. However, no examples of HR-PKS engineered by site-directed 
mutagenesis are known in the literature to date.69,157–159 The major reason for this is that 
engineering of PKS requires detailed knowledge about structural arrangements, the active 
site and the entire PKS itself, and to-date this information has not been available because 
of the lack of structural data for HR-PKS domains.  
Hence, our first aim was to build and validate a model of the SQTKS ER domain 
which had a high enough quality to perform in silico studies. The validation of the 
generated model of the ER domain was done through different parameters (Chapter 2.4-
2.6). One of the validation parameters was the QMEAN score of Swiss-Model. The 
QMEAN score verified that it was possible to create a detailed model of the ER domain, 
which was suitable for docking studies. However, it should be always kept in mind, that 
homolog modelling is always based on the structure of another protein. It cannot reflect 
the exact structure of the modeled PKS or PKS domain, like crystal structures. Even so, 
a crystal structure also does not display the exact reality, because it is only a snapshot of 
a certain state of the enzyme. However, enzymes are flexible structures and can have 
different conformations. Hence, the protein or the active site could have different states 
or structural conformations, which could not be displayed in the crystal structure. 
However, in addition to the good QMEAN value, the generated model showed that after 
different minimization steps no change in its overall structure could be observed. This 
indicates that the ER domain, or rather the active pocket of the ER domain, is not highly 
flexible. We also docked the cofactor NADPH 11 and showed that this docks in a sensible 
way, preserving known protein-cofactor contacts and exposing the correct 4'-pro-R 
hydrogen known to be transferred during the reduction reaction. In addition, the template 
that was chosen for the modeling had a high resolution of 1.0 Å. Taking everything 
together: the QMEAN, the inflexible structure and the good template resolution, it can be 
concluded that the generated ER model of the SQTKS is good enough for further study. 
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Afterwards, docking studies were performed with AutoDock Vina, which indicated 
possible residues for a rational engineering approach. Two aims were reconsidered doing 
the docking studies. The mutations should lead to a conversion of longer substrates, which 
should be achieved through an elongation of the pocket or/and an increase of the pocket 
volume. In addition, the mutations should lead to a conversion of the squalestatin 
tetraketide-pantetheine 93a.  
 The docking experiments of the ER domain SQTKS then indicated different 
amino acids for a mutagenesis approach. The amino acids, which were selected for the 
mutagenesis included F1941, for a conversion of the squalestatin tetraketide pantetheine 
93a. In addition, mutation of the amino acid F2157 in different combinations should allow 
longer chains to bind productively for reduction. Further, a decrease of the active pocket 
was observed, if certain amino acids were mutated, for example I2147Aor L2146A. 
Hence, these amino acids might have a critical influence on the scaffold of the active 
pocket. Even so, shorter chains might bind more productively for reduction through the 
volume decrease of the active pocket. 
 Overall, the models were suitable to rationally design different potential site-
directed mutants in silico. These amino acids shall be subsequently mutated and 
investigated in the in-vitro studies. 
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4 In Vitro Engineering of the SQTKS ER domain 
 
4.1  Introduction 
 
In chapters 2 and 3 (section 2.4-2.6 and 3.2-3.5) fundamental in silico studies for the in 
vitro engineering of the ER domain from SQTKS were performed. This included the 
creation of a homology model of the ER domain. The quality of the model was verified 
by various means (chapters 2 and 3). The modelled ER domain was then used as a scaffold 
for further in silico studies, which included, amongst other things, different docking 
experiments which indicated possible residues for a rational engineering approach 
(Chapter 3, section 3.3 and 3.4). Two aims were considered during the docking studies. 
The mutations should lead to a conversion of longer substrates, which should be achieved 
through an elongation of the pocket and/or an increase of the pocket volume. In addition, 
the mutations should lead to a conversion of the squalestatin tetraketide-pantetheine 93a. 
For this, hydrophobic residues were considered. The selected residues were mutated in-
silico, and the results of further docking studies suggested different effects on the 
behavior of substrates in the active site. For example, the mutation F1941A indicated that 
the tetraketide intermediate 93a could become a substrate. For the F2591A mutation, the 
docking studies suggested that the active site is expanded and that pentaketide substrates 
could possibly be reduced. 
 
4.2 Aim of the Project 
 
The aim of this project was to rationally engineer HR-PKS by introducing a small number 
of residue changes, rather than the much larger domain-swap which have been previously 
reported. Previously, the isolated ER domain of SQTKS was analyzed in silico and a plan 
for the rational redesign was proposed (chapter. 3, section 3.2-5). This shall be applied 
on the ER domain of SQTKS and effects of the mutagenesis verified through suitable in 
vitro assays. For this purpose, amino acids that had been selected in the docking 
experiments (Chapter 3, section 3.2-5), were mutated in the ER domain through 
molecular biological methods. Afterwards, the ER protein was expressed in E. coli BL21 
and purified. In parallel, a substrate library for the ER domain, varying in chain length 
and methylation pattern, was synthesized. These natural and unnatural substrates were 
used together with the expressed enzymes in either UV-assays or LCMS-assays to 
characterize the influence of the introduced mutations on the enzyme activity.  
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Overall, the experiments should reveal if it is possible to rationally engineer an HR-
PKS or a sub-domain. In addition, the effect of the different mutations on the intrinsic 
programming of the ER domain will be investigated, especially how the chemical 
selectivity and kinetics of the different substrates are influenced by the changes 
introduced into the ER domain.  
 
4.3 Substrate Synthesis 
 
For the kinetic assays, as in the previous studies, acyl pantetheines were used (Figure 
36).58,137 Since ACP-bound substrates are hard to produce and to analyse, acyl-ACP 
mimics such as SNACS and pantetheines are widely used. 58,137 Previous work in the Cox 
group had shown that pantetheine-bound substrates have higher specificity (kcat/KM) than 
SNACS for the SQTKS ER domain.137 Additionally, compared to SNAC substrates 
pantetheines are more water soluble which is especially important for longer (and hence 
more hydrophobic) acyl groups.  
 
Figure 36: Structure of Coenzyme A 
 
In addition, the synthesis of the library was focused on specific substrates to compare 
them to previous studies.137 In the previous studies, the main goal was to test a wide range 
of different pantetheine substrates, from diketides to pentaketides. The library which was 
generated here also includes natural substrates (77 and 86) and unnatural substrates, e.g. 
with modifications in the chain length (e.g. 94, 95 and 112); the methylation pattern (e.g. 
90 and 91) and the methylation position. Additionally, a long chain substrate (112) and a 
cinnamic acid derivative (113, Figure 37) were included. 
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Figure 37: Synthesized pantetheine substrates for the enzyme assays. 
 
Wittig reactions were mostly used to create the α-methylated or non-methylated 
unsaturated carboxylic acids (Scheme 23). Therefore, different aldehydes were used as 
the starting materials for elongation by Wittig salts. Both starting materials were stirred 
in CH2Cl2 at RT for 15-18 hours and the olefinic products were purified by flash column 
chromatography. The resulting esters were cleaved by potassium hydroxide in a mixture 
of ethanol and water (5:1). After three hours under reflux, the mixture was acidified and 
extracted to isolate the final acids (Scheme 23). 
 
 
Scheme 23: Synthesis route of α-methylated and non-methylated carboxylic acids. 
 
In parallel, protected pantetheine 121 was produced following a previously published 
protocol (Scheme 24).160 The pantothenic acid hemi-calcium salt 119 was protected in 
acetone at 25 °C in the presence of p-toluene sulfonic acid to give the acetal 120. After 
that, a coupling with CDI and cysteamine in THF was used to generate the pantetheine 
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dimethyl ketal 112 (Scheme 23). This was then coupled to the previously synthesised 
carboxylic acids through an EDCI/DMAP coupling protocol (Scheme 24) to give 122a-
j. The yields of 80-84% for the reaction are similar to the previous studies.58,137 
 
Scheme 24: Synthesis route of pantetheine substrates 
 
The introduced protection group changes the solubility of the pantetheine so that 122a-j 
are soluble in CH2Cl2, EtOAc and MeCN. In the previous studies, the deprotection of 
122a-j was done with aqueous TFA.137 However, this method causes partial cleavage of 
the thiolester, which results in lower yields. A new deprotection method of the pantetheine 
dimethyl ketal substrates 122a-j was therefore established using InCl3 catalysis in 
aqueous CH3CN which avoided the thiolester hydrolysis problem (Scheme 24). In total, 
eleven pantetheine substrates 77-95 and 112-113 were successfully synthesized which 
varied in the methylation pattern, chain length and the methylation position (Figure 37). 
The exception is substrate 93a, which was produced by hydrolysis from squalestatin S1 
itself followed by coupling to 121 and standard deprotection.137 All compounds were fully 
characterised by NMR and MS. This substrate library of diketides, triketides, tetraketides 
and pentaketides, heptaketides and cycloketides completes the chemical part of the 
project. 
 
4.4 Site Directed Mutagenesis 
 
Besides synthesizing a suitable substrate library, the desired mutations (chapter 3.2-3.5) 
should be inserted into the isolated ER domain. Then the mutated proteins should be 
expressed in a suitable host and be purified using Ni-affinity chromatography.  
 The docking studies in the in silico analysis (chapter 3.2-3.5) revealed that the 
mutation of the amino acids, which are displayed in table 8, had an effect on either the 
volume of the active site of the ER domain or the orientation of the substrates in its 
binding pocket. The SQTKS ER domain has been previously cloned into an expression 
vector (pET28a) from an E. coli optimized sequence.161 This vector was used as the 
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template for the introduction of mutations. For the insertion of mutations into proteins 
there are different methods known in literature.162 In this project, a site directed 
mutagenesis approach, was chosen. The template DNA of the isolated ER was contained 
on a pET28a (+) vector with an N-terminal his6-tag. This vector was available in the 
stocks of the Cox group and was generated by a previous PhD-student in the lab (David 
Ivison).163 The vector also contains a kanamycin resistance gene and the expression was 
regulated through the Lac-Operon (Figure 38). 
Different, non-overlapping, short DNA primers were generated which contained 
the required mutations on the sense primer and no mutations on the antisense primer. 
These synthetic primers were complementary to the template DNA around the mutation 
site, so they can hybridize with the DNA sequence of the gene of interest (Scheme 25). 
Afterwards, the primer was extended using a high-fidelity DNA polymerase Q5, which 
amplifies the rest of the plasmid and results in a blunt ended PCR product (Scheme 25).162 
The amplified DNA sequence then contains the mutated gene. After the elongation, the 
amplified PCR product was closed through a ligation step using Quick Ligation™ Kit 
(New England Biolabs, Inc.) to ligate the blunt ends. Next, the template DNA was 
removed through a DpnI digestion which digests methylated template DNA, but not 
unmethylated PCR products (Scheme 25). The plasmid was then transformed into E.coli 
TOP10. Clones were selected and isolated and miniprep-DNA was prepared. Finally, 
mutants were selected by DNA sequencing to check if they contained the desired 
mutation.  
 
Scheme 25: Schematic overview over the individual steps of the site directed mutagenesis protocol 162 
 
Overall, nine theoretical mutations should be inserted into the ER domain (table 8). 
However, only five mutated ER proteins, which contained one or more mutated amino 
acids, were successfully generated. For the mutation I2147A, it was not even possible to 
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insert the desired mutation into the vector (Table 8). All sequencing results were negative 
and showed that the base pair sequence in the specific ER domain was not changed. 
Variation of the conditions for the site directed mutagenesis did not lead to an insertion 
in the vector (Table 8). The variation included different primers and annealing 
temperatures. There are different possible explanations for the failed creation of these 
mutants. The most obvious reason could be the high GC content in this area of the DNA. 
This could prevent the correct binding of the primer to the DNA. Another reason could 
be that the primer still contained secondary structures such as hairpins and even higher 
temperatures could not unfold these secondary structures. 
Table 8: Overview of generated mutants of the ER domain from SQTKS: Red text indicates mutants 
predicted to reduce active site volume; green text indicates mutations predicted to increase active site 
volume. 
 Mutated 
amino acids 
Stability of the 
mutated ER protein 
Predicted effect on the substrate or 
the ER domain (chapter 3.2-3.5) 
1 F1941A Stable 
Orientation  
Volume 1405 Å3 
2 L2146A Unstable protein Volume 1367 Å3 
3 L2146V Unstable protein Volume 1376 Å3 
4 I2147A 
Mutation was not 
possible 
Volume 1375 Å3 
5 F2157A Stable Volume 1444 Å3 
6 
L2146A 
I2147A 
Unstable protein Volume 1269 Å3 
7 
I2147A 
F2157V 
Stable Volume 1317 Å3 
8 
F1941A 
F2157A 
Stable 
Orientation 
Volume 1467 Å3 
9 
F1941A 
I2147A 
F2157V 
Stable 
Orientation 
Volume 1392 Å3 
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Figure 38: Plasmid in pET28a (+) _ER and ER* (mutated) which was transformed into in E. coli. 
 
Successful transformation of the plasmid into E. coli was confirmed by colony PCR, 
amplifying a ca. 1kb DNA fragment specific of the ER domain. An example is shown in 
Figure 39 for the F1941A mutant ER. The expression of the wild type and mutated ER 
protein was achieved by heterologous expression of the plasmid in E. coli BL21. 
 
 
Figure 39: Colony PCR of different E. coli transformants (1-10) for the F1941A mutant ER. Marker (M) 
displayed on the left, on the right different analyzed colonies numbered from 1-10. A band corresponding to 
the desired ER DNA fragment was observed at 1.2 kb 
 
Positive strains were grown in a starter culture of 2TY-medium. This starter culture was 
incubated overnight. The next day 100 ml batches of 2TY- media were inoculated with 
the starter culture. The protein production was induced with iso-propyl 
β-D-1-thiogalactopyranoside (IPTG, 0.1 mM) at an OD600 of 0.6 and at 16 °C. After 
incubation overnight, the media was centrifuged and the pellet was collected. The cells 
were lysed through sonification and the purification of the ER protein was accomplished 
through Ni-affinity chromatography. The separation of the ER protein from the lysate 
was done using the N-terminal His6-tag with the corresponding columns (Chapter 8, 
section 8.4). Overall, five of the seven mutated proteins and the wild type ER were 
successfully expressed without any contaminations (Figure 40).  
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Figure 40: SDS Gel of the different expressed mutated ER domains. M = Marker, WT = Wild type, F1941A-
F2157A/V = different mutants. Selected marker bands are highlighted in kDa. 
 
Expression of the mutated ER domains (L2146A, L2146V and L2146A/I2147A) resulted 
in no production of protein or rather no corresponding band could be observed in the 
SDS-PAGE Gel. As an example, the SDS-PAGE gel of the different obtained fractions 
after the Nickel and Superdex-columns for the ER mutant (L2146A / I2147A) is shown 
in Figure 41. In the lysate fraction there is still a band to the corresponding mass of 32 
kDa. However, this band cannot be observed in the following fractions of the next 
purification steps. Possibilities are that the protein was misfolded because of the mutation 
of the amino acid residues. If the protein would then form inclusions bodies, these could 
not be observed in the lysate fraction, but only in the pellet. Hence, the inclusion bodies 
are insoluble. Another possible reason could be that the N-terminal His6-tag was 
destroyed or impaired; hence, the protein cannot interact any more with the Nickel-
column for the purification. Even so, most likely is that the protein got unstable or 
misfolded through the mutation of L2146. Miss folding could result in quicker 
degradation by the proteasome or decomposition into smaller parts. This would explain 
the degradation over time and the reason that no protein was observed in the later fractions 
of the purifications steps. 
 
 
Figure 41: SDS gel of the different fraction of the Nickel-column and size exclusion column chromatography 
for the purification of the ER(L2146A / I2147A). M: Marker: not purified Lysate, Fr1-F3: Fractions from the 
Nickel column. All: united Nickel-columns; Fr4-F5: Fractions from the exclusion column chromatography; 
All.2 united Fractions from the exclusion column chromatography. 
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The instability or mis-folding of the single mutated protein and double mutated proteins 
could be explained through residue L2146 and its significant influence on protein 
stability. The sequence alignment for the ER domain from SQTKS (Chapter 3, section 
3.3, table 6) showed that this position was highly conserved in the ER domain from 
different organisms. It is also conserved in mouse and pig FAS ER. In combination with 
the observation that every mutant in which L2146 was mutated, no protein could be 
purified, it could be assumed that this amino acid plays a role in the overall structure 
stability of the ER domain. These observations also correspond with the observed 
collapse of the substrate-binding pocket when L2146 and I2147 were mutated in silico 
(Chapter 3, section 3.5). Hence, if this amino acid, which is buried deep into the protein 
active site, is changed to something smaller, the change influences an overall critical 
change in the protein structure and it is degraded or broken down.  
 Overall, five stable mutant proteins were expressed in E. coli BL21 to successfully 
give soluble protein. These were then used for the enzymatic investigations. In the 
enzyme assays, the substrate range and the kinetic conversion of wild type ER domain 
and mutated ER domains will be compared. 
 
4.5 In Vitro Enzymatic Investigation of the ER domain 
 
Kinetic investigations of the wild type ER and the mutated ER domains were performed 
with the synthesized substrates to compare the influence of the mutation on the kinetic 
values, in particular the specificity constant (kcat/KM). Since VMAX = kcat·[enzyme 
concentration] it is usually more convenient to measure VMAX at constant enzyme 
concentration and the specificity constant becomes VMAX / KM. The specificity constant is 
a measure of how efficiently an enzyme converts substrates into products. A comparison 
of specificity constants can be used as a measure of the preference of an enzyme for 
different substrates (i.e. its substrate specificity). The higher the specificity constant, the 
more the enzyme “prefers” that substrate.164 
 
Scheme 26: Reaction of the enoyl reductase in the presence of NADPH 
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A continuous assay was performed. This method is based on the absorption wavelength 
of the NADPH cofactor (340 nm). The ER oxidizes NADPH during the conversion of the 
substrate and therefore its concentration decreases over time in the assay, which is 
measured continuously at 340 nm (Scheme 26). Since the reaction stoichiometry is 1:1, 
the change in NADPH concentration equals the change in substrate (or product) 
concentration. For standardisation, the enzyme and cofactor concentration are the same 
in every performed assay. Only the substrate concentration varies in the assays. 
 
Figure 42: Absorption curves (green, blue, red) of the three replicates of tigloyl pantetheine 77 at 1 mM. 
 
This data is then used to obtain the rate of reaction for different substrates at different 
concentrations using Microsoft EXCEL (Figure 42). The rate data were plotted with the 
software Curve Expert (Figure 43).58,137 In that way, it was possible to generate a 
nonlinear fit of initial rates in triplicate by direct fit to the Michaelis Menten equation 
(Figure 43).164 In all cases, these data are of good quality, as shown with the simplest 
substrate tigloyl pantetheine 77 (Figure 42 and 43). With this, it was possible to determine 
the Michaelis Menten constant KM and the rate of reaction VMAX. Further calculations gave 
the value of VMax/KM (the specificity constant, Figure 44), which is the gradient of the 
curve at [S] = 0. 
 
Figure 43: Michaelis Menten curve with tigloyl 77 with the mutant F2571A as a general example, substrate 
concentration against the rate. 
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Before the specifity constants of the mutants could be compared with the constants of the 
wild type (WT) ER, first the specifity constants of the WT ER had to be measured. In 
addition, the obtained values should be compared to the specifity constant of the WT ER 
for the specific substrate from the previously published studies137 (Figure 44). This should 
ensure that the assays are reproducible and show whether a deviation in the values for the 
respective kinetics could be observed. The results are shown in a logarithmic scale in 
Figure 44. It can be observed that the experiments were reproducible and lead to nearly 
the same specifity constants. Hence, the mutated proteins can be measured and compared 
with the wild type, without apprehension that deviations occur through the measurement. 
 
 
Figure 44: Graphical display of the specificity constants of the comparison of the wild type in this study 
(blue) and the wild type of the previous study137(red). Logarithmical scale. 
 
The results of the different mutant ER proteins and the wild type ER protein for the 
different measured substrates are shown in Figure 45. Statistical evaluations were done 
with Sigma Plot (version 12.00). The paired t-test was performed to test the influence of 
the mutation on the specifity constant for the different substrates compared to the WT 
ER.165 Where a significant change in the specifity constant was observed after the 
mutation this is marked by an asterisk (* p < 0.05) in Figure 45. The test for normality 
was performed by the Shapiro-Wilk test. Groups with (n = 3) were examined.166 
Overall, all substrates were converted by the mutant isolated ER domains. The 
exceptions are the heptaketide 112 and the cinnamic acid derivative 113, which were not 
converted by either the WT or any mutant enzymes under the conditions tested.  
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Table 9: Overview over the specifity constants for the ER wild type and the different ER mutants. R = 
CH2CH2NHCOCH2CH2COCOHC(CH2)2CHOH 
Substrate WT F1941A F2157A 
F1941A / 
F2157A 
I2147A / 
F2157V 
F1941A / 
I2147A / 
F2157V 
 Specificity constant (Vmax/km) [M
-1s-1] 
 
 
11.2 
 
22.7 
 
257.8 
 
107.6 
 
128.0 
 
483.5 
 
 
730.2 
 
179.0 
 
679.1 
 
101.0 
 
5483.0 
 
403.5 
 
 
27.6 
 
28.7 
 
415.3 
 
197.3 
 
226.0 
 
669.5 
 
 
128.6 
 
48.5 
 
342.6 
 
115.3 
 
577.0 
 
397.2 
 
 
22.0 
 
21.4 
 
380.0 
 
123.4 
 
518.0 
 
621.6 
 
 
12.7 
 
12.9 
 
176.6 
 
90.5 
 
487.5 
 
430.4 
 
 
0.0 
 
19.7 
 
0.0 
 
23.4 
 
0.0 
 
20.1 
 
 
20.7 
 
32.7 
 
126.7 
 
137.3 
 
13.5 
 
25.5 
 
 
23.6 
 
28.4 
 
76.4 
 
157.4 
 
17.2 
 
27.5 
 
 
0.0 
 
0.0 
 
0.0 
 
0.0 
 
0.0 
 
0.0 
 
 
0.0 
 
0.0 
 
0.0 
 
0.0 
 
0.0 
 
0.0 
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Figure 45: Specifity constants for the different tested substrate s displayed for the wild type ER and the different mutated ER domains. The paired t-test was performed 
as investigation to compare the wild type to the mutated enzymes. The asterisk marks a significant change in the specifity constant. 
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Figure 45 shows the various specifity constants for the investigated substrate analog with 
the WT ER and the various mutant ER domains. Different effects of the mutations on the 
specificity constants of the respective substrate analogs can be observed. 
 Starting with diketide tigloyl substrate 77, all introduced mutations increase the 
specifity constant significantly. The smallest increase in the specificity constant is 
observed in the F1941A mutation. The triple-mutant F1941A/I2147A/F2157V shows the 
greatest effect (Figure 45). This is probably because the α/β-unsaturated carbonyl of the 
substrate has the shortest distance to the reactive β-carbon from the cofactor's reactive 4´-
pro-R hydrogen compared of all mutants (chapter 3.5).  
 For the triketide substrate 83, each of the mutated ERs F1941A, 
F1941A/F2157A, and I2147A/F2157V show a significant influence on the specificity 
constant (Figure 45). This substrate 83 is contrary to the other substrates. Hence, 
increasing the volume of the product decreases the specifity constant, but decreasing the 
pocket volume increases the specifity constant for this substrate.  
 The mutations also influence the specificity constants for the triketide 
methylation isomer 84. The only exception is the F1941A mutation, which shows no 
significant difference for the specificity constant compared to the specificity constant of 
the wild type. In general, F1941 makes, no significant effect for most substrates, but it 
allows the turnover of 93a as designed (Chapter 3.4). The highest specificity constant is 
again for the triply mutated ER F1941A / I2147A / F2157V. 
 In the case of the dimethylated triketide substrate 86, it could be observed that 
the F1941A and F1941A/F2157A mutations have no significant difference in their 
specificity constants compared to the wild type ER. The F1941A/I2147A/F2157V mutant 
shows a significantly greater specificity constant than the wild type ER (Figure 45). 
 Interestingly, there is no significant difference between the double mutated ER 
I2147A/F2157V and the triple mutated ER F1941A/I2147A/F2157V for substrate 86. 
The only difference between these mutants was the additional mutation of the amino acid 
F1941. This mutation, however, seems to lose its influence on the specificity constant 
with increasing methylation and chain length (Figure 45). The same observation can be 
made for the non-methylated tetraketide substrate 90 and the monomethylated tetraketide 
91. The specifity constant for the mutated ERs I2147A/F2157V and 
F1941A/I2147A/F2157V is still significantly different compared to the WT ER (Figure 
45). Likewise, the specificity constants of the mutated ERs F2157A and F1941A/F2157A 
are increased for the tetraketide substrates 90 and 91 compared to the wild type (Figure 
45). This is in agreement with the docking experiments (Chapter 3.5), where the in silico 
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analysis indicated that mutation of the position F2157 would lead to an elongation of the 
active pocket. Hence, a more productive pose for the conversion of longer substrates 
could be obtained or rather an increased specifity constant. This effect could be observed 
both for the mutation to valine at this position and for the mutation to alanine. 
 The observations for the substrate 93a are interesting. In every ER containing 
the F1941A mutation, a conversion of the substrate could be observed (Figure 45). The 
conversion was not observed in the WT ER. This confirms the hypothesis that this 
position in the ER domain of SQTKS prevents conversion of 93a, as suggested by the in-
silico experiments (chapter 3.4). This appears to be controlled via an interaction of the γ-
CH3 group of the substrate with the amino acid F1941 (Chapter 3.4). However, after the 
mutation of this position to alanine, additional volume is generated in the active pocket 
at this position, hence, the CH3 group has more space in the pocket. From this, follows 
that the substrate may be able to adopt a productive s-cis reaction conformation in relation 
to the cofactor as the docking experiments suggested (Chapter 3.4). Hence, it seems not 
important if an additional volume increase, like in the mutated ER 
F1941A/I2147A/F2157V or an additional elongation of the pocket, like in the mutated 
ER F1941A/F2157A was additionally integrated into the ER domain. Only the mutation 
of the residue F1941 determines whether the substrate 93a can be converted or not. 
 The last two substrates 94 and 95, which were observed in the UV assay, only 
with the mutated ERs F2157A and F1941A/F2157A, are significantly different in their 
specifity constants compared to the wild type ER (Figure 45). In this case, it was observed 
that the elongation of the active pocket, through the mutation F2157A has a significant 
influence on the conversion of substrates with longer chain length (Figure 45). This agrees 
with the in silico calculations (Chapter 3.5). Further, significant differences could be 
observed, depending on whether the position was mutated to alanine or valine. Finally, 
conversion of the heptaketide substrate 112 and the aromatic 113 could not be observed 
in the UV-assay in either the wt or any mutant. 
 Table 10 shows the change in the specificity constant of the mutated ER 
domains for the specific substrate compared to the wt activity, as a logarithmic 
representation.  
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Table 10: Change in the specifity constant of the mutated ER domains, as a logarithmic representation. 
Color code: 0.0 (grey) no change, -0.4--0.0 (light blue) small decrease, -1.9- -0.5 (blue) decrease, 0.1-04. 
(green) nearly no increase, 0.5-.9 (orange) small increase, 1.0-1.5 (red) increase, 1.6< (dark red) strong 
increase in the specifity constant. R = CH2CH2NHCOCH2CH2COCOHC(CH2)2CHOH 
Mutant/ 
Substrate 
F1941A F2157A 
F1941A / 
F2157A 
I2147A / 
F2157V 
F1941A / 
I2147A / 
F2157V 
 Log ([kcat/Km)]mutant/[kcat/Km)]wt) 
 
0.3 1.3 0.9 1.0 1.6 
 
-0.6 -0.1 -0.9 0.9 -0.3 
 
0.0 1.2 0.9 0.9 1.4 
 
-0.4 0.4 0.0 0.7 0.5 
 
0.0 1.2 0.7 1.4 1.5 
 
0.0 1.2 0.9 1.6 1.6 
 
1.7 0.0 1.7 0.0 1.7 
 
-0.8 0.8 0.8 -0.2 0.1 
 
0.1 0.5 0.8 -0.1 0.1 
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For the F1941A mutant, the specifity constant for di- 77, tetra- 90, 91 and pentaketide 95 
were nearly the same as in the WT ER. Only for the substrate 93a was an increase of the 
specifity constant observed (Table 10). The only exception are both methylated triketides 
83 and 86 at the α-position. For these substrates, a decrease of the specifity constant was 
observed. This decrease was also observed by every other mutant with a mutation of the 
position F1941 (e.g. F1941A/F2157A and F1941A/I2147A/F2571A). Especially was this 
observed for the tetraketide 83. Otherwise, every mutant with the inserted mutation 
F1941A converted the squalestatin tetraketide 93a, which agrees with the in silico studies 
(chapter 3.4). 
 Further, the ER mutants F2157A and F1941A/F2157A show a general increase of 
the specifity constants for the di-, tri-, tetra- and pentaketides (Table 10). The exception 
again were the tetraketides, which are methylated at the α-position. However, these 
mutants are the only mutated ER domains, which showed an increase of the specifity 
constants for longer substrates, such as pentaketides. Through the increase and elongation 
of the active pocket, which agrees with the in silico studies (chapter 3.5). 
 On the other hand, the mutated ER domains I2147A/F2157V and 
F1941A/I2147A/F2157V showed especially for substrates with shorter chain length (e.g. 
di-, tri- and tetraketides) an increase of the specifity constant (Table 10). This increase is 
particularly pronounced in contrast to the other mutated ER domains by the triketide, 
which has a methylation at the α- and γ- position and tetraketides, and even stronger than 
for the mutations F2157A and F1941A/F2157A (Table 10). The exception again were the 
mutated ER domain F1941A/I2147A/F2157V, where the specifity constant for the 
trikeitde 83 was decreased.  
 Overall, the in-vitro assay showed three different effects. First, mutated ER 
domains with the residue F1941A were able to convert the squalestatin tetraketide 93a. 
Second, mutated ER domains with a mutation of F2157A possess a higher specifity 
constant for longer substrates (eg. pentakeitdes). Third, mutated ER domains of the 
residue I2157A, F2157V and in addition with or without F1941A possess a higher 
specifity constant for shorter substrates (e.g. di-, tri- and tetraketides). 
 
 
 
 
 
 
 89 
4.5.1 Stereoselectivity of the Mutated ER Domains  
 
The stereoselectivity of the isolated SQTKS-ER domain was investigated in previous 
work by Doug Roberts (Cox Group) using Parker`s in situ NMR method for the 
determination of chirality of α-substituted carboxylic acids.161 The in vitro assays showed 
that the isolated ER domain is not able to control the stereochemistry of the α-position. 
Hence, all substrates were produced as racemates, although transfer of hydride to the beta 
position is highly stereoselective suggesting that the substrate takes up a single defined 
conformation in the active site. 
The ER product 2-methylpantetheine 124 was used to investigate the 
stereoselectivity. By hydrolysing and adding 1R,2R-1,2-diphenylethylenediamine 126 to 
the NMR sample, resonances for the methyl groups of 125 are shifted enantioselectively, 
meaning the R and S enantiomers of 125 are resolved in the 1H NMR spectrum. 
 
 
Scheme 27: Investigation of C2-position stereochemistry. 
 
Results are shown in Figure 46 for products obtained from the F1941A and F2157A ER 
mutants. The 1H NMR spectrum of racemic 2-methylbutyric acid (-)-126 was measured 
first (Figure 46, control) at 500 MHz in CDCl3. In the presence of 1R,2R-1,2-
diphenylethylenediamine 126 the methyl resonances of 125 are shifted to higher field and 
the R and S enantiomers are resolved.58,161 Next, the isolated mutated ER domains were 
incubated with tigloyl pantethine 77 and an excess of NADPH for 24 h. The reaction was 
acidified to pH 3, extracted directly into CDCl3 and two equivalents of 1R,2R-1,2-
diphenyl-ethylenediamine 126 was added before examination by 1H NMR. In mutants, 
the 1H NMR indicated that racemic product was again produced (Figure 46, shown for 
ER F1914A and F2157A). 
In the isolated mutated ER domains, it is also not possible to predict the 
stereochemistry of the α-position. The test substrate 125 was produced as racemate. This 
is similar to the results found in previous studies 58,137 and shows that the inserted 
mutations did not have any influence on the outcome of the stereochemistry for the 
isolated ER domain. However further studies by Hao Yao with a multi domain construct, 
which included the ER domain, build up from the DH to KR showed that bigger pieces 
control the stereochemistry at the α-position better (data not shown).56 It was suggested, 
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that for the optimal control of the stereochemistry in the ER domain all interactions with 
the other domains from the SQTKS have to be present. Hence, the extrinsic programming 
was in the isolated ER domain, through the missing interactions with the other domains, 
not given.  
 
 
 
Figure 46: Examples of two 1H NMR spectra of substrate 125 with 126 and the control (-)-2-methylbutanoic 
acid. 
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4.6 Discussion and Outlook 
 
The aim of this project was to rationally engineer HR-PKS by introducing a small number 
of residue changes, rather than the much larger domain-swaps previously used to change 
the selectivity of these types of HR-PKS domains. Therefore, one or more amino acid 
mutations were inserted into the ER mono domain simultaneously. This combination of 
different mutations should reveal if the combination of two or more mutations at the same 
time would have further effects on the intrinsic programming of the ER mono domain. 
 First, the results show that it is possible to generate functional structures of 
SQTKS ER even with a lack of structural data for complete HR-PKS. The validation of 
the generated SQTKS model showed further that a variety of features of the model 
correlate well with measured parameters. These include the stereochemistry of the 
reduction reaction and the conformation and distance of the substrate towards to the 
cofactor for example.  
 Subsequently it was possible to generate and investigate nine mutations in silico. 
However, it was possible to produce only seven mutated ER expression vectors. These 
contained one or more mutated amino acids. From the seven generated mutant vectors, 
five proteins were successfully expressed and purified and were stable enough for in vitro 
study.  
 Through the subsequent in-vitro assays, it was then possible to show three 
different aspects concerning the in-silico calculations. First, that it was possible to achieve 
the aim to rationally engineer the ER domain to convert the SQTKS product 93a, which 
cannot be reduced by the WT enzyme. In addition, rational engineering of the ER domains 
enabled the significantly faster conversion of substrates with longer chains (e.g. 
pentaketides). Hence, a higher specificity constant for the specific substrates was 
observed. Third, to engineer ER domains, which possess a higher specifity constant for 
shorter substrates (e.g. di-, tri- and tetraketides) which is even dependent on the 
methylation pattern of the substrate. 
 
The results confirm the hypothesis that the position F1941 in the ER domain of SQTKS 
prevents conversion of SQTKS, as suggested by the in-silico experiments (Chapter 3.4). 
This is probably mediated via an interaction of the 4S-CH3 group of the substrate with the 
amino acid F1941. After the mutation of this position to alanine, additional volume was 
generated in the active pocket at this position, hence, the CH3 group has more space in 
the pocket. From this, follows that the substrate may be able to adopt a conformation in 
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relation to the cofactor 11, in which it can be converted, as the docking experiments 
(Chapter 3.4) suggest. 
 No similar studies on the ER domain from HR-PKS are known in the literature 
until today. Hence, generally it cannot be assumed that this position has a similar 
influence in other ER domains of HR-PKS. 
 Furthermore, it could be shown that it is possible to change specific amino acids, 
which play a key role for the chemical selectivity of individual HR-PKS catalytic domains 
and to change the substrate selectivity of SQTKS. Hence, it could be shown that a 
decrease in the volume, like mutation I2147A/F2157V, and/or an elongation and volume 
increase, like mutants F2157A and F1941A/I2147A/F2157V, of the active pocket have 
significant effects on the specificity constants for various substrates, hence how fast the 
enzyme converts them. This agrees with the prediction of the in silico studies (Chapter 
3.5). 
 Interestingly, both volume expansion and volume reduction have a similar effect 
for shorter substrates (e.g, di-, tri, and tetraketide). The results showed that the specifity 
constant is mostly increased. Hence, the substrates are converted faster. This may be 
because due to the increase in volume, the substrates can more quickly accommodate their 
correct poses in the active pocket. In contrast, for the mutant I2147A/F2157V in 
particular, the volume loss has been observed. However, the scaffold break could lead to 
the substrates already being forced to come into their active pockets in their correct 
conformation. Which then also increase the specifity constant in comparison to the WT.  
 Even so, the results in this study give a further insight into the intrinsic 
programming of this domain, especially in the SQTKS. Nevertheless, it could be assumed 
that in other HR-PKS the chemical selectivity is also in a large part regulated through 
specific amino acids. Overall, it was possible to change the substrate specificity of the ER 
domain in vitro and therefore to change the intrinsic programming of the ER domain of 
SQTKS.  
 
Concerning the reaction stereochemistry, it could be shown, that isolated mutant ER 
domains are not able to control the stereochemistry of the α-position. Hence, the test 
substrate 77 was reduced to give a racemate. This agrees with the previous studies of the 
wild type ER, where the isolated ER domain of SQTKS was also not able to control the 
correct stereochimstry.56,58 
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Overall, it was possible for the first time to rationally re-design an ER domain of an 
iterative HR-PKS. Thereby, it could be shown that the mutations significantly influenced 
the kinetic conversion, hence the specificity constant for different substrates, were altered 
in different ways. Mostly a faster conversion of the substrates was observed. Furthermore, 
it was possible to create mutants which accept the natural product of the SQTKS, as a 
substrate, and thus enhance the substrate variability. This, may further extend the β-
processing reactions. The results expand the few examples of other ER engineering 
approaches, which are found in literature so far. In these studies, only the stereochemistry 
of the ER domains was targeted. For example, the ER domain in DEBS module 4 was 
targeted the conserved “HAAAGGVGMA” NADPH binding motif for engineering.70 
Resulting in a different stereochemistry in the product. 
 Hypothetically, it should also be possible to decrease the active site of the ER 
domain further. For example, if the residue F2157 is mutated to some more voluminous 
amino acids, like tryptophan or arginine in combination with the mutation of the residue 
I2147. Overall, these studies lead to a better understanding of the programming of PKS 
modules and PKS in general. As a long-term aim, it might be possible to rationally 
engineer PKS in such a way that new metabolites could be generated. If one or more PKS 
modules could be rationally engineered like the ER domain it would be possible to get 
access to a multitude of different compounds. For example, the ER domain in a PKS 
could be engineered together with the C-MeT or KR domain. This would give access to 
new metabolites, which differ in the chain length, methylation pattern and/ or in the 
saturation of the chain.  
 Finally, the work described here shows that modelling of HR-PKS domains can 
be a successful method for the generation of hypotheses for the rational re-engineering of 
HR-PKS. Despite the fact that many assumptions had to be made, the fact that many 
levels of modelling were applied and the fact that there are almost no existing X-ray or 
NMR structures of HR-PKS catalytic domains, it proved possible to generate and validate 
models of the SQTKS ER which could be successfully used to both understand and re-
engineer the substrate specificity of the domain. This gives significant hope that similar 
methods could be applied to other HR-PKS with the aim of rationally engineering other 
aspects of their programming, without the loss of fidelity and titer which often 
accompanies engineering based on domain swaps. 
 In the future, the generated mutants should be inserted into the whole SQTKS 
gene on a suitable expression vector. However, mutations will not be able to be inserted 
via SDM, as it was done in this study, on such a large gene (ca 8 Kb) or vector containing 
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the whole PKS gene without the risk of introducing unwanted mutations. The reason for 
this is, that the SDM is limited to small vectors.167,168 However, the mutations could be 
inserted by using homologous recombination in the yeast Saccharomyces cerevisiae. This 
method is used with a DNA fragment which is homologous to the digest a plasmid via 
30-50 bp homology at both ends.169,170 Subsequently, generated mutants should be 
expressed in the producing strain Aspergillus orazye NSAR1 as host. The grown culture 
should be extracted and the investigated by LCMS for the production of new compounds.  
 This would first show that the successfully mutated ER domains in-vitro could 
be applied to the in vivo level. This could give information if the extrinsic programming 
would be disturbed by the mutations. Alternatively, new derivatives of SQTKS could be 
generated dependent on the specific mutant. If this would be successful not only the ER 
domain could be mutated in-vivo, but combined with the KR and C-MeT domain, as these 
are still domains that underlie programming in PKS. Such further studies would then give 
the understanding about not only intrinsic but also extrinsic programming of PKS. In 
addition, the possibilities for the rational engineering of PKS and thus the access to new 
metabolites can be investigated. 
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5 Modelling Studies of the TENS C-MeT and KR Domains  
 
5.1 Introduction 
 
Discovering the mechanism of the programming of HR-PKS is an important goal in order 
to rationally engineer these systems. This aim is difficult to achieve if no structural data 
for partial or complete fungal HR-PKS are available. However, since fungal HR-PKS are 
closely related to mammalian FAS at the peptide sequence level, for which structures are 
known, mammalian FAS can be used as an overall template for the structure organisation 
of HR-PKS.79 In addition, other modules from known PKS can be used as a template for 
homology modelling of single or multiple domains. 
 The TENS and DMBS polyketide synthases are 86% identical, but produce 
polyketides which differ in chain-length and methylation pattern.76 The products of TENS 
and DMBS are pretenellin A 73 and predesmethylbassianin A 74, respectively (Figure 
47). In previous experiments, a part of the programming mechanism in the HR-PKS 
TENS was successfully elucidated (Chapter 1, section 1.17).48,75–77 It was shown that the 
exchange of entire functional domains between closely related (but differently 
programmed) HR-PKS, in this case TENS and DMBS, could lead to the creation of new 
polyketides (Chapter 1, section 1.16 and 1.17).76  
 In parallel to this study, Dr. Katherine Willams, Dr. Xiao-Long Yang, Dr. Steffen 
Friedrich and Sen Yin (members of the Cox group) performed a large number of swaps 
of smaller domain fragments on the KR and C-MeT domains of TENS.79 In total, the C-
MeT, ΨKR and KR domains of TENS were divided into 14 sub-fragments and 31 
different swaps were achieved with the corresponding fragments of DMBS. Additionally, 
a swap using a KR domain from the PKS involved in the biosynthesis of the heptaketide 
militarinone C 127 (MILS) was created. Most of these experiments resulted in functional 
hybrid PKS systems and examination of the structures of the respective products led to 
conclusions about the mechanism of programming within such PKS and the prospects for 
their rational engineering.79  
 
 
Figure 47: Structure of pretenellin 73, predesmethlybassianin A 74 and premiliatrone 127. 
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5.2 Aims of the Project 
 
The aim of this project was, in parallel to the molecular-biological work, to provide the 
structural-biological foundations and analysis for the domain swaps between TENS, 
DMBS and MILS. Subsequently, this analysis should provide the knowledge for future 
targeted mutations and rational enzyme engineering. There is no existing structural 
information for complete fungal iterative HR-PKS such as TENS. However, in order to 
understand the programming mechanism and to perform rational site-directed 
mutagenesis of these systems, it will be necessary to obtain useful structural models of 
the specific catalytic domains.  
 As mentioned before, there are significant homologies between mFAS and HR-
PKS (Chapter 1, section 1.5, 1.10 and 1.11) which suggest that mFAS is an appropriate 
model for fungal HR-PKS. While the mFAS structure gives good information regarding 
the likely quaternary arrangement and interactions of the HR-PKS catalytic domains, it 
was obtained at relatively low resolution (3.2 Å). The mFAS ΨC-MeT domain, in 
particular, is represented poorly, and significant deletions and sequence variations from 
the PKS C-MeT domains are indicated by the sequence alignment (Chapter 10.2). In order 
to obtain better quality information, the individual domains of TENS should be modelled. 
 The enzyme domains that are of interest for engineering, and thus modelling, are 
the C-MeT and KR domain of TENS, because changes in these domains resulted in 
changes in programming.76 Information on individual domains would be useful to identify 
the active site and thus to investigate the influence of the domain-swap on the active site, 
but it would also be useful to generate multi-domain models, which could help to show 
how the domains interact. The modelling performed in this work should be done by 
homology modelling. As mentioned before, a critical requirement for homology 
modelling is the availability of a suitable template. Hence, the first steps will be to find 
appropriate templates for the individual domains and use these for homology modelling. 
After the modeling, the quality of the modelled structure will be validated. With the 
generated protein model in hand, the substrate-binding pocket should be identified. 
Afterwards, different docking studies with AutoDock Vina will be performed and 
validated considering the known stereochemistry of the KR and C-MeT domains using 
substrates and cofactors (Chapter 1.11).  
 The best generated homology models will then be used as the basis for the design 
of a chimeric model structure using TENS and the mammalian FAS (Chapter 6). The 
respective chimeric model and its modelled single domains will then serve as the basis 
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for further in silico experiments considering the domain swap experiments (Chapter 6). 
Subsequently, this knowledge will be used to apply a first rational engineering approach 
to the β-processing domains of TENS. 
 
5.3 In Silico Studies of the TENS C-MeT Domain 
 
The first step was to model the TENS C-MeT domain. A search in the available structural 
databases revealed that, to date, no crystal of any HR-PKS is available, although PKS C-
MeT domains from fungal Type I NR-PKS and bacterial modular systems are known, as 
well as from bacterial Type II iterative PKS systems. Therefore, homology modeling was 
performed using the open free software Swiss-Model.91–95 However, prior to homology 
modelling the domain boundaries of the C-MeT domain of TENS had to be determined. 
Therefore, two methods were used: first, the protein sequence of TENS was examined 
with BLAST (basic local alignment search tool)138 and subsequently a conserved domain 
search (CD-Search) was performed to determine the domain boundaries.139–142 Second, a 
multiple alignment between mFAS, TENS, DMBS and MILS was performed (Chapter 
10.2). The CD-search determined the likely boundaries for the C-MeT domain from 
H1347 to Q1669 and the multiple alignment confirmed these boundaries through the 
inclusion of known C-MeT sequence motifs. Swiss-Model selected 50 possible templates 
based on the selected sequence. These included templates such as the CurJ C-MeT, (Type 
I modular, PDB 5thy),171 citrinin polyketide synthase (Type I NR-PKS, PDB 5mpt),172 
AprA C-methyl transferase (Type I modular NR-PKS, PDB 6d6y),173 DisA (Type I 
modular, PDB 6cca)174 and protein RdmB (Type II, PDB 1xds).175  
 For the selection as template the GMQE score (section 2.1.1), sequence identity 
and the resolution of the templates were considered and compared. Among the proposed 
templates, the SeMet-substituted CurJ C-MeT from the curacin A biosynthetic pathway 
(PDB 5thy) was selected as the template. The CurJ PKS module is an unusual 
cyanobacterial PKS, which contains all functional β-processing domains (Chapter 1, 
section 1.8).145 The CurJ and TENS C-MeT domains have the highest sequence identity 
(35%) of all templates (Table 11). Furthermore, the CurJ template had the highest GMQE 
score (0.65) of all possible templates. In addition, the CurJ C-MeT has a good X-Ray 
resolution of 2.1 Å. Overall, modelling created a structural model of the C-MeT of TENS 
with a QMEAN value of -3.16, which indicates, that the quality of the generated structural 
model was good enough to proceed.91–95  
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Table 11: Sequence alignment of the C-MeT sequence of TENS with the CurJ C-MeT template sequence 
(5thy); yellow, conserved residues; green, catalytic residues; blue, conserved cofactor motif. * His-Glu diad. 
Template  (1)     MSSGVDLGTENLYFQSNALPPDFLLDPVEVSQQLAPSLTELVTLLDNARTSE  
TENS C-MeT  (1347) HNLSEAIERVSLFYVRQLMGELSTADRRQANWYHTRMLAAFDYHLAKVHEET  
 
Template  (53)   IGTQLEELSVDYIVQGLLQMGWSYQPTESFDLDAAAQCLGVVPTQVRLFERL 
TENS C-MeT  (1399) HLHLRPEWLADDWAVIQTIDEAYPDAVELQMLHAVGQNVADV---------- 
 
Template  (105)  LLQILAEVGILQSNQQQWQVQKTAQKVNPSKQSQSLLSQYPDEAATLTLLER 
TENS C-MeT  (----) ---------------------------------------------------- 
 
Template  (157)  CASQLSGVLRGEIDPVQLVFPQGDLTTATQLYKDYAVAKVMNTIVEKVIMKA 
TENS C-MeT  (1441) --------------IRGKKHLLEVLRVDNLLDRLYTEDKGMHMANLFLANAL 
 
Template  (209)  MEKLPPSRGIRLLEIGAGTGGTTSYILPHLNPNQTEYIFTDIGALFTSKAQE  
TENS C-MeT  (1479) EEITFKFPRCKILEIGAGTGATTWAALSAIGEAFDTYTYTDLSVGFFENAVE 
 
                                                                                                                                           * 
Template  (261)  KFQDYRF-LGYQTLDIEVDPSSQGFESHRYDVIIAANVLHATTSLKQTLSHV 
TENS C-MeT  (1531) RFSAFRHRMVFRALDIEKDPASQSFDLNSYDIIIATNVLHATRNLGVTLGNV 
 
                                                                             * 
Template  (313)  RQLLAPGGILVLYEATTRSRWVDLIFGLLEGWWKFTDYELRPDYPLLNREQW 
TENS C-MeT  (1583) RALLKPGGYLLLNEKTGPESLRATFNFGGLEGWWLAEEKERQLSPLMSPDGW 
 
Template  (385)  KKVLSETGFTQVVTLPEVEGMAEALSQQTVIVAQAAS  
TENS C-MeT  (1635) DAQLQKASFSGVDHI--VHDVQEDQQDKQQNSMIMSQ  
 
In the next step, the homology model and the template were aligned in PyMOL (Fig. 48). 
The alignment resulted in Cα- RMSD value of 0.62 Å, which is very good. However, it 
was observed that a structural α-helix, which is present in the template, is missing in the 
TENS C-MeT model (Figure 48, marked with the grey box). In the model of TENS, this 
region is replaced by a short loop region. This correlates with the sequence alignment 
between the C-Met sequence of TENS and CurJ in which a gap in the alignment was 
observed at this position (Table 11). 
 Skiba et. al. crystalized the template CurJ as a single protein and determined its 
domain organization and active site architecture.171 The missing α-helix is a structural 
feature without any obvious catalytic relevance; hence, on the one hand, this structural 
part could have degenerated in TENS over time, or it might represent a special structural 
feature of the C-MeT domain of CurJ. The second hypothesis is corroborated by the fact 
that a similar gap can also be found in the sequence alignment between the SQTKS C-
MeT and CurJ (data not shown). However, the missing helix should not influence the 
overall quality of the generated model as the remaining structural features are similar. 
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Figure 48: Alignment of the TENS C-MeT model (blue) with the template CurJ (PDB 5thy, red) displayed in 
PyMOL. A, Front view; B, Back view. 
 
Skiba et. al. further identified four main structural features for the CurJ C-MeT domain. 
Here, these structural features were assigned to the generated model of the C-MeT domain 
of TENS. The lid is displayed in grey (H1347-K1444, Fig. 49). The core structure is 
displayed in cyan (M1467-K1597 and W1634-Q1669, Fig. 49). Displayed in orange, 
above the core (T1598-G1633), is the so-called core insertion. The final structural feature 
in green is the junction (K1445-G1466), located between the lid and the core insertion. 
Overall, the QMEAN of the model together with the conserved structural features indicate 
that the generated model of the C-MeT from TENS should be suitable for further in silico 
studies.  
 
Some catalytic residues were already determined amongst others by Skiba et. al. and 
Kishimoto et. al., such as the His-Glu dyad which is invariant in all bacterial and fungal 
PKS C-MeTs.171,176 In TENS C-MeT these are residues H1570 and E1596 (Table 11). It 
is proposed that the imidazole acts as a catalytic base to deprotonate the substrate α-
carbon and form a carbanion nucleophile to facilitate the C-MeT reaction.171,176,177 
Kishimoto et. al. and Skiba et. al. showed through site directed mutagenesis experiments 
in vitro that the histidine and glutamic acid of the dyad are required for catalysis by the 
respective C-MeT since in the mutants a significant loss of activity was observed.171,174 
The distance of the imidazole to the α-carbon can vary between 2.5 - 4 Å.171,176 This 
catalysis may be enhanced by the surrounding hydrophobic environment (Template 5thz: 
Ala281, Phe318, Trp 324 and Pro337).171 Additionally, they described a conserved 
tyrosine between 3 - 4 Å away from the substrate which may facilitate the methyl transfer 
through carbonyl polarization via hydrogen bonding.171,176 The mutation of this residue 
in vitro by Kishimoto et. al. and Skiba et. al. showed that in the respective mutants also 
a significant loss of activity was observed. 
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These conserved residues were also found in the model of TENS near the active site 
pocket (Figure 51) as well as in the sequence alignment of TENS with the template (Table 
11). For example the catalytic Tyr1461, the conserved His-Glu dyad His1570 and 
Glu1596 (Chapter 10.2). 
 
 
Figure 49: Model of the C-MeT domain of TENS. Shown are the structural features. Cyan, core structure; 
orange, core insertion; green, junction; grey, lid.  
 
5.4 Integration of the cofactor into the modelled C-MeT domain of TENS 
 
The generated model did not have the S-adenosyl methione (SAM) 35 integrated in the 
active site. Hence, the next step was to integrate the cofactor into the active site of the 
model (Figure 52), before further docking studies were performed. Therefore, a PDB file 
of SAM 35 was created. Then, SAM 35 was aligned with the cofactor S-adenosyl 
homocysteine (SAH) 39 from the CurJ  template in PyMOL and subsequently the cofactor 
SAM 35 was integrated into the model.146,147 Then, the generated C-MeT domain plus 
cofactor was minimized in YASARA to refine the protein-cofactor interaction (section 
2.1.3, Fig. 16).135 Finally, the extracted and refined cofactor 35 was aligned with the SAH 
cofactor 39 from the template (Fig. 50). The alignment resulted in an RMSD of 1.4 Å.  
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Fig. 50: Alignment of the cofactor from the TENS C-MeT model (green) with the cofactor from the CurJ 
(blue) 
 
The cofactors overlay reasonably well. Hence, the cofactor in the C-MeT TENS model 
was in the correct position and orientation and is located in the active pocket. Different 
SAM cofactor binding motifs, depending on the class of SAM binding protein, are known 
in the literature. These were determined by sequence analysis and crystal structure 
analysis.178 
 In the TENS C-MeT, which is a Rossman fold like protein, the expected 
interaction of a conserved binding motif “EIGAGTG” with the SAM cofactor 35 was 
observed.171,176 Overall, the QMEAN and the structural features of the model generated 
for the TENS C-MeT indicated that the quality should be suitable for further in silico 
studies. 
 
 
Figure 51: Model of the C-MeT domain of TENS with mesh surface. The cofactor SAM 35 is displayed in 
green. Red, catalytic residues Y1461, H1570, and E1596; blue, cofactor binding “EIGAGT” motif. 
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The proposed stereochemical course for the methylation of 128 catalyzed by the isolated 
C-MeT domain is shown in Scheme 28 (Chapter 1.11).57 The hypothesized mechanism is 
through an SN2 attack by a nucleophilic carbon of 129 on the electrophilic SAM 35 methyl 
group, resulting in the C-2 methylated 2R-3-oxo diketide 130a. Important is also that the 
SN2 mechanism follows a transition state in which a carbon under nucleophilic attack is 
penta-coordinated and approximately sp2 hybridised. The nucleophile attacks the carbon 
at 180° to the sulfonium leaving group, since this provides the best overlap between the 
nucleophile's lone pair and the C–X σ* antibonding orbital. 
 
Scheme 28: Proposed stereochemical course of the methylation catalyzed by the isolated TENS C-MeT 
domain 
 
5.5 Development of Ligand and Cofactor Docked Models for the C-MeT of TENS 
 
To this point, it was possible to generate a structural model of the C-MeT domain of 
TENS and to integrate the cofactor SAM 35 or SAH 39 (data not shown) into the model. 
By means of the cofactor positioning, it was then possible to roughly estimate the position 
of the active pocket in PyMOL. Next, different ligands, such as the substrate 3-
oxobutanoyl pantetheine 128, the intermediate enol 3-hydroxybut-2-enolate pantetheine 
129 and the proposed product of the methylation 2R-methyl-3-oxobutanoylpantetheine 
130a, and the other possible product stereoisomer 2S-methyl-3-oxobutanoylpantetheine 
130b, were docked into the estimated active pocket. In the case of the methylated products 
both enantiomers were docked. It was initially assumed that the C-MeT domain produces 
the 2R product 130a which is the substrate for the later KR domain. However, it is also 
possible that the 2S product 130b is produced and later a racemisation occurs before the 
KR domain reaction takes place.  
 Overall, the docking experiments were done in order to further define the shape 
and catalytic residues of the C-MeT domain (Figure 52-54).  
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For the docking, as achieved for the ER domain of SQTKS (Chapter 2.6), PDB data files 
of the different ligands were generated. The PDB files included three-dimensional 
parameters of the substrate 3-oxobutanoyl pantetheine 128, the intermediate enol 129 and 
the products 2R/S-methyl-3-oxobutanoylpantetheine 130a and 130b. The subsequent 
docking steps and quality validations follow the same standard operational protocol as 
used during the ER docking (Chapter 2.6) and will be not be described here in detail 
again. The best docking results, which were obtained with optimization of different 
parameters of the Grid Box in the docking procedure with AutoDock Vina (Chapter 
2.1.2), are shown in Chapter 5.5.1-3. 
 
5.5.1 Docked Model of the Ketone Substrate 128 and Cofactor SAM 35 
 
The first docked ligand is the substrate 3-oxo-diketide 128 and is shown in Figure 52. The 
conserved catalytic residues H1570, E1596 and Y1461, which are important for the 
catalytic deprotonation of the hydrogen of the substrate at the α-carbon, are displayed in 
brown.  
Figure 52: Active site of the C-MeT domain. In white the Cofactor SAM 35 and. In blue the possible substrate 
3-oxobutanoylpantetheine 128. In brown the catalytic residues which are involved deprotonation of the 
substrate. R = CH2CH2NHCOCH2CH2COCOHC(CH2)2CHOH 
 
The imidazole, which is proposed to act as a catalytic base, is placed 3.1 Å away from the 
hydrogen of the α-carbon in the model (Figure 52). This distance correlates to the 
observations known in literature (Section 5.3). In addition, the catalytic tyrosine Y1461 
which is proposed to stabilize the ketone at the β-carbon is placed 4.0 Å away from the 
residue. Hence, this residue is also in the observed range known from the literature 
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(Section 5.3). The observed interaction geometries for these catalytic residues differ 
sligthly from the optimal angles known from literature. For example, for the hydrogen 
bonding of Y1461 to the β-ketone an angle of 120 ° was expected (Figure 52).179 In the 
model 107° was observed. The same applies to the catalytic His-Glu dyad. The angle for 
deprotonation between the His1570 and Glu1596 represents also not the optimum angle 
of 180° but is 168°. The biggest difference in the interaction geometries in the model was 
observed for the angle between the histidine α-hydrogen-carbon deprotonation. A value 
of 116° was observed in the model, whereas an optimal angle of 180° was expected. 
 
5.5.2 Docked Model of the Enol Intermediate 129 and Cofactor SAM 35 
 
Next, the enol 129 was docked into the model, to observe the intermediate state of the 
methylation reaction in silico (Figure 53). The nucleophilic carbon of 129 is 3.5 Å away 
from the electrophilic SAM 35 methyl group (Figure 53). This may be a good distance 
for the conversion of 129, but the substrate is not in a position which would allow an SN2 
attack to take place. The reason for this is that the optimal angle of the nucleophilic attack 
in the SN2 reaction would be 180°. However, in the docked model was an angle of 160° 
was observed. Furthermore, the angle of the attack between the plane and SAM 35 should 
be 90°, but only an angle of 54 ° was observed. Hence, in this case, the geometry of the 
substrate would have to change significantly with respect to the cofactor.  
 Overall, comparing the geometry of the transition state of the SN2 reaction with 
the geometry of the substrate 129 after the docking in the active site of C-MeT TENS 
reveals that it is not satisfactory (Figure 53). 
 
Figure 53: Active site of the C-MeT domain. In white the Cofactor SAM 35 and. In blue the possible 
intermediate enol 3-hydroxybut-2-enolatepanthetine 129. R = 
CH2CH2NHCOCH2CH2COCOHC(CH2)2CHOH 
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5.5.3 Docked Model of the Products 130a, 130b and Cofactor SAH 39 
 
Finally, the two possible stereoisomer products 130a and 130b were docked in the SAH-
bound model (Figure 54). If the position between the methylated α-carbon and the SAH 
39 was observed, could be determined that the position did not match the expected 
position at the time after the nucleophilic attack. The expected angle right after the SN2 
attack would be 180°. Even so, an angle of 142°, which is even lower than for the enol 
substrate 129, but still in a suitable range, was observed after the docking. However, the 
distance of the α-carbon to the cofactor SAH with 3.4 Å was in the expected distance 
range. 
 The observation that the expected product does not fit well in the active pocket 
after the docking could also be found even more for the 2S-stereoisomer of the methylated 
product 130b (Figure 54B). The reason for is, that the 2S-methylated product possesses 
an orientation in the active site, which places the CH3-group of the α-carbon away from 
the SAH cofactor. This orientation of the CH3 group after methylation is more than 
illogical, since, on the one hand, the angle for the SN2 reaction is not right and on the 
other hand, the cofactor would then have to be oriented differently to the product. Hence, 
it is unlikely that this stereoisomer is produced. 
 
Figure. 54: Active site of the C-MeT domain. In white the Cofactor SAM 35 and SAH 39. In blue the model 
biosynthesis products 2R-methyl-3-oxobutanolypantetheine 130a and 2S-methyl-3-oxobutanolypantetheine 
130b. R = CH2CH2NHCOCH2CH2COCOHC(CH2)2CHOH 
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Furthermore, all docking or co-crystallization experiments in literature were only done 
with the corresponding substrate of the C-MeT domain and not with its corresponding 
product.171,176 Therefore, it is difficult accurately to determine if there were expected 
product-domain or product-cofactor interactions at this point. 
 
5.5-4 Overall assessment of C-MeT modelling and docking 
 
It was observed that in each individual docking experiment the distances and geometries 
for the different ligands were in a suitable parameter range (Fig. 52-54). However, the 
position of the respective ligand, especially the panthetine part are inconsistent if 
compared between each other (Figure 55). It would be expected that the pantetheine, and 
–S-CO- of the thiolester would be very similarly positioned in each case. However, as 
Figure 55 shows, this was not observed. 
 The template structure contains the reacted cofactor SAH 39 (the product of the 
reaction) and does not contain a polyketide substrate or mimic. It may therefore represent 
a “closed” conformation of the C-MeT and may thus be unsuitable for modelling ligands.  
 In conclusion, it was not possible to generate high confidence representative 
ligand-cofactor docked models for the TENS C-MeT. However, the boundaries of the 
active site were roughly identified. Hence, with regards to domain swap experiments 
described in Chapter 6 it is possible to observe if a domain-swap probably resulted in an 
amino acid in the active site being changed or not. Even so, there is no possibility to 
accurately predict how any specific swap is going to effect the active pocket. In this 
respect, our results differ from the ER studies (Chapter 2-3), where docked substrates did 
appear to take up realistic conformations. 
 
 
Figure. 55: Overlay of the different docked ligands. White, possible substrate 3-oxobutanoylpantetheine 
128; blue, possible intermediate enol 3-hydroxybut-2-enolatepanthetine 129, yellow, products 2R-methyl-3-
oxobutanolypantetheine 130a. 
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5.6  In Silico Studies of the TENS KR Domain  
 
The second domain that was modelled was the KR domain of TENS. However, prior to 
homology modelling the domain boundaries of the KR domain of TENS had to be 
determined. Therefore, the sequence of TENS was analysed with BLAST.138 
Subsequently a conserved domain search (CD-Search) was performed to determine the 
domain boundaries.139–142 In addition to the CD-Search a multiple alignment between 
mFAS, TENS, DMBS and MILS was performed in order to find the boundaries of the 
KR domain of TENS. The search determined the likely boundaries for the KR domain 
from L2203 to A2484.  
 Homology modelling was performed for TENS KR using Swiss-Model.83,92,95,105 
Swiss-Model selected 50 possible templates including the polyketide extender module 2 
from the spinosin modular PKS (PDB 3slk),180 AmphB from the amphotericin modular 
PKS (PDB 3mjs),181 Plm1 from the phoslactomycin modular PKS (PDB 4hxy),182 mFAS 
(PDB 2vz9)25 and polyketide synthase PksJ (PDB 4jq1).183 For the selection as a template 
the GMQE score (section 2.1.1), sequence identity and the resolution of the templates 
were considered and compared. A low GMQE score, identity or resolution of the 
template, would result in a low quality model. From the available templates, the AmphB 
2 KR , which is an A-type KR domain (Chapter 1.11.1) from the amphotericin modular 
polyketide synthase (PDB 3mjs) was selected.181 A part of the biosynthesis of 
Amphotericin B 134 is displayed in Figure 56. 
 
 
Figure 56: Part of the biosynthesis of Amphotericin B 134. 
 
 
 108 
The AmphB module 2 KR was chosen for various reasons: on the one hand, the structures 
have a sequence identity of 27 % to the TENS KR, which is low, but amongst the best 
available (Table 12). Further, the template had a high GMQE score of 0.55. The crucial 
reason was the quality of its X-Ray resolution. The other templates were obtained at low 
X-ray resolutions between 1.7 - 3.8 Å. In contrast, the X-Ray resolution of AmphB KR 
is 1.4 Å. In addition, the PKS AmphB might be closer to the actual structure of TENS 
compared to mFAS KR. However, a disadvantage of AmphB is that its modules are 
missing other domains such as an ER domain (Fig. 56). The other disadvantage might be 
that SQTKS and mFAS KR produces the 2R,3R product 63a. However, the AmphB KR2 
produces the 2R,3S product 63b, hence the stereochemistry might be not correct. Still, 
considering all parameters, AmphB is the best choice as a template. Hence, this should 
not influence the overall structure of the KR domain since three-dimensional protein 
structures are evolutionarily conserved. Hence, if the sequence similarity is high, the 3D 
structure should be also similar. Moreover, AmphB and KR TENS have the highest 
sequence similarity (Chapter 2.1).  
 Overall, a structural model of the KR of TENS with a QMEAN (section 2.1.1) 
value of -2.82 was obtained after the modeling, which indicates that the quality of the 
generated structure was good enough to proceed.91–95  
 
Table 12: Sequence alignment of the KR sequence of TENS with the template sequence of 3mjs and a B1 
type KR (2Z5L). Light blue, conserved residues for NADPH cofactor binding; green, conserved residues of 
the catalytical triad; red, B1 specific LDD (VDD) motif, yellow, conserved residues. 
Template    (1)    ---SVLVTGGTGGIGGRVARRLAEQGAAHLVLTSRGADAPPGGAELRAELEQ 
TENS KR     (2204) FDRTYLMVGAAGGLGTSICRWMVRNGARHVVVTSRNPKADP---EMLNEAER 
B1 KR (2Z5L) (1)   ---TVLITGGMGAIGRRLARRLAAEGAERLVLTSRRGPEAPGAAELAEELRG 
 
Template  (50)   LGVRVTIAACDAADREALAALLAELPEDA-PLTAVFHSAGVAHDDAPVADLT 
TENS KR (2251) YGAAVQVVPMDACSKDSVQTVVDMIRATMPPIAGVCNAAMVLRDKL-FLDMN 
B1 KR (2Z5L)(50)    HGCEVVHAACDVAERDALAALVTAYPPNA-----VFHTAGILDDAVIDTLSP 
 
Template  (101)  LGQLDALMRAKLTAARHLHELTADLDLDAFVLFSSGAAVFGSGGQPGYAAAN 
TENS KR (2303) VDHMKDVLGPKMQGTEHLDSIFAQEPLDFFVLLSSSAAILNNTGQSNYHCAN 
B1 KR (2Z5L)(97)   ESFETVRGAKVCGAELLHQLTADIKGLDAFVLFSSVTGTWGNAGQGAYAAAN 
 
Template  (153)  AYLDALAEHRRSLGLTASSVAWGTWGEVGMATDPEVHDRLVRQGVLAMEPEH 
TENS KR (2358) LYMDSLVTNRRSRGLAASIIHVGHVCDTGYVARLVDDTKVQMSLGTTTVMSV 
B1 KR (2Z5L)(149)   AALDALAERRRAAGLPATSVAWGLWGGGGMAAGAGEESLSRRGLRAMDPDAA 
 
Template  (205)  ALGALDQMLENDDTA------------------------------------- 
TENS KR  (2410) SETDVHHAFAEAVRGGQPDSRSGSHNIIMGIEPPTKPLDLTKRKPVWISDPR 
B1 KR (2Z5L)(201)  VDALLGAMRGRNDVCV------------------------------------ 
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In the next step, the homology model and the template were aligned in PyMOL (Fig. 57). 
The alignment resulted in Cα- RMSD value of 0.1 Å, which is very good, for the blue 
(catalytic) part of the structure. 
 
 
Figure 57: Alignment of the TENS KR model (red) with the template AmphB (PDB 3mjs, blue, catalytic part; 
grey, structural part) displayed in PyMOL. A, Front view; B, Back view. 
 
Zheng et. al. crystalized the template AmphB as a single protein and determined its 
domain organization and active site architecture.181 The overall structure of AmpB KR2 
consists of two subdomains, each a variation of the Rossmann fold. The N-terminal 203 
residues constitute the structural subdomain, which lacks the traditional SDR cofactor 
binding site and catalytic residues and apparently serves a structural role in stabilizing the 
catalytic subdomain.181 The generated TENS KR domain only aligns with the catalytic 
C-terminal 210 residues of the AmphB KR domain (Figure 57). The structural subdomain 
is a particularity of the PKS which lack ER domains. The modelled TENS KR should not 
include this structural feature (Figure 57). In systems with an ER (such as TENS, mFAS 
and “full modules” of modular PKS), the ER is inserted into the KR between the structural 
and catalytic domains. In these systems the “structural” part is then known as ΨKR and 
the catalytic part is known as KR. 
 
However, the domain organization described Zeng et al. for the KR domain is very crude. 
The generated model of the whole TENS KR corresponds to the catalytic subdomain of 
AmphB KR. Hence, a simple color scheme was used in Figure 58. The α-helices are 
colored in red, β-sheets in yellow and loops in green. 
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Figure 58: Model of the KR domain of TENS. In red the α-helices; in yellow the β-sheets and loops in green. 
 
In addition, Keatinge-Clay et al. and  Caffrey and Reid et al. observed that the conserved 
catalytic residues of KR domains cooperate as observed in other short-chain 
dehydrogenase/reductase (SDR) enzymes.60,62,184 Furthermore, through this knowledge 
and subsequent experiments the catalytic residues were identified: Reid and co-workers 
showed through structural analyses and SDM experiments that Tyr159, Ser146, and 
Lys163 form the catalytic triad in the tropinone KR II domain from Datura stramonium 
(PDB 2AE2).60 It was hypothesised that the tyrosine is activated by the neighbouring 
lysine to donate its proton to the carbonyl oxygen during hydride transfer.60,183,62 
 This conserved catalytic triad was also found in the model of TENS KR near the 
active site pocket (Figure 61). For example, the catalytic Y2353, the conserved S2340 
and N2357 (Table 12 and Chapter 10.2). In addition, the LDD motif, which is 
characteristic for B1-type KR domains, was also found (Chapter 1.11.1). In the TENS 
KR, this is represented with the residues L2292, R2293 and D2294 (Table 11 and Chapter 
10.2). 
 
The proposed stereochemical course for the reduction of 136 catalyzed by the KR domain 
is shown in Scheme 29. Previous studies demonstrated that the cofactor must be rigidly 
located in the active site for the highly stereoselective transfer of the 4´-pro-S hydrogen 
of NADPH 11. Furthermore, the transfer of the hydride to the 3-carbon of the substrate is 
also highly stereoselective, indicating that the substrate must take a single conformation 
relative to NADPH. 
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Scheme 29: Proposed Stereochemical course of the reduction catalyzed by the isolated TENS KR domain 
 
5.7 Integration of the cofactor into the modelled KR domain of TENS 
 
The next step was to add the cofactor NADPH 11 into the active site of the KR domain 
(Figure 60). This was done by alignment of the homology model with the template in 
PyMOL (Figure 57).146,147 The cofactor was extracted from the template and then 
manually integrated into the structural model of TENS KR. The generated KR domain 
plus cofactor was then minimized in YASARA to refine the protein-cofactor interaction 
(section 2.1.3, Figure 16).135 Subsequently the extracted and refined cofactor 11 was 
aligned with the cofactor 11 from the template (Figure 59). The alignment resulted in a 
RMSD of 0.3 Å. Hence, the cofactor in the TENS KR model is likely to have the correct 
position and orientation. 
 
 
Figure 59: Alignment of the cofactor 11 from the TENS KR model (green) with the cofactor from the AmphB 
(blue) 
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The NADPH cofactor binding motif for B1-type KR domains are known in the literature 
(Chapter 1.11.1). These were determined by sequence analysis and crystal structure 
analysis.15,184,185 
 NADPH 11 contacts one side of the active site, making specific contacts with 
residues S2239, R2240 and A2265. In addition, the interaction of the conserved 
dinucleotide binding motif “GXGXXG” with the NADPH cofactor 11 was observed (Fig. 
60 and Table 12).181 Further, the expected nicotinamide 4´-pro-S hydrogen is exposed for 
reaction.56,57 Overall, the QMEAN and the structural features of the model generated for 
the TENS KR indicate that the quality should be suitable for further in silico studies.  
 
 
Figure 60: Model of the KR domain of TENS with the mesh surface. Green, the cofactor 11; blue, conserved 
cofactor binding motif; grey, conserved LDD-motif (L2292, R2293, D2294); pink, catalytic residues (Y2353, 
S2340, N2357). 
 
5.8 Development of a Substrate and Cofactor Docked Model for the KR of TENS 
 
It was possible to generate the KR domain of TENS using Swiss-Model as well as to 
integrate the cofactor NADPH 11 into the model. With respect to the cofactor, it is now 
possible to roughly identify the active pocket in PyMOL. Therefore, a PDB file was 
generated which included three-dimensional parameters of the respective 2R-methyl-
acetoacetylpantetheine 135a, which is known to be the correct substrate for the KR 
 113 
domain of SQTKS and mFAS (Chapter 1.11). Since TENS is also a HR-PKS this 
stereoisomer was chosen for the docking experiments.  
 The subsequent docking steps and validation criteria followed the usual standard 
operation protocol (Chapter 2.6) and will not be described again here in detail. The best 
docking results were obtained by optimization of different parameters of the Grid Box in 
the docking procedure with AutoDock Vina (section 2.1.2, Figure 61 and 62). 
 
The docked model of the substrate 135a is shown in figures 61 and 62. The active site of 
the TENS KR domain with a mesh surface is shown in Figure 61. In addition, the cofactor 
11, substrate 135a, the catalytic tyrosine and the LDD-motif are displayed. KR domains 
control the stereochemistry of the β-hydroxyl group of a polyketide by the direction that 
the polyketide enters the active site in relation to the NADPH cofactor (Chapter 1.11.1).185 
Hence, the first structural feature which is conserved in KR domains is the entrance of 
the substrate into the domain. In B-type KR domains, such as SQTKS or mFAS, if the 
phosphopantetheine arm enters from the right side it will encounter the LDD motif 
(Figure 61, Chapter 1.11.1).185 The LDD motif prevents the substrate from slipping 
behind the lid helix.185,62 
 
 
 
Figure 61: Mesh surface of the KR domain with the Cofactor, substrate 135a, the conserved LDD-motif and 
catalytical residue Y2353. 
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In Figure 62, for a better display only the cofactor 11 and the substrate 135a are shown. 
In the model, the catalytic nicotinamide moiety of the NADPH cofactor 11 is located 
inside the KR-domain. 
 
 
Figure 62: Acitve site of the KR domain; Green, the cofactor 11; Blue, the substrate 135a; Grey LLD-motif 
(L2292, R2293, D2294); Pink, catalytic residue Y2353. 
 
The 2R-methyl-acetoacetylpantetheine 135a extends into the protein (Figure 62), from 
the right site and is located near the cofactor NADPH 11. This places the reactive β-
carbon 3.8 Å away from the cofactor's correct/observed reactive 4´-pro-S hydrogen (Fig 
62). The substrate is orientated towards the cofactor with the expected Si-face of the 3-
oxo group facing the NADPH 4´-pro-S hydrogen. The Burgi-Dunitz angle for the 
substrate-cofactor complex is 83° and the dihedral angle 37.5°. 
 The conserved LDD-motif was also observed. However, the substrate is not in 
direct contact with the LDD-motif (Figure 61) which was to be expected since the chosen 
diketide substrate is still an early intermediate of the biosynthesis. Later longer 
intermediates of the biosynthesis might interact with the LDD-motif. 
 Furthermore, an α-helix, which is in contact with the substrate at the opening of 
the active site, was observed (Figure 61). This α-helix will be referred to as substrate 
binding helix in the following and will be discussed in detail in sections 6.3 and 6.6-7.  
 Finally, the catalytical residues, which were determined by Reid and Keating-Clay 
et. al., were observed near the substrate.60,185,62 Y2353, from the catalytic triad, is located 
4.8 Å away from the substrate 3-oxo group. Furthermore, an angle of 84.2° was observed 
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for the possible hydrogen bond between the tyrosine and the 3-oxo group. However, this 
angle differs from the optimal angle of 120°.179 Keatinge-Clay et. al. did not determine 
an optimal bond length between the catalytic residues and the substrate. Hence, the only 
factor, which is not particularly good in the TENS model, is the angle of the hydrogen 
bond between the tyrosine and the substrate. In this case, the geometry of the substrate 
would have to change with respect to catalytic residue. However, the KR domains may 
also exist in different conformations. Therefore, in vivo it is quite possible that the KR 
domain would slightly change its conformation with could orient the substrate differently 
to reach the optimal angles. 
 The results of the in silico docking which placed the substrate 135a towards the 
cofactor with the expected Si-face of the 3-oxo group facing the NADPH 4´-pro-S 
hydrogen, results in similar stereochemistry of the reduction as observed for other B1 
type KR domains, such as SQTKS and corresponds with the known stereochemical 
course of mFAS (Chapter 1.11, 1.11.1 and Scheme 26).56,57 The actual stereochemistry 
of the TENS KR domain is not known, but the results give a good evidence that it should 
be similar to other HR-PKS and mFAS. Overall, a representative substrate and cofactor-
docked model of the KR of TENS was developed.  
 
5.9 Conclusion 
 
Structural information of the single or mutli-domains are necessary for understanding 
mechanism of the programming of HR-PKS and the subsequent rational engineering of 
these domains. Here, the enzyme domains that are of interest for engineering and thus 
modelling are the C-MeT and KR domain of TENS.  
 Our first aim was to build and validate models of the TENS KR and C-MeT 
domains that ultimately met with quality criteria to perform in silico studies. The 
validation of the generated models of the KR and C-MeT domain were done similarly to 
the ER domain of SQTKS (Chapter 5.3-5.7). One of the validation parameters was the 
QMEAN score of Swiss-Model. The QMEAN score verified that it was possible to create 
a detailed model of each respective domain, which was suitable for docking studies. 
Further, the respective cofactor NADPH 11 or SAM 35 was docked into the domain and 
showed that this docks in a sensible way preserving known protein-cofactor contacts. In 
addition, it was shown that the KR domain exposes the correct 4'-pro-S hydrogen known 
to be transferred during the reduction reaction.56,57 The docking experiments placed the 
KR substrate in a potentially correct orientation within the active site towards the cofactor 
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with the expected Si-face of the 3-oxo group facing the NADPH 4´-pro-S hydrogen. The 
subsequent hydride transfer would result in the correct stereochemical product, which 
corresponds to the known stereochemical course in the mFAS and SQTKS KR domains.56 
It should be noted, however, that the actual stereochemical course of the TENS KR is not 
known. Hence, for the KR domain of TENS it was possible to predict the substrate-
binding pocket and to perform docking experiments, which indicated that the docked 
substrate has the likely correct stereochemical orientation in the active site. 
In the case of the C-MeT model, the distance of the cofactor to the substrate was 
in a suitable parameter range. It was not possible to generate a substrate-cofactor docked 
model for TENS C-MeT, which would be representative. However, it was possible to 
roughly predict the active site of the C-MeT domain. 
The templates chosen for the modeling had a high resolution of 2.1 Å (C-MeT) 
and 1.4 Å (KR). Overall the QMEAN, the inflexible structure, the good substrate docking 
and the good template resolution, indicate that the models generated for KR and C-MeT 
of the TENS were good enough for further study.  
 Overall, the models should be suitable to model a chimeric model of TENS and 
mFAS in silico. For the KR domain, the model should be suitable to investigate the 
influence of the domain swaps on the active site. These models shall be used to understand 
the molecular basis of the methylation and chain-length programming in silico.  
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6 Development of a chimeric C-MeT-ΨKR-KR sub-structure of 
TENS to Understand the Molecular Basis of Methylation and 
Chain-Length Programming in-silico. 
 
6.1 Introduction  
 
The generation of models of the TENS KR and C-MeT was described in chapter 5. These 
model proteins were validated by various methods which suggested that the binding of 
cofactors is chemically reasonable in both cases but the binding of substrates is only 
chemically reasonable in the case of the KR domain. Therefore, it was considered that 
these models could form a valid basis for the design of a chimeric model of TENS and 
mFAS which could give some structural support to the results of domain-swap 
experiments. 
 
6.2 Aims of the Project 
 
The first aim was to design a chimeric quaternary structural model of TENS by using the 
generated TENS KR and C-MeT domain with the mFAS as a scaffold. This generated 
chimeric model should then serve as the foundation for the design and understanding of 
the domain swaps. Further, the chimeric model structure in combination with the single 
domains and the multiple sequence alignment should be used to understand the molecular 
basis of the methylation and chain-length programming. Afterwards, this knowledge 
could be used to perform a first rational engineering approach on the KR domain of 
TENS. 
 
6.3 Development of a Chimeric Multidomain Model of TENS 
 
In the first step, a hybrid model for TENS based on mFAS was created (Figure 66), 
assuming that the general structure of HR-PKS is similar to mFAS (Chapter 1.10). The 
hybrid model only included the β-processing domains, which are the DH, ER, KR, ΨKR 
and C-MeT domain. Such hybrid models have been used successfully in other studies. 
For example, Skiba et. al. used this technique to generate a model of the quaternary 
structure of the CurJ PKS.171 
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The chimeric mFAS/TENS structure should include the DH and ER and ΨKR domains 
from mFAS and the C-MeT and KR domain from TENS, respectively. The DH and ER 
were not changed to the corresponding domains of TENS in the chimeric model, because 
in these particular domains no domain swap was performed. In addition, the ΨKR from 
TENS was not modelled and integrated into the chimeric model, because of the difficulty 
to model this domain. This is due to sparse literature information about ΨKR domains as 
well as their high structural variability. In addition, while the mFAS possesses an active 
ER domain, the ER0 domain from TENS is present but inactive and its function is replaced 
by a trans-ER (Chapter 1.13 and 1.17). Yet, the ER0 from TENS and the ER from mFAS 
are similar in terms of sequence and likely structure. 
 The C-MeT and KR domains in the chimeric model were based on the model 
structures built in the previous chapter, because domains swaps of these two domains 
were already performed between DMBS, TENS and in some cases MILS. Additionally, 
the mFAS ΨC-MeT domain is functionally inactive, degraded in terms of sequence and 
would therefore poorly represent the active C-MeT domain of TENS. 
 
In order to generate the desired hybrid model, the model KR and C-MeT domains 
(Chapter 5) from TENS were aligned with the mFAS structure in PyMOL (Figure 64). 
The alignment resulted in an RMSD value for KR of 1.0 Å and for C-MeT of 2.7 Å, 
respectively. The RMSD value for the alignment of the C-MeT domain between TENS 
and FAS is relatively high, but the two structures overlay very well (Figure 64). The 
higher RMSD value for the C-MeT results from the missing structural part of the C-MeT 
domain of mFAS.  
 Furthermore, a gap in the loop structure in the KR domain of mFAS was observed 
(Figure 63B). In contrast to mFAS, this area in the TENS model KR contains a structured 
α-helix which is in contact with the substrate (Chapter 6.6) and will be referred to as the 
substrate binding helix in the following. However, no gap in the protein sequence of the 
mFAS was observed. This gap can also be observed in an isolated crystallized KR domain 
of the mFAS with a better resolution of 2.3 Å (PDB 5c37).186 However, it is most likely 
that this region is poorly resolved in the crystal, suggesting a highly flexible loop region, 
in mFAS which is replaced by a longer and more structured helix in the PKS KR domains. 
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Figure 63: A, In blue, the KR domain of TENS aligned with the KR domain of mFAS in grey; B, part of the 
KR domain of mFAS. 
 
 
Figure 64: Alignment of the generated mono domains of TENS KR and C-MeT with the corresponding 
domain models of mFAS; A, In blue, the KR domain of TENS aligned with the KR domain of mFAS in grey; 
B, In red the C-MeT domain of TENS aligned with the C-MeT domain of mFAS in grey; C, overall alignment 
of the C-MeT domain (red) and KR domain (blue) models of TENS with the DH, CMeT, ΨKR, ER and KR 
domain of mFAS (grey).  
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If the missing part of the C-MeT domain is observed in detail, with regards to the 
structural elements described by Skiba et. al., it can be stated that these structural features 
are the so-called lid, core insertion and insertion (Figure 65, Chapter 5.4).171 These 
structural features are important for stabilization (lid) and catalytic activity (core insertion 
and core) of the domain. Therefore, one can assume that the lid, core insertion and 
insertion structures have been lost during evolution of the Ψ-C-MeT of mFAS. Even so, 
the core structure of the TENS and mFAS Ψ-C-MeT domains overlap very well. In 
addition, if the alignment of the C-MeT domains is examined on a bigger structural scale 
(Figure 64C). The core structure is positioned directly next to the ΨKR domain. Further, 
the interface of the C-MeT domain and the ΨKR domain overlay very well. Hence, after 
the alignment of the TENS C-MeT domain core structure with the core structure of the 
mFAS C-MeT domain, the missing parts (e.g. lid, core insertion and insertion) should 
take up the correct 3D orientation. 
 
 
Figure 65: A, Alignment of the generated C-MeT domain of TENS (red) with the corresponding ΨC-MeT 
domain of mFAS (grey); B, C-MeT domain of TENS displayed with the structural features according to Skiba 
et. al.; cyan, core; orange, core insertion; green, insertion; grey, lid. 
 
Based on the mFAS scaffold (Figure 64) the TENS KR and C-MeT domain were now in 
the correct orientation in PyMOL. The coordinates of the PDB files of the KR and C-
MeT domains were adjusted considering the mFAS scaffold, since every atom of a protein 
can only have one specific coordinate in a PyMOL file. 
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The original mFAS C-MeT and KR domains were then deleted from the PyMOL file and 
both the remaining mFAS domains (DH, ER ΨKR ) and the modeled KR and C-MeT 
domain of TENS were combined in PyMOL to yield a new structure. The chimeric 
mFAS/TENS model was then submitted for refinement to YASARA. The resulting 
chimeric model of the mFAS/TENS is shown in Figure 66. 
 The hybrid model generated for TENS indicates how the ΨKR forms a linking 
domain between the KR and C-MeT domain and it shows the presumed quaternary 
structure of the β-processing region of TENS (Figure 66). In addition, it can be observed 
that the model C-MeT from TENS does not only overlay well with the ΨC-MeT domain 
of mFAS (Figure 64C), but also fits perfectly in the “old” position of the C-MeT domain 
in the quaternary structure.  
 
 
Figure 66: Modelled structures of the TENS iterative HR-PKS. Focus on β-processing domains of TENS 
model. Colors: light grey, DH; dark grey, ER; red C-MeT; green, KR; blue, ΨKR; A, displayed from the front; 
B, Displayed from behind.79 
 
Using the hybrid model, the TENS C-MeT-ΨKR region was then divided (including 
proposed linker regions) into ten sub fragments of between 27 and 80 residues (1A1-2B2, 
ΨKR1 and ΨKR2, Table 11 and Figure 67). The KR of TENS was also divided into four 
sub-regions of approximately 70 amino acids each (4A-5B, Table 11 and Figure 67). 
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Figure 67: Modelled structures of the TENS iterative HR-PKS. Focus on KR, ΨKR and C-MeT domains of 
TENS model. Colors: See table 12; A, displayed from the front; B, Displayed from behind.79 
 
6.4 Overview of the Molecular-Biological in vivo work. 
 
Molecular biology work was performed by K. Williams, S. Friedrich and S. Yin (who 
worked on the KR domain swaps) and X.-L. Yang (who worked on the C-MeT domain 
swaps) and shall be briefly discussed.  
The fragment-exchange procedure was based on combining overlapping DNA 
fragments constructed from tensS, dmbS or milS templates with the linearized tenS 
cloning vector and transforming the mixture into yeast.79 The assembled plasmids were 
transformed into E. coli and domain encoding gene cassettes were transferred by in vitro 
recombination methodology into the expression vectors, which contained tenC. These 
were then transformed into A. oryzae. After selection, multiple A. oryzae transformants 
were grown in media containing maltose, which induces expression of the hybrid tenS 
gene, and organic extracts were prepared and examined using a standardised extraction 
and LCMS protocol.  
 
 
Figure 68: Schematic example for the different domain swaps which were performed in the KR domain of 
TENS. For example, in some domain swaps a quarter of the tenS KR-region was swapped with the 
corresponding region of dmbS, whereas in other swaps up to one half of the domain was switched. 
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In total nine swaps within the KR domain were achieved, resulting in different products 
(Figure 69). The most characteristic result was obtained when the TENS KR domain was 
exchanged with the DMBS KR, which led to the formation of different pentaketides, for 
example 75, 138, 139, 140 and 141 (green) and the hexaketides 76 and 142 (blue). When 
the TENS KR domain was swapped with the MILS KR heptaketides 143 (red) were 
produced. 
 
 
Figure 69: Example of products observed after the domain swaps of TENS with DMBS and MILS. 
Pentaketides (green), hexaketides (blue) and heptaketides (red) were observed. 
 
The swapped fragments are referred to by a combination of numbers and letters. Fragment 
I is the first half of the C-MeT, and is further divided into quarters 1A and 1B. In turn, 
these are further divided into eighths. For example, fragment 1A2 is the second eighth of 
the C-MeT. The labelling scheme is shown in full in Table 13. For consistency, these 
fragments are also given fixed colours, which are used, in the following sections.  
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Table 13. Summary of swaps made and LCMS results. Bar graph shows % difference in sequence (similarity green, identity blue), e.g. fragment 1A1 is 92%/81% similar/identical = 8%/19% 
expressed as a difference. Red bars show donated fragments from DMBS; green bar shows donated fragment from MILS.79 
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6.5 Structural Analysis of the Chimeric Multidomain Model of TENS 
 
A detailed structural analysis of the models in comparison to the multiple sequence 
alignment (Chapter 10.2) was performed. This revealed that the swap fragments 1B1, 
1B2, 2A1, 2A2, 2B1, 4A, 4B and 5A contained swapped residues contacting either the 
cofactor or the substrate (Table 14). Only the fragments 1B1 (C-MeT) and 5A (KR) 
contain mutations in these residues. All other fragments contain no changes in contact-
residues and would not be expected to directly alter the active site upon exchange. 
 
Table 14: Summary of the swap positions and structural features.  
Fragment 
Putative Active site Contact Residues Other 
Non-
Surface 
Change 
Note TENS/DMBS Identical 
TENS/DMBS non-
identical 
Cofactor Substrate Cofactor Substrate 
C-MeT 
1 
1A1 - - - - S1350A Linker 
1A2 - - - - -  
1B1 
R1452, L1457, 
D1458, 
Y1461 - L1451M 
V1433I, 
V1437M 
 
1B2 
1489-
KILEIGAGTGAT-
1500 
- - - A1504V SAM 
2 
2A1 
D1519, L1520, 
S1521, F1524, 
L1595, D1595, 
I1596 
E1597 - - -  
2A2 
T1566, N1567, 
V1568 
H1569, A1570, 
T1571, K1597 
- - -  
2B1 - 
A1605, F1609, 
L1612, E1613, 
G1614, W1615, 
L1617, P1627, 
L1628 
- - -  
2B2 - - - - -  
ΨKR 3 
ΨKR1 - - - - -  
ΨKR2 - - - - -  
KR 
4 
4A 
2213-VGAAGGLG-
2220, 2239-
SRNPKA-2244 
2264-MDAC-2267 
- - - I2223L NADPH 
4B 
2292-AAMV-2295, 
P2315, K2316, 
L2338, S2340, 
L2296, A2342 S2341A - 
V2336I, 
S2339G 
NADPH 
5 
5A 
Y2353 2379-GHV-
2381, 2384-TGY-
2386 
L2345, N2346, 
N2347, Q2350, 
V2387 
V2378I 
V2397I, 
S2400N, 
L2401I, 
T2404M, 
V2406A 
- 
Substrate-
binding 
helix 
5B - - - - -  
 
For the fragment 1B1 in the C-MeT, the mutation is the highly conserved L1451M (Table 
14). The swap fragment 1B1 alone leads to formation of pretenellin isomer 140, which 
features a non-standard methylation pattern. The product 140 was also observed in other 
swaps not involving fragment 1B1 (e.g. experiments 5–17, Table 13). For fragment 4B 
in the KR, there is variation at position 2341, which contacts the cofactor only, and change 
of fragment 4B is not associated with a change in programming. In case of fragment 5A 
in the KR, there are five changes in the amino acid residues (Table 14, Figure 72), which 
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appear to contact the substrate in the structural model (Figure 72), compared to DMBS. 
These residues are clustered on the substrate contacting helix (Chapter 6.3) which is 
absent in mFAS (Figure 64, 66 and 72). The significance of the substrate contacting helix 
will be discussed later in more detail (section 6.6). 
 Positions which are different between the sequence of TENS and DMBS were 
mapped onto the structural model (Figure 70), revealing that most of the positions with 
different amino acids are located at solvent-exposed surfaces (Figure 70). Hence, they are 
unlikely to be involved in significant substrate selectivity effects. 
 
 
Figure 70: Modelled structures of the TENS iterative HR-PKS. Displayed are the C-MeT, KR and ΨKR of 
the TENS model. Colors: red, C-MeT; blue, KR; green, ΨKR. Changed surface residues in comparison to 
DMBS are displayed in black. A, Front view; B, Back view. 
 
However, some changed residues are not located at the surface, such as V1433I and 
V1437M in the C-MeT domain and I2223L and V2336I in the KR domain. Since these 
residues are in buried hydrophobic regions, they are also unlikely to be in contact with 
active sites (Figure 71).  
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Figure 71: Modelled structure of the TENS HR-PKS. Focus on a part of the β-processing domains of TENS 
model. Colors: red; C-MeT; green, KR; blue, ΨKR. Changed non-surface residues in comparison to DMBS 
are displayed in orange (KR domain) or cyan (C-MeT domain). 
 
6.6 In silico Studies with the Single KR Model of TENS 
 
In the following, the single KR domain of TENS (Figure 72A-B) and the importance of 
the substrate-binding helix for the chain length were investigated in silico. First, the 
TENS KR domain, which was modelled in the previous chapter (5.6-5.8), will be 
analyzed. Afterwards, the KR domains of DMBS and MILS should be modelled. This 
was done to compare KR domains of TENS, DMBS, MILS and mFAS with special 
consideration of the substrate-binding helix structures, which the domain swap 
experiments showed was important for chain-length programming.76 
 The KR domain of TENS with the swap fragments (4A-5B) is displayed in Figure 
72A. In addition, the non-identical amino acids between TENS and DMBS (Table 14), 
which are involved in a possible substrate interaction, are shown. It was observed that all 
these residues are located on the substrate-binding α-helix (Table 14). Further, the swap 
experiments showed that if the specific fragment 5A, which includes the substrate-
binding α-helix, is swapped to either DMBS or MILS sequences, the chain length of the 
product was influenced (Table 13).76 Hence, this substrate-binding helix appears to have 
a critical role in the control of the chain length of the respective product.  
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Fig 72: Focus on the active pocket of the KR domain of TENS with bound NADPH 11 (green) and 2R-
methyacetoacetylpantetheine 135a. Red residues indicate positions of L2363, V2397, S2400, L2401, T2404 
and V2406. Cartoon colors correspond to peptide colors according to table 12.  
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In order to determine the role of the substrate-binding helix in the programming 
mechanism of the chain length, the KR domains of TENS, DMBS, MILS and mFAS were 
compared. Therefore, the KR domains of DMBS and MILS were individually modelled 
via Swiss Model. The KR of mFAS was available in the protein data bank (PDB 2vz8). 
Hence, it was not necessary to model this domain.  
 The homology modelling of the KR domain of DMBS and MILS was similar to 
the procedure for the KR domain of TENS (Chapter 5.6) and will be therefore not be 
described here in detail again. Prior to the actual modelling the domain boundaries had to 
be determined. This was done through a conserved domain search (CD-Search) and 
through an alignment with the TENS KR. Afterwards, AmphB KR was chosen as a 
template again. This was done for a better comparison of the generated models, since the 
TENS model was already modelled with AmphB KR as a template. 
 Overall, the homology modelling resulted in structural models for the DMBS KR 
with a QMEAN value of -2.35 (sequence similarity 27%) and for the MILS KR with a 
QMEAN value of -2.81 (sequence similarity 25 %). The QMEAN values indicate that the 
quality of the generated structural models were good enough to proceed. Afterwards, the 
cofactor NADPH 11 was integrated into the domains in PyMOL (Chapter 5.7). 
 
The structural models for the KR of TENS (blue), DMBS (green), MILS (red) and mFAS 
(orange, PDB 2vz8) are displayed in Figure 74. In each domain, the substrate-binding 
helices are colored in grey (Figures 73A-D). 
 With an increase of the chain length of the product (TENS < DMBS < MILS < 
mFAS), it was observed that the substrate-binding helices lose their “structural scaffold 
displaying more and more of an unstructured loop. The TENS and DMBS substrate-
binding regions are α-helices, whereas in mFAS the structural motif of this region is 
“reduced” to a loop. In the swap experiments (Chapter 6.4-6.5, table 14) and in the 
modelling of the single KR domain (Chapter 6.6) it was elucidated that some residues 
(e.g. L2363, V2397, S2400, L2401, T2404 and V2406) on this substrate-binding helix 
differ between the different PKS. It was hypothesized that a specific combination of these 
residues would be important to build either a helix structure or a loop in this region. If the 
KR domain has at this region a structured α-helix, only shorter substrates will be 
recognized. If there is a more flexible loop region, then longer substrates could be 
recognized by the KR domain. These observations are consistent with the result of the 
swap experiments (Chapter 6.4-6.5), showing that the structure of the substrate-binding 
helix is correlated to the observed control of the chain length of the respective product.  
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Fig 73: Modell structures of KR domains with different substrate selectivity. A, in blue KR domain of TENS; 
B, in green KR of DMBS; C, in red KR domain of MILS; D, in orange KR domain of mFAS. The substrate-
binding region is marked in grey.  
 
6.7 In silico swap experiments with the KR domain 
 
The comparison between TENS, DMBS, MILS and mFAS KR domains (Chapter 6.6) 
indicated that the structural feature of the substrate-binding region controls a crucial role 
in the mechanism of the programming of the chain length. In the following, a simple in 
silico swap experiment was performed. On the one hand, this in silico experiment should 
elucidate the effect on the substrate-binding helix in the domain swaps in vivo; on the 
other hand, the experiment should provide first ideas for a rational engineering approach 
of the KR domain of TENS.  
 
The specific amino acids (e.g. S2400, L2401, T2404 and V2406), which are part of the 
substrate binding helix and known to be different between TENS, DMBS and MILS (table 
14, sequence alignment chapter 10.2), were swapped in the sequence of TENS with the 
specific amino acids of MILS (Table 15). If these residues were correlated to the structural 
building of the helix or loop scaffold, the switch of these amino acids from TENS to 
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MILS should reduce the helix structure of the TENS substrate-binding helix to a loop 
structure.  
 
Table 15: Sequence alignment of a part of the TENS KR, DMBS KR, MILS KR and mutated TENS KR*; 
Yellow, mutated amino acids in the TENS KR* domain.  
                   5A                                                5A 
TENS KR  (2343) AILNNTGQSNYHCANLYMDSLVTNRRSRGLAASIIHVGHVCDTGYVARLVDD 
DMBS KR  (2338) AILNNMGQSNYHCANLYMDSLVKHRRSRGLAASIIHIGHVCDTGYVARMVDD 
MILS KR  (2236) TIANNIGQSNYHCANLYMDSLVAQRRSRGLAASIIHIGYICDTGYVARLGDD 
TENS KR* (2343) AILNNTGQSNYHCANLYMDSLVTNRRSRGLAASIIHIGHVCDTGYVARLVDD 
 
                   5A                                                5A 
TENS KR  (2395) TKVQMSLGTTRVMSVSETDVHHAFAEAVRGGQPDSRSGSHNIIMGIEPPTKP 
DMBS KR  (2390) NRIQSNIATMRAMRLSETDVHHAFAQAVRGGQLDSRSGSYNIIMGIEPPTKP 
MILS KR  (2288) AKVHSNRDVMRATTLSETDVHHAFAEAVRGGSPGSPIGSYNIIMGIDPPTKS 
TENS KR* (2395) TKVQMNRGVTRAMSVSETDVHHAFAEAVRGGQPDSRSGSHNIIMGIEPPTKP 
 
                   5A                               5A 
TENS KR  (2447) LDLTKRKPVWISDPRLGPCLPFSTLENQMMASEQA 
DMBS KR  (2442) LDLTRRQAVWLSDPRLGHMLPYSTLENQMIASGQA 
MILS KR  (2440) LDLTKRKPVWISDPRLGHMVPYSASADQAVTSEQA 
TENS KR* (2447) LDLTKRKPVWISDPRLGPCLPFSTLENQMMASEQA 
 
The exchange of the amino acids (e.g. S2400N, L2401R, T2404V and V2406A) was 
performed manually in the Fasta file of TENS. Afterwards, this mutated TENS KR 
domain was again modelled with SwissModel. As template AmphB KR was chosen once 
more. Overall, the homology modelling resulted in structural models of the mutated 
TENS KR with a QMEAN value of -2.80 (sequence similarity 27%). Nearly the same 
validation parameters as for the WT TENS KR were observed (Chapter 5.6). Afterwards, 
the cofactor NADPH 11 was integrated into the model and minimized via YASARA 
(Chapter 5.7). 
 The result are displayed in Figure 74. It was observed that after exchange of the 
specific amino acids from TENS to MILS the substrate-binding helix (Figure 74A) 
“loses” its scaffold and takes up a loop structure, which is similar to the native structure 
in MILS (Figure 74B and Figure 72C). Hence, this mutated TENS KR domain should 
now be able to recognize longer substrates. 
 Overall, the exchange of these amino acids changed the scaffold of the substrate-
binding region. Hence, the in silico swap experiment offers a possible structural 
explanation for the structural changes in the KR domain in the in vivo swap experiments. 
Furthermore, these amino acids could be further targeted by engineering experiments of 
the KR domain in vitro or in vivo, since the chain length seems to be programmed through 
this specific substrate binding helix. 
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Fig 74: A, KR domain of TENS with native amino acids; B, KR domain of TENS with swapped amino acids 
from MILS. In grey swapped amino acids (V2397I, S2400N, L2401R, T2404V and V2406A). 
 
6.8 Discussion and Outlook 
 
HR-PKS synthesize complex products using a single set of domains in a highly 
programmed, iterative fashion. Although many examples of type I HR-PKS are described 
in the literature, the mechanism that controls the iteration processes in these iPKS has not 
been clearly understood.78 This stands in contrast to modular Type I PKS. In this type of 
PKS the programming is simply controlled through the assembly of the modules and the 
availability of the specific β-processing domains in the respective domain (for example 
Curacin A 52, chapter 1.8). However, in the literature there is only a limited number of 
in vitro and in vivo investigations of HR-PKS catalytic domains and very little evidence 
for a possible mechanism of programming to be found.  
 The programming of the TENS, DMBS and MILS PKS systems appears to be 
controlled by four catalytic domains: KS, C-MeT, KR and the trans-acting ER (Scheme 
30). The catalytic domains have a chemical selectivity, whereby they only act on 
substrates which are chemically competent. For example, the DH domain always acts on 
ACP-bound β-alcohols and the AT always supplies extender units.79 This is supported by 
the limited number of reported in vitro investigations of HR-PKS catalytic domains.58,80,81 
 For example, Cox et al. recently showed that the functional ER domain from 
squalestatin tetraketide synthase (SQTKS) has low selectivity and is able to effectively 
reduce a wide range of enoyl-pantetheines including even unnatural isomers and 
stereoisomers.58 Furthermore, Vederas et al. showed that the C-MeT domain from the 
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lovastatin nonaketide synthase displays tight selectivity for its substrate, while the KR in 
the same system is less selective.80 In addition, in the KR domains the stereo-chemical 
course of each β-ketoacyl-ACP reduction is programmed and is independent of either 
modular context or substrate structure, including chain length and substitution pattern.81 
 Overall, the selectivity of the single domains can be referred to as intrinsic 
selectivity e.g. within their own active sites. This stands against the extrinsic factors such 
as domain-domain and protein-protein interactions, which may also be a significant 
determinant of PKS-programming. 
 Cox et. al. gave evidence of such an extrinsic protein-protein interaction between 
the catalytic domains in recent domain swap studies. The swaps appear to affect the rates 
at which the domains compete for ACP-bound intermediates without changing their 
active sites. This was also supported by previous domain-swap studies in which the 
cleanest change in selectivity was observed when the complete C-MeT-ΨKR-ER0- KR 
tetra-domain fragment was exchanged, consistent with the limited introduction of 
deleterious extrinsic protein-protein interactions.76 
 These observations are consistent with a programming mechanism which arises 
by competition between the selective domains for the ACP-bound substrate. A 
programming hypothesis, which is derived from these ideas, is shown in Scheme 30. 
 Synthesis starts with the KS domain, which catalyses the chain extension and is 
not selectively programmed, although it does not usually extend β-keto intermediates. 
Subsequently, a competition between the C-MeT domain, the KR domain and the chain 
release takes place. Depending on the intrinsic and extrinsic specification of the different 
domains, the kinetic parameters for the respective domains for the specific substrate at 
the specific time of the biosynthesis can differ (Scheme 30A). Hence, depending on how 
the kinetics for the domains for the specific substrate are currently, for example either 
methylation through the C-MeT domain or the β-reduction through the KR domain takes 
place. 
 Chain elongation is always followed by the β-processing domains (C-MeT, KR, 
DH and ER), which can be active to a variable degree in HR-PKS. Subsequently, the KS 
domain extends the chain again. After the elongation (Scheme 30B), the C-MeT and the 
KR domain compete again with each other. Depending on the kinetic parameters for the 
respective substrate at the current time point in the biosynthesis, the intrinsic specificity 
and extrinsic specificity are different. Hence, either the C-MeT or the KR domain will be 
active. However, many iPKS products have fewer methylations with an increase of the 
chain length. Hence, the kinetic advantage could be more on the side of the KR domain, 
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than on the C-MeT domain (Scheme 30B). Depending on the PKS a termination of the 
elongation with subsequent modifications or cyclisation etc is possible as well. The 
release of the polyketide is marked by the orange ball in Scheme 30B. As displayed in 
Scheme 30C, methylation of the growing polyketide chain becomes less likely to occur 
with an increasing chain length. Even if the C-MeT theoretically could have the intrinsic 
specificity for the substrate, extrinsic factors in the programming are probably coming 
into play, ensuring that the kinetic advantage is on the side of the KR or the chain release.  
 Overall, depending on the PKS, this programming may vary in its intrinsic and 
extrinsic factors. As shown in Scheme 30C it is again possible that the chain release could 
occur, which is always more probable with increasing chain length. This may be the case 
because a longer elongation product or rather a product from a late step of the biosynthesis 
is more likely not to be a specific substrate for the individual domains any longer. Hence, 
the kinetic parameters will most likely favour reactions marked by the chain release. 
 Thus, a mechanism in which competition for substrates by a limited number of 
catalytic domains is the underlying principle, can explain the observed programming 
outcomes. The results also show that programming in these iterative PKS arises due to a 
combination of intrinsic and extrinsic factors rather than simply because of direct 
substrate-selectivity of each catalytic domain. 
 
The clearest evidence for intrinsic selectivity of a catalytic domain for its substrate comes 
from the KR domain. Here, our modelled structure indicates that five key residues on a 
substrate-binding helix appear to form part of the substrate binding pocket, and the 
difference of these residues between TENS, DMBS and MILS appears to account for the 
observed change in KR substrate selectivity and hence chain-length control. The domain 
swap of fragment 5A for the corresponding fragment from DMBS gave hexaketides, 
while the same fragment from MILS specifies chain-lengths up to heptaketides. This also 
corresponds with additional variations in the MILS KR active site (e.g. L2345A). This 
result is confirmed by the observation that exchange of a 12-residue fragment 
corresponding to Q2398 - V2409 of the substrate binding helix of the TENS KR (Table 
13) reprograms the system to produce hexa- and heptaketides. 
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Scheme 30: Course of polyketide biosynthesis: A, First condensation and subsequent selectivity; B, 
Second condensation and subsequent selectivity; C, Third condensation and subsequent selectivity. R = H 
or Me. 
 
In turn, this swap in particular validates the modelling of the TENS PKS which predicts 
that these residues are most likely in contact with the substrate in the KR active site 
(Figure 69). This sequence is absent or of very low homology in the mFAS and AmphB 
KR sequences which correlates with the absence of programming in these systems - in 
both cases the mFAS and AmphB KR domains need only an unselective ability to reduce 
the β-ketothiolesters supplied to them.79 
 
This clear evidence for intrinsic selectivity in the KR domain, however, is lacking for the 
C-MeT domain where there appears to be no significant changes in the active site itself 
when comparing the TENS and DMBS sequences. 
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Evidence for the operation of extrinsic programming effects in the TENS PKS is 
widespread. First, programming changes are usually not limited to changing a single 
structural factor of the product. Second, unreduced compounds 138 and 141 must arise 
through inactivity of the trans-acting ER TenC, which was not changed in the expression 
experiments. This suggests that TenC does not interact with a 'free' substrate-bound ACP, 
but with a substrate-bound ACP intimately associated with the rest of the PKS. Swaps 
which result in failure of TenC to reduce correctly are associated with the C-MeT and 
ΨKR domains, although not with the KR, suggesting that the trans-acting ER associates 
with C-MeT and ΨKR.  
 Third, all active swaps still produce the native product 73, either as the major 
product or as part of a mixture, again indicating that there is no simple control of overall 
selectivity. Finally, swaps within non-catalytic domains such as the ΨKR (experiments 
15 - 17) also lead to changes in methylation pattern (e.g. compound 142), although not to 
changes in chain-length.79 All these factors suggest that extrinsic protein-protein 
interactions between the catalytic domains can affect the rates at which they compete for 
ACP-bound intermediates.  
 In further studies, a rational engineering of the KR domain of TENS could 
be performed. Therefore, the residues of the substrate-contacting-helix will be 
mutated to the corresponding residues of either DMBS or MILS. The first in silico 
experiments indicated that the chain length of the product might be programmed through 
this helix. Hence, it should be possible to perform a rational enzyme engineering as it was 
done for the ER domain from the HR-PKS SQTKS.  
 Afterwards, the generated mutants could be cloned into suitable expression 
vectors. The mutations will be inserted via homologous recombination in the yeast 
Saccharomyces cerevisiae. Finally, the mutated protein could be expressed in the fungal 
host strain Aspergillus oryzae NSAR1 and the transformants will be screened by LCMS 
for the production of new compounds.  
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7 Overall Conclusion 
 
The first aim of this study was to engineer the ER domain of the HR-PKS SQTKS in a 
rational approach. Thereby, for the first time it was shown, that it is possible to use a in 
silico approach to generate and validate models of the SQTKS ER which could be 
successfully used to both understand and re-engineer the substrate specificity of the 
domain. Even with a lack of structural data, such as NMR or X-Ray, for the respective 
domain. In the subsequent in vitro assay, it was possible successfully to introduce the 
different mutation into an expression vector through site directed mutagenesis. 
Afterwards, expression and purification of different mutated SQTKS ER proteins was 
achieved.  
 The synthesis of the substrates for the SQTKS ER domain was already literature 
known, even so through a new established deprotection method using InCl3 catalysis in 
aqueous CH3CN it was possible that the thioester hydrolysis problem was avoided. 
 In the enzyme assays, it was shown that the mutations have significant influence 
on the kinetic conversion, hence the specificity constant for different substrates, were 
altered in different ways. Mostly a faster conversion of the substrates was observed. 
Furthermore, it was possible to construct mutants, which accept the natural product of the 
SQTKS, as a substrate, and thus enhance the substrate variability. 
 In the future, the generated mutants should be inserted into the whole SQTKS 
gene on a suitable expression vector to investigate the influence of the mutants in vivo. 
Furthermore, to investigate if it would be possible to generate new metabolites. In 
addition, other domains, such as the KR domain or the C-MeT should be investigated 
through the rational engineering. The combination of the different engineered domains 
could give access to a completely new range of metabolites. 
 Overall, it was shown for the first time that modelling of HR-PKS domains can 
be a successful method for the generation of hypotheses for the rational re-engineering of 
HR-PKS. 
 
In the second project, the aim is to provide in parallel to the molecular-biological work, 
the structural-biological foundations and analysis for the domain swaps between TENS, 
DMBS and MILS. On the one hand to understand the molecular basis of methylation and 
chain length programming in silico. On the other hand, to perform first in silico studies 
for the subsequent rational-engineering of the TENS KR domain.  
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Thereby, it was shown, that it was possible to model and validate models of the TENS 
KR and C-MeT domain in silico. Furthermore, a quaternary hybrid structure of the TENS 
and mFAS domains, including the DH, ER, ΨKR (mFAS) and C-MeT and KR (TENS) 
with the mFAS as a scaffold was generated. This generated chimeric model was 
successfully used to design and understand the domain swaps. Further, under 
consideration of the chimeric model structure in combination with the single domains and 
the multiple sequence alignment it was possible to understand the molecular basis of the 
methylation and chain-length programming. Hence, that programming in these iterative 
PKS arises due to a combination of intrinsic and extrinsic factors rather than simply 
because of direct substrate-selectivity of each catalytic domain.  
 In the case of the KR domain, it was possible to show for the first time the 
influence of the so-called substrate-binding helix. This helix forms part of the substrate 
binding pocket, and the difference of these residues between TENS, DMBS and MILS 
appears to account for the observed change in KR substrate selectivity and hence chain-
length control. Furthermore, first in silico studies concerning the substrate-binding helix 
of the KR domain successfully showed that it should be possible to rationally-engineer 
the KR domain. In further studies, mutants of the TENS KR domain shall be constructed 
and cloned into suitable expression vector for the subsequent in vivo expression. Overall, 
these studies lead to a better understanding of the programming mechanism of PKS 
modules and PKS in general.  
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8 Experimental Section 
 
8.1 Equipment 
 
NMR analysis: 1H-NMR analysis was performed using BRUKER DPX 200, Avance 
400, DPX 400 and DRX 500 instruments. Signals are determined in some cases with two 
dimensional NMR 1H, 1H-COSY, 13C-HSQC and 1H, 13C-J3-HMBC. 
13C-NMR analysis 
was performed using BRUKER Avance 400, DPX 400 and DRX 500 instruments. 
Deuterated chloroform (ref. 7.26 ppm / 77.2 ppm)187 and deuterated acetonitrile (ref. 1.94 
ppm / 118.4 ppm) were used as solvents and served as internal references. All δ values 
are reportet in ppm. All J values are reported in Hz. 
 
Column Chromatography: For column chromatography silicageol 60 (particle size 35-
70 micron, Sigma-Aldrich or 40-63 micron, Macherey-Nagel) was used. Columns were 
packed wet under N2 pressure. Products were eluted with the indicated solvent mixtures. 
Purified fractions were analysed by TLC and combined if same Rf was observed. Final 
products were evaporated in vacuo.  
 
TLC: TLC analysis was performed on TLC plates with a polyester backed 0.2 mm silica 
gel phase from Macherey and Nagel using the indicated solvent systems. Analysis of the 
plates were performed by ultraviolet light (254 nm) or with potassium permanganate (5 
mmol) or o-anisaldehyde (anisaldehyde [15 g], EtOH [250 ml] and concentrated H2SO4 
[2.5 ml]) solution.  
 
Analytical LCMS: Analytical LCMS data were obtained with using a Waters LCMS 
system comprising of a Waters 2767 autosampler, Waters 2545 pump system, a 
Phenomenex Kinetex column (2.6 μ, C18, 100 Å, 4.6 × 100 mm) equipped with a 
Phenomenex Security Guard precolumn (Luna C5 300 Å) eluted at 1 mL/min. Detection 
was by Waters 2998 Diode Array detector between 200 and 600 nm; Waters 2424 ELSD 
and Waters SQD-2 mass detector operating simultaneously in ES+ and ES- modes 
between 100 m/z and 650 m/z. Solvents were: A, HPLC grade H2O containing 0.05% 
formic acid; B, HPLC grade MeOH containing 0.045% formic acid; and C, HPLC grade 
CH3CN containing 0.045% formic acid. Gradients were as follows. Method 1. 
Kinetex/CH3CN: 0 min, 10% C; 10 min, 90% C; 12 min, 90% C; 13 min, 10% C; 15 
min, 10% C. 
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Preparative LCMS: Purification of final compounds was generally achieved using a 
Waters mass-directed auto purification system comprising of a Waters 2767 autosampler, 
Waters 2545 pump system, a Phenomenex Kinetex Axia column (5μ, C18, 100 Å, 21.2 × 
250 mm) equipped with a Phenomenex Security Guard precolumn (Luna C5 300 Å) eluted 
at 20 mL/min at ambient temperature. Solvent A, HPLC grade H2O + 0.05% formic acid; 
Solvent B, HPLC grade CH3CN + 0.045% formic acid. The post-column flow was split 
(100:1) and the minority flow was made up with HPLC grade CH3CN + 0.045% formic 
acid to 1 mL·min-1 for simultaneous analysis by diode array (Waters 2998), evaporative 
light scattering (Waters 2424) and ESI mass spectrometry in positive and negative modes 
(Waters SQD-2). Detected peaks were collected into glass test tubes. Combined tubes 
were evaporated (vacuum centrifuge), weighed, and residues dissolved directly in solvent 
for use or analysis. 
 
Protein purification: The protein purification was performed with an FPLC ÄKTA pure 
system from the company GE Healthcare. For FPLC analysis a combination with the 
software UNICORN 7.0 and different columns (Nickel column Protino Ni-NTA Columns 
5 mL, Size exclusion column- HiLoad 26/600 Superdex 200pg (GE Healthcare), 320 mL) 
was used.  
 
UV-Analysis: UV assays were measured with a JASCO-V630-spectrophotometer in 
quartz glass cuvettes with a diameter of 10 mm. The temperature was controlled by the 
JASCO-V630-Spectrophotometer at 25 °C. The processed data (by 
JASCO/Spectramanager) was after that recalculated with Microsoft EXCEL. 
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8.2 Buffer, antibiotics, media and solutions 
 
All enzymes used in this work were purchased from Thermo Fisher Scientific (Waltham, 
MA, USA), Takara Bio Inc. (Shiga, J), Invitrogen Life Technologies (Darmstadt, D), or 
Bioline (London, UK). All enzymes were used according to manufacturer’s instructions 
with appropriate supplied buffers. Buffers and media used in this work were sterilized by 
autoclaving 15 min at 121 °C (Autoclave 2100 Classic, Prestige Medical) or by disposable 
sterile filter (0.45 μm pore size, Roth) and are summarized in tables 16 and 17.  
 
Table 16: Media used in this work 
Media Composition [% (w/v)] Ingredients 
2TY 
1 
0.5 
1.6 
Yeast extract 
Sodium chloride 
Tryptone 
LB 
0.5 
1 
0.5 
Yeast extract 
Tryptone 
Sodium chloride 
SOC 
0.5 
2 
0.06 
0.02 
25 mM 
1 
Yeast extract 
Tryptone 
Sodium chloride 
Potassium chloride 
Magnesium chloride x 6 H20 
D(+)-Glucose 
 
Table 17: Agar used in this work 
Agar 
Composition [% 
(w/v)] 
Ingredients 
LB agar 
0.5 
1 
0.5 
1.5 
Yeast extract 
Tryptone 
Sodium chloride 
Agar 
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Antibiotics stock solutions were prepared in distilled water or ethanol. They were filter 
sterilized through 0.45 μm syringe filter and stored at −20 C°. Stock and working 
concentrations are listed in table 18 
 
Table 18: Agar used in this work 
Antibiotic Solvent 
Stock concentration [mg / 
ml] 
Working concentration [µg / 
ml] 
Carbenicillin H2O 50 50 
Kanamycin H2O 50 50 
 
Information about E. coli strains used in this work are summarized in table 19. 
 
Table 19: E. coli strains used in this work 
Bacteria Reference 
BL21 (DE3) Thermo Fisher Scientific 
OneShot ccdB survival 2T1R Thermo Fisher Scientific 
OneShot Top10 Thermo Fisher Scientific 
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8.3 Synthesis of Pantetheine Substrates 
 
The used solvents were used without any purification or drying process. Tetrahydrofuran, diethyl 
ether and dichloromethane in the dry version and NADPH were bought from Carl Roth. Other 
chemicals were ordered from Sigma Aldrich or TCI Deutschland GmbH. The syntheses were 
done established protocols from Christoph Bartel,58,137 where this was not the case it was recorded. 
 
8.3.1 Preparation of precursor substrates 
 
General Methods58,137 
I. A solution of dichloromethane (5 mL) and the respective aldehyde (1.00 mmol) was stirred at 
0 °C. (Carbethoxyethylidene)triphenyl phosphorane (0.72 g, 2.00 mmol) or 
Carbethoxymethylidene)triphenyl phosphorane (0.69 g, 2.00 mmol) was added to this solution 
warmed to 25 °C and stirred for 16-18 hours. Then the solvent was evaporated under a nitrogen 
flow. The crude product was purified by column chromatography. 
 
II. To a solution of the corresponding ester in ethanol/water 5:1 (5 mL/ 1 mL) potassium 
hydroxide (22 mmol) was added to the solution. After stirring under reflux for 3 hours diethyl 
ether was added. The mixture was washed with NaHCO3 (3 × 10 mL). Then the aqueous layer 
was acidified with 2 M HCl until pH 1 and extracted with ethyl acetate (3 x 10 ml). The organic 
layer was dried over MgSO4 and concentrated in vacuo. 
 
III. Malonic acid (2.5 g, 24.0 mmol) and aldehyde (38.0 mmol) were dissolved in pyridine (8 ml) 
and morpholine (35 µl). The solution was stirred for 17 hours at 25 °C and was heated to 115 °C 
and stirred for further 6 hours. The mixture was quenched with 1M NaOH (20 ml) and extracted 
with diethyl ether (3 x 15 ml). Then the water layer was acidified with 2M HCl and extracted with 
diethyl ether (6 x 15 ml). The organic layer was dried over MgSO4 and concentrated in vacuo. 
 
IV. To a solution of squalestatin S1 (1.00 g, 1.40 mmol) in ethanol/water 5:1 (5 mL/ 1 mL) 
potassium hydroxide (22.00 mmol) was added to the solution. After stirring under reflux for 3 
hours, diethyl ether was added through the solution and washed 3 × with NaHCO3 (3 × 10 mL). 
The aqueous layer with the (4S, 6S)-2-4-dimethyloct-2-enoic acid was acidified with 2 M HCl 
until pH 1 and extracted with ethyl acetate (3 × 10 mL). The organic layer was dried over MgSO4 
and concentrated in vacuo. 
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E-Ethyl 2-methylhex-2-enoate 161188 
 
The obtained product was a colorless oil (0,18 g, 1.15 mmol, 57.6 %) 
Rf 0.21(EtOAc / PE 1: 10) 
1H-NMR (CDCl3, 400 MHz): δ 0.93 (t, 3H, 6-CH3); 1.29 (t, 3H, 9-CH3); 1.39-1.55 (m, 2H, 5-CH2); 1.82 
(s, 3H, 7-CH3); 2.18 (q, 2H, 4-CH2); 4.18 (q, 2H, 8-CH2); 6.74 (t, 1H, 3-CH). 
 13C-NMR (CDCl3, 100 MHz): δ12.4 (6-CH3), 13.9 (9-CH3), 14.3 (7-CH3), 21.9 (5-CH2); 30.7 (4-CH2); 
60.4 (8-CH2); 127.9 (2-C); 142.2 (3-CH); 168.4 (1-CO) 
.ESMS: m/z: 179 [M + Na]H+, 157 [M]H+, 129 [M - CH2CH3]H+. 
 
E-Methylhex-2-enoic acid 16258,137 
 
The obtained product was a red oil (0.11 g, 0.85 mmol, 74.7 %). 
1H-NMR (CDCl3, 400 MHz): δ 0.91 (t, 3H, 6-CH3); 1.32-1.50 (m, 2H, 5-CH2); 1.85 (s, 3H, 7-CH3); 2.22 
(q, 2H, 4-CH2); 6.93 (t, 1H, 3-CH). 
 13C-NMR (CDCl3, 100 MHz): δ12.0 (6-CH3), 13.8 (7-CH3), 21.7 (5-CH2), 30.6 (4-CH2), 127.0 (2-C), 
145.2 (3-CH), 173.1 (1-CO). 
ESMS: m/z: 152 [M + Na]H+, 129 [M]H+; 111 [M - H2O] H+. 
 
E-4-Methylhexenoic acid 16358,137 
 
The obtained product was a yellow oil (1.43 g, 11.17 mmol, 47 %). 
1H-NMR (CDCl3, 400 MHz): δ 0.88 (t, 3H, 6-CH3); 1.04 (d, 3H, 7-CH3); 1.36-1.44 (m, 2H, 5-CH2); 2.17-
2.27 (m, 1H, 4-CH); 5.78 (d, 1H, 2-CH); 6.87 (t, 1H, 3-CH). 
 13C-NMR (CDCl3, 100 MHz): δ11.7 (6-CH3), 18.9 (7-CH3), 28.7 (5-CH2), 38.1 (4-CH), 119.3 (2-CH), 
154.8 (3-CH), 167.3 (1-CO)  
ESMS: m/z:152 [M + Na]H+, 129 [M]H+ 
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E-Ethyl-2,4-dimethylhex-2-enoate 164188 
 
The obtained product was a colorless oil (0.29 g, 1.60 mmol, 85.3%).  
Rf: 0.78 (EtOAc / PE 1: 10).  
1H-NMR (CDCl3, 400 MHz): δ 0.85 (t, 3H, 6-CH3); 1.00 (d, 3H, 7-CH3); 1.28-1.55 (m, 2H, 5-CH2); 1.30 
(t, 3H, 10-CH3); 1.82 (s, 3H, 8-CH3); 2.41 (m, 1H, 4-CH); 4.19 (q, 2H, 9-CH2); 6.52 (d, 1H, 3-CH).  
13C-NMR (CDCl3, 100 MHz): δ11.9 (6-CH3), 12.6 (7-CH3), 14.3 (10-CH3), 19.7 (8-CH3), 29.7 (5-CH2), 
34.9 (4-CH), 60.4 (9-CH2), 126.6 (2-C), 147.9 (3-CH), 168.4 (1-CO) 
ESMS: m/z: 193 [M + Na]H+, 171 [M]H+ 
 
E-2,4-Dimethylhex-2-enoic acid 16558,137 
 
The obtained product was a red oil (0.17 g, 1.19 mmol, 70.8 %). 
1H-NMR (CDCl3, 400 MHz): δ 0.86 (t, 3H, 1-CH3); 1.01 (d, 3H, 4-CH3); 1.24-1.49 (m, 2H, 2-CH2); 1.85 
(s, 3H, 7-CH3); 2.38-2.49 (m, 1H, 3-CH); 6.68 (qq, 1H, 5-CH).  
13C-NMR (CDCl3, 100 MHz): δ11.8 (1-CH3), 12.2 (7-CH3), 19.5 (4-CH3), 29.5 (2-CH2), 35.1 (3-CH), 
125.7 (6-C), 150.8 (5-CH), 173.3 (8-COOH).  
ESMS: m/z: 184 [M + CH3CN]H+, 143 [M]H+ 
 
E-(4S,6S)-2-4-Dimethyloctenoic acid 16658,137 
 
The obtained product was yellow solid (0.22 g, 1.29 mmol, 84 %) 
1H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 7.4, 6H, 8-9-CH3); 1.07 (d, J = 6.2, 3H, 10-CH3); 1.27-1.46 (m, 
5H, 7-5-CH2-6-CH); 2.41-2.52 (m, 1H, 4-CH), 5.81 (d, J = 1.7, J = 16.0, 1H, 2-CH), 6.96 (dd, J = 8.8, J = 
16.0, 1H, 3-CH).  
13C-NMR (CDCl3, 100 MHz): δ 11.1 (8-CH3); 20.2 (9-CH3); 20.7 (10-CH3); 29.8 (7-CH2); 31.9 (6-CH); 
34.4 (4-CH); 43.1 (5-CH2), 118.3 (2-CH); 164.6 (3-CH); 176.7 (1-CO). 
ESMS: m/z:193 [M + Na]H+, 171 [M]H+  
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E-oct-2-enoic acid 16758,137 
 
The obtained product was a yellow oil.(1.69 g, 11.9, 49.5 %) 
1H-NMR (CDCl3, 400 MHz): δ 0.92 (t, 3H, 8-CH3); 1.26-1.52 (m, 6H, 5-6-7-CH2); 2.22 (q, 2H, 4-CH2); 
5.78 (dd, 1H, 2-CH); 6.94 (tq, 1H, 3-CH).  
13C-NMR (CDCl3, 100 MHz): δ12.0 (8-CH3), 22.5 (7-CH2), 28.1 (5-CH2), 28.8 (4-CH2), 31.5 (6-CH2), 
126.8 (2-C), 145.5 (3-CH), 173.1 (1-CO). 
ESMS: m/z: 143 [M-H]-  
 
E-Ethyl-2-methyloct-2-enoate 168188 
 
The obtained product was a colorless oil (0.23 g, 1.25 mmol, 59.5%).  
Rf: 0.65 (EtOAc / PE 1: 10).  
1H-NMR (CDCl3, 400 MHz): δ 0.88 (t, 3H, 8-CH3); 1.25-1.55 (m, 9H, 5-7-CH2, 11-CH3); 1.82 (s, 3H, 9-
CH3); 2.15 (q, 2H, 4-CH2); 4.18 (q, 2H, 10-CH2); 6.77 (t, 1H, 3-CH).  
13C-NMR (CDCl3, 100 MHz): δ12.3 (8-CH3), 14.0 (9-CH3), 14.3 (11-CH3), 22.5 (7-CH2), 28.3 (5-CH2), 
28.7 (4-CH2), 31.6 (6-CH2), 60.4 (10-CH2), 127.7 (2-C), 142.5 (3-CH), 168.4 (1-C)  
ESMS: m/z: 207 [M + Na]H+, 185 [M]H+. 
 
E-2-Methyloct-2-enoic acid 16958,137 
 
The obtained product was a red oil (0.11 g, 0.7 mmol, 56.4 %). 
1H-NMR (CDCl3, 400 MHz): δ 0.92 (t, 3H, 8-CH3); 1.26-1.52 (m, 6H, 5-6-7-CH2); 1.86 (s, 3H, 9-CH3); 
2.22 (q, 2H, 4-CH2); 6.94 (t, 1H, 3-CH).  
13C-NMR (CDCl3, 100 MHz): δ12.0 (8-CH3), 14.0 (9-CH3), 22.5 (7-CH2), 28.1 (5-CH2), 28.8 (4-CH2), 
31.5 (6-CH2), 126.8 (2-C), 145.5 (3-CH), 173.1 (1-CO). 
ESMS: m/z: 179 [M + Na]H+, 157 [M]H+ 
 
E-Dec-2-enoic acid 17058,137 
 
The obtained product was a yellow oil (0.17 g, 1 mmol, 62.9 %) 
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1H-NMR (CDCl3, 400 MHz):δ 0.90 (t, 3H, 10-CH3); 1.29-1.50 (m, 10H, 5-9-CH2); 2.25 (dq, 2H, 4-CH2); 
5.84 (d, 1H, 2-CH); 7.10 (dt, 1H, 3-CH).  
13C-NMR (CDCl3, 100 MHz): δ14.1 (10-CH3), 22.6 (9-CH2); 27.8 (8-CH2); 29.0 (7-CH2); 29.1 (6-CH2); 
31.7 (5-CH2); 32.3 (4-CH2); 120.5 (2-CH); 152.5 (3-CH); 171.9 (1-CO). 
ESMS: m/z: 212.4 [M]H+, 193.2 [M - Na]H+, 153.5 [M - H2O]H+  
 
E-Ethyl-2-methyldec-2-enoate 171188 
 
The obtained product was a colorless oil (0.27 g, 1.27 mmol, 63 %). 
Rf: 0.85 (EtOAc / PE 1:7). 
1H-NMR (CDCl3, 400 MHz): δ 0.88 (t, 3H, 10-CH3); 1.25-1.58 (m, 13H, 5-9-CH2, 13-CH3); 1.82 (s, 3H, 
11-CH3); 2.15 (q, 2H, 4-CH2); 4.18 (q, 2H, 12-CH2); 6.75 (t, 1H, 3-CH). 
 13C-NMR (CDCl3, 100 MHz): δ12.3 (10-CH3), 14.1 (11-CH3), 14.3 (13-CH3), 22.6 (9-CH2), 28.6 (7-CH2), 
28.7 (6-CH2), 29.1 (5-CH2), 29.4 (4-CH2), 31.8 (8-CH2), 60.4 (12-CH2), 127.6 (2-C), 142.5 (3-CH), 168.4 
(1-CO)  
ESMS: m/z: 254 [M + CH3CN]H+, 213 [M]H+. 
 
E-2-Methyldec-2-enoic acid 17258,137 
 
The obtained product was a red oil (0.17 g, 0.92 mmol, 62.9 %) 
1H-NMR (CDCl3, 400 MHz): δ 0.87-0.90 (m, 3H, 10-CH3); 1.26-1.30 (m, 10H, 5-9-CH2); 1.83 (s, 3H, 11-
CH3); 2.19 (q, 2H, 4-CH2); 6.90 (t, 1H, 3-CH).  
13C-NMR (CDCl3, 100 MHz): δ12.3 (10-CH3), 14.1 (11-CH3), 22.6 (9-CH2), 28.4 (7-CH2), 28.9 (6-CH2), 
29.1 (5-CH2), 29.3 (4-CH2), 31.8 (8-CH2), 126.8 (2-C), 145.6 (3-CH), 172.8 (1-CO). 
ESMS: m/z: 226 [M + CH3CN]H+, 167 [M - H2O]H+. 
 
E-Ethyl-2-methyltetradec-2-enoate 17374 
 
The obtained product was a colorless oil (0.34 g, 1.27 mmol, 63.4 %) 
Rf: 0.9 (EtOAc / PE 1:7). 
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1H-NMR (CDCl3, 400 MHz): δ 0.88 (t, 3H, 14-CH3), 1.24-1.36 (m, 18H, 5-13-CH2), 1.43 (t, 3H, 17-CH3), 
2.16 (q, 2H, 4-CH2), 6,76 (d, 1H, 3-CH), 1.82 (s, 3H, 15-CH3), 4.19 (q, 2H, 16-CH2). 
13C-NMR (CDCl3, 100 MHz): δ 13.2 (15-CH3), 14.0 (14-CH3), 14.0 (17-CH3), 22.5 (13-CH2), 28.1-31.8 
(4-12-CH2), 61.1 (16-CH2), 142.8 (2-C), 126.5 (3-CH), 168.1 (1-CO).  
ESMS: m/z: 291 [M+Na]H+  
 
E-2-Methyltetradec-2-enoic acid 17474 
 
The obtained product was a red oil (0.29 g, 1.2 mmol, 85.3 %) 
1H-NMR (CDCl3, 400 MHz): δ 0.88 (t, 3H, 14-CH3), 1.24-1.36 (m, 18H, 5-13-CH2), 2.16 (q, 2H, 4-CH2), 
6.76 (d, 1H, 3-CH), 1.82 (s, 3H, 15-CH3). 
13C-NMR (CDCl3, 100 MHz): δ 13.2 (15-CH3), 14.0 (14-CH3), 22.5 (13-CH2), 28.1-31.8 (4-12-CH2), 142.8 
(2-C), 126.5 (3-CH), 168.1 (1-CO).  
ESMS: m/z: 263 [M + Na]H+, 223 [M - H2O]H+ 
 
8.3.2 Preparation of panthetine dimethyl ketal substrates 
 
Preparation of pantetheine dimethyl ketal 121189,58,137 
 
D-pantothenic acid hemicalcium salt (2.50 g, 10.50 mmol), p-toluensulfonic acid (2.30 g, 13.00 
mmol) and 5 g molecular sieves were suspended in 125 mL dry acetone and stirred at 25 °C for 
12 hours under a nitrogen atmosphere. The suspension was filtered with celite and washed with 
200 ml acetone. The filtrate was concentrated to a colorless oil, redissolved in 200 ml ethyl acetate 
and washed two times with brine (25 ml) and dried over MgSO4. After that the ethyl acetate was 
removed under vacuum and hexane was added to the flask to get a white solid that was dried 
under high vacuum. The corresponding D-pantothenic dimethyl ketal (1.90 g, 7.00 mmol) was 
dissolved in 40 mL dry THF with CDI (1.70 g, 11.00 mmol) and stirred for one hour at 25 °C. 
Then cysteamine (1.30 g, 11.00 mmol) was added to the solution and stirred for 12 hours. The 
solution was concentrated under vacuum and dichloromethane was added. The organic layer were 
washed with NH4Cl (25 mL) and brine (25 mL), dried over MgSO4 and concentrated in vacuo. 
After that, the colorless oil was purified by column chromatography.  
 
The obtained product was a white solid (1.82 g, 5.74 mmol, 85 % over to steps) 
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Rf: 0.2 (EtOAc). 
1H-NMR (CDCl3, 400 MHz): δ[ppm]: 0.98 (s, 3H, 11-CH3); 1.05 (s, 3H, 12-CH3); 1.39 (t, 1H, SH); 1.43 
(s, 3H, 15-CH3); 1.47 (s, 3H, 16-CH3); 2.40 (t, 2H, 5-CH2); 2.64-2.70 (m, 2H, 1-CH2); 3,29 (d, 1H, 13a-
CH2); 3.37-3.63 (m, 4H, 2-6-CH2); 3,69 (d, 1H, 13b-CH2); 4.09 (s,1H, 9-CH); 6.37 (bt, 1H, 3-NH); 7.03 
(bt, 1H, 7-NH). 
13C-NMR (CDCl3, 100 MHz): δ [ppm]: 18.7 (12-CH3); 18.9 (11-CH2); 22.1 (15-CH3); 24.6 (1-CH2); 
29.5 (15-CH3); 33.0 (10-C); 34.9 (6-CH2); 36.2 (5-CH2); 42.4 (2-CH2); 71.4 (13-CH2); 77.2 (9-CH); 99.1 
(14-C); 170.3 (4-CO); 171.1 (8-CO). 
ESMS: m/z: 319 [M] H+, 261 [M - (CH3)2CO]H+ 
 
General procedure pantetheine dimethyl ketal-compounds137 
Acid (1.00 mmol) and pantetheine dimethyl ketal (0.32 g, 1.00 mmol,) were dissolved in 
dichloromethane (8 ml). The mixture was cooled to 0 °C. Then N,N-dimethyl aminopyridine (0.10 
g, 0.80 mmol,) and N-(3-Diethylamino-propyl)-N-ethyl carbodiimide (0.38 g, 2.00 mmol) were 
added. The mixture was warmed to 25 °C and stirred for 4 hours. After that the mixture was 
quenched with 2M HCl (10 ml) and extracted with dichloromethane (3x 25 ml). The organic layer 
was washed with saturated NaHCO3 (20 ml) and brine (20 ml). The product was dried over 
MgSO4 and concentrated under vacuo. The crude product was purified by column 
chromatography 
 
Tigloyl pantetheine dimethyl ketal 175189,58,137 
 
The obtained product was a colorless oil (0.318 g, 0.795 mmol, 79.5 %) 
Rf: 0.46 (EtOAc). 
1H-NMR (CDCl3, 400 MHz): δ 0.99 (s, 3H, 17-CH3); 1.04 (s, 3H, 18-CH3); 1.44 (s, 3H, 21-CH3); 1.48 (s, 
3H, 22-CH3); 1.85-1.87 (m, 6H, 4-5-CH3); 2.44 (t, J = 6.5, 2H, 10-CH2); 3.08 (t, J = 6.3, 2H, 6-CH2); 3.28 
(d, J = 11.7, 1H, 16a-CHH); 3.41-3.62 (m, 4H, 7-11-CH2); 3.68 (d, J = 11.6, 1H, 16b-CHH); 4.08 (s, 1H, 
14-CH); 6.13 (bt, J = 5.8, 1H, 8-NH); 6.93 (q, J = 1.4, 6.8, 1H, 3-CH); 7.03 (bt, J = 5.9, 1H, 12-NH). 
 13C-NMR (CDCl3, 100 MHz): δ12.2 (4-CH3); 14.4 (5-CH3); 18.7 (17-CH3); 18.9 (18-CH3); 22.1 (21-CH3); 
28.3 (6-CH2); 29.5 (22-CH3); 32.9 (15-C); 34.8 (10-CH2); 35.9 (11-CH2); 39.7 (7-CH2); 71.5 (16-CH2); 
77.2 (14-CH); 99.1 (19-C); 136.8 (2-C); 136.9 (3-CH); 170.1 (9-CO); 171.1 (13-CO); 190.2 (1-CO) 
ESMS: m/z: 423.3 [M + Na]H+, 401 [M]H+ 
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E-2-Methylhex-2-enoyl pantetheine dimethyl ketal 176179,58,137 
 
The obtained product was a yellow oil (0.38 g, 0.88 mmol, 88 %). 
Rf: 0.45 (EtOAc). 
1H-NMR (CDCl3, 400 MHz): δ 0.96 (t, J = 7.6, 3H, 6-CH3); 0.97 (s, 3H, 19-CH3); 1.04 (s, 3H, 20-CH3); 
1.44-1.55 (m, 2H, 5-CH2); 1.41 (s, 3H, 22-CH3); 1.46 (s, 3H, 23-CH3); 1.87 (s, 3H, 7-CH3); 2.20 (q, J = 
7.4, 2H, 4-CH2); 2.42 (t, J = 6.1, 2H, 12-CH2); 3.05 (t, J = 6.5, 2H, 8-CH2); 3.27 (d, J = 11.2, 1H, 18a-
CHH); 3.39-3.62 (m, 4H, 9-13-CH2); 3.68 (d, J = 11.7, 1H, 18b-CHH); 4.07 (s, 1H, 16-CH); 6.10 (bt, J = 
5.7, 1H, 10-NH); 6.77 (t, J = 1.3, 6.9, 1H, 3-CH); 7.03 (bt, J = 5.7, 1H, 14-NH). 
13C-NMR (CDCl3, 100 MHz): δ12.5 (6-CH3); 13.9 (7-CH3); 18.7 (19-CH3); 18.9 (20-CH3); 21.8 (5-CH2); 
22.1 (22-CH3); 28.4 (8-CH2); 28.8 (4-CH2); 29.5 (23-CH3); 32.9 (17-C); 34.8 (12-CH2); 35.9 (13-CH2); 
39.7 (9-CH2); 71.5 (18-CH2); 77.2 (16-CH); 99.1 (21-C); 135.9 (2-C); 142.1 (3-CH); 170.0 (11-CO); 171.2 
(15-CO); 193.7 (1-CO). 
ES-MS: m/z: 429.7 [M]H+ 
 
E-4-Methylhex-2-enoyl pantetheine dimethyl ketal 177179,58,137 
 
The obtained product was a colorless oil (0.35 g, 0.82 mmol, 82 %). 
Rf: 0.47 (EtOAc) 
1H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 7.2, 3H, 6-CH3); 0.97 (s, 3H, 19-CH3); 1.04 (s, 3H, 20-CH3); 
1.06 (d, J = 6.7, 3H, 7-CH3), 1.40-1.45 (m, 2H, 5-CH2); 1.41 (s, 3H, 22-CH3); 1.46 (s, 3H, 23-CH3); 2.17-
2.26 (m, 1H, 4-CH); 2.42 (t, J = 6.3, 2H, 12-CH2); 3.05 (t, J = 6.3, 2H, 8-CH2); 3.27 (d, J = 11.9, 1H, 18a-
CHH); 3.40-3.62 (m, 4H, 9-13-CH2); 3.68 (d, J = 11.7, 1H, 18b-CHH); 4.07 (s, 1H, 16-CH); 6.08 (dd, J = 
1.2, 15.6, 1H, 2-CH); 6.12 (bt, J = 5.1, 1H, 10-NH); 6.77 (dd, J = 7.5, 15.5, 1H, 3-CH); 7.03 (bt, J = 6.0, 
1H, 14-NH). 
13C-NMR (CDCl3, 100 MHz): δ11.6 (6-CH3); 12.2 (7-CH3); 18.7 (19-CH3); 18.9 (20-CH3); 22.1 (22-CH3); 
28.3 (5-CH2); 28.4 (8-CH2); 29.5 (23-CH3); 32.9 (17-C); 34.8 (12-CH2); 35.9 (13-CH2); 38.1 (4-CH); 39.7 
(9-CH2); 71.5 (18-CH2); 77.2 (16-CH); 99.1 (21-C); 126.7 (2-CH); 151.7 (3-CH); 170.0 (11-CO); 171.2 
(15-CO); 190.3 (1-CO) 
ESMS: m/z (%): 429.7 [M]H+, 452 [M + Na]H+ 
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E-2-4-Dimethylhex-2-enoyl pantetheine dimethyl ketal 178179,58,137 
 
The obtained product was a colorless oil (0.38 g, 0.89 mmol, 89%). 
Rf: 0.45 (EtOAc).  
1H-NMR (CDCl3, 400 MHz): δ 0.87 (t, J = 7.9, 3H, 6-CH3); 0.97 (s, 3H, 20-CH3); 1.04 (s, 3H, 21-CH3); 
1.03 (d, J = 7.5, 3H, 7-CH3), 1.24-1.49 (m, 3H, 4-CH, 5-CH2); 1.41 (s, 3H, 23-CH3); 1.46 (s, 3H, 24-CH3); 
1.88 (s, 3H, 8-CH3); 2.42 (t, J = 5.9, 2H, 13-CH2); 3.05 (t, J = 6.4, 2H, 9-CH2); 3.27 (d, J = 11.4, 1H, 
19a-CHH); 3.39-3.64 (m, 4H, 10-14-CH2); 3.68 (d, J = 11.7, 1H, 19b-CHH); 4.07 (s, 1H, 17-CH); 6.09 (bt, 
J = 5.4, 1H, 11-NH); 6.53 (dd, J = 1.4, 9.8, 1H, 3-CH); 7.03 (bt, J = 5.8, 1H, 15-NH).  
13C-NMR (CDCl3, 100 MHz): δ11.9 (6-CH3); 12.2 (7-CH3); 18.7 (20-CH3); 18.9 (21-CH3); 19.9 (8-CH3); 
22.1 (23-CH3); 28.5 (9-CH2); 29.5 (24-CH3); 29.6 (5-CH2); 32.9 (18-C); 34.4 (13-CH2); 35.0 (4-CH); 35.9 
(14-CH2); 39.7 (10-CH2); 71.5 (19-CH2); 77.2 (17-CH); 99.1 (22-C); 134.5 (2-C); 147.6 (3-CH); 170.0 (12-
CO); 171.2 (16-CO); 193.9 (1-CO). 
ESMS: m/z: 471 [M]H+, 493 [M + Na]H+ 
 
E-Oc-2-enoic pantetheine dimethyl ketal 179179,58,137 
 
The obtained product was a colorless oil (0.35 g, 0.79 mmol, 56.1 %) 
Rf: 0.56 (EtOAc / PE, 9:1) 
1H-NMR (CDCl3, 400 MHz): δ 0.90 (t, J = 7.4, 3H, 8-CH3); 0.97 (s, 3H, 19-CH3); 1.04 (s, 3H, 20-CH3); 
1.31-1.51 (m, 6H, 5-6-7-CH2); 1.41 (s, 3H, 23-CH3); 1.46 (s, 3H, 24-CH3); 2.21 (g, J = 7.3, 2H, 4-CH2); 
2.42 (t, J = 5.8, 2H, 13-CH2); 3.05 (t, J = 6.7, 2H, 9-CH2); 3.27 (d, J = 11.8, 1H, 21a-CHH); 3.39-3.62 (m, 
4H, 10-14-CH2); 3.68 (d, J = 12.2, 1H, 21b-CHH); 4.07 (s, 1H, 17-CH); 6.08 (bt, J = 5.8, 1H, 11-NH); 6.92 
(t, J = 1.5, 7.4, 1H, 3-CH); 7.03 (bt, J = 5.8, 1H, 15-NH).  
13C-NMR (CDCl3, 100 MHz): δ12.5 (8-CH3); 18.7 (19-CH3); 18.9 (20-CH3); 22.1 (24-CH3); 22.5 (7-CH2); 
28.2 (10-CH2); 28.4 (5-CH2); 28.8 (4-CH2); 29.5 (23-CH3); 31.6 (6-CH2); 32.9 (18-C); 34.8 (13-CH2); 35.9 
(14-CH2); 39.7 (9-CH2); 71.5 (21-CH2); 77.2 (17-CH); 99.1 (22-C); 135.7 (2-C); 142.4 (3-CH); 170.0 (12-
CO); 171.1 (16-CO); 193.7 (1-CO). 
ESMS: m/z: 443.62 [M]H+  
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E-2-Methyloct-2-enoyl pantetheine dimethyl ketal 180179,58,137 
 
The obtained product was a colorless oil (0.27 g, 0.60 mmol, 60%). 
Rf: 0.47 (EtOAc).  
1H-NMR (CDCl3, 400 MHz): δ 0.90 (t, J = 7.4, 3H, 8-CH3); 0.97 (s, 3H, 19-CH3); 1.04 (s, 3H, 20-CH3); 
1.31-1.51 (m, 6H, 5-6-7-CH2); 1.41 (s, 3H, 24-CH3); 1.46 (s, 3H, 25-CH3); 1.87 (s, 3H, 9-CH3); 2.21 (g, J 
= 7.3, 2H, 4-CH2); 2.42 (t, J = 5.8, 2H, 14-CH2); 3.05 (t, J = 6.7, 2H, 10-CH2); 3.27 (d, J = 11.8, 1H, 22a-
CHH); 3.39-3.62 (m, 4H, 11-15-CH2); 3.68 (d, J = 12.2, 1H, 22b-CHH); 4.07 (s, 1H, 18-CH); 6.08 (bt, J = 
5.8, 1H, 12-NH); 6.92 (t, J = 1.5, 7.4, 1H, 3-CH); 7.03 (bt, J = 5.8, 1H, 16-NH). 
13C-NMR (CDCl3, 100 MHz): δ12.5 (8-CH3); 13.9 (1-CH3); 18.7 (19-CH3); 18.9 (20-CH3); 22.1 (24-CH3); 
22.5 (7-CH2); 28.2 (10-CH2); 28.4 (5-CH2); 28.8 (4-CH2); 29.5 (25-CH3); 31.6 (6-CH2); 32.9 (21-C); 34.8 
(14-CH2); 35.9 (15-CH2); 39.7 (11-CH2); 71.5 (22-CH2); 77.2 (18-CH); 99.1 (23-C); 135.7 (2-C); 142.4 (3-
CH); 170.0 (13-CO); 171.1 (17-CO); 193.7 (9-CO). 
ESMS: m/z: 457.7 [M]H+ 
 
E-4S-6S-Dimethyl-octenoyl-pantethine dimethyl ketal 181179,58,137 
 
The obtained product was colorless oil (0.22 g, 0.47 mmol, 36.2 %) 
Rf: 0.47 (EtOAc / PE, 9:1) 
1H-NMR (CDCl3, 400 MHz): δ 0.87 (m, 6H, 8-9-CH3); 0.97 (s, 3H, 22-CH3); 1.04 (s, 3H, 23-CH3); 
1.13-1.19 (m, 2H, 7-CH3), 1.26-1.49 (m, 3H, 5-6-CH2); 1.44 (s, 3H, 25-CH3); 1.48 (s, 3H, 26-CH3); 2.34 
(m, 1H, 4-CH); 2.45 (t, J = 5.9, 1H, 14-CH); 3.10 (t, J = 6.5, 2H, 11-CH2); 3.27 (d, J = 11.7, 1H, 21a-CHH); 
3.42-3.62 (m, 4H, 12-16-CH2); 3.70 (d, J = 11.6, 1H, 21b-CHH); 4.09 (s, 1H, 19-CH); 6.12 (dd, J = 1.0, 
16.0, 1H, 2-CH); 6.28 (bt, J = 6.3, 1H, 13-NH); 6.80 (d, J = 8.2, 15.8, 1H, 3-CH); 7.06 (bt, J = 5.8, 1H, 17-
NH).  
13C-NMR (CDCl3, 100 MHz): δ11.1 (8-CH3); 14.2 (9-CH3); 18.7 (22-CH3); 18.9 (23-CH3); 22.1 (25-CH3); 
28.2 (11-CH2); 29.5 (26-CH3); 29.7 (7-CH2); 32.9 (6-CH); 32.9 (18-C); 34.4 (4-CH); 34.7 (15-CH2) 35.9 
(16-CH2); 39.7 (12-CH2); 43-5 (5-CH) 71.5 (21-CH2); 77.2 (19-CH); 99.1 (24-C); 126.6 (2-CH); 152.1 (3-
CH); 170.1 (14-CO); 171.1 (18-CO); 190.1 (1-CO). 
ESMS: m/z: 471 [M]H+, 493 [M + Na]H+ 
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E-Dec-2-enoyl pantetheine dimethyl ketal 182179,58,137 
 
The obtained product was a colorless oil (0.18 g, 0.38 mmol, 38.3%) 
Rf: 0.49 (EtAc / PE, 9:1) 
1H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 7.6, 3H, 10-CH3); 0.97 (s, 3H, 21-CH3); 1.04 (s, 3H, 22-CH3); 
1.30-1.47 (m, 10H, 5-6-7-8-9-CH2); 1.41 (s, 3H, 25-CH3); 1.46 (s, 3H, 26-CH3); 2.21 (q, J = 7.1, 2H, 4-
CH2); 2.42 (t, J = 6.2, 2H, 15-CH2); 3.05 (t, J = 6.2, 2H, 11-CH2); 3.27 (d, J = 12.2, 1H, 23a-CHH); 3.39-
3.62 (m, 4H, 12-16-CH2); 3.68 (d, J = 12.2, 1H, 23b-CHH); 4.07 (s, 1H, 19-CH); 6.08 (bt, J = 5.0, 1H, 13-
NH); 6.77 (t, J = 1.9, 6.9, 1H, 3-CH); 7.03 (bt, J = 5.5, 1H, 17-NH).  
13C-NMR (CDCl3, 100 MHz): 14.0 (10-CH3); 18.7 (21-CH3); 18.9 (22-CH3); 22.1 (25-CH3); 22.6 (9-CH2); 
28.4 (5-CH2); 28.5 (12-CH2); 28.8 (6-CH2); 29.1 (7-CH2); 29.5 (26-CH3); 31.8 (8-CH2); 33.2 (4-CH2); 34.8 
(15-CH2); 35.9 (16-CH2); 39.7 (11-CH2); 71.5 (23-CH2); 77.2 (19-CH); 99.1 (20-C); 135.7 (2-C); 142.4 (3-
CH); 170.0 (14-CO); 171.2 (18-CO); 193.7 (11-CO). 
ESMS: m/z: 471.76 [M]H+, 493 [M + Na]H+  
 
E-2-Methyldec-2-enoyl pantetheine dimethyl ketal 183189,58,137 
 
The obtained product was a colorless oil (0.225 g, 0.53 mmol, 63 %). 
Rf: 0.45 (EtOAc). 
1H-NMR (CDCl3, 400 MHz): δ 0.87 (m, 6H, 8-9-CH3); 0.97 (s, 3H, 22-CH3); 1.04 (s, 3H, 23-CH3); 
1.13-1.19 (m, 2H, 7-CH3), 1.26-1.49 (m, 3H, 5-6-CH2); 1.44 (s, 3H, 25-CH3); 1.48 (s, 3H, 26-CH3); 2.34 
(m, 1H, 4-CH); 2.45 (t, J = 5.9, 1H, 14-CH); 3.10 (t, J = 6.5, 2H, 11-CH2); 3.27 (d, J = 11.7, 1H, 21a-CHH); 
3.42-3.62 (m, 4H, 12-16-CH2); 3.70 (d, J = 11.6, 1H, 21b-CHH); 4.09 (s, 1H, 19-CH); 6.12 (dd, J = 1.0, 
16.0, 1H, 2-CH); 6.28 (bt, J = 6.3, 1H, 13-NH); 6.80 (t, J = 8.2, 15.8, 1H, 3-CH); 7.06 (bt, J = 5.8, 1H, 17-
NH).  
13C-NMR (CDCl3, 100 MHz): δ11.1 (8-CH3); 14.2 (9-CH3); 18.7 (22-CH3); 18.9 (23-CH3); 22.1 (25-CH3); 
28.2 (11-CH2); 29.5 (26-CH3); 29.7 (7-CH2); 32.9 (6-CH); 32.9 (18-C); 34.4 (4-CH); 34.7 (15-CH2) 35.9 
(16-CH2); 39.7 (12-CH2); 43-5 (5-CH) 71.5 (21-CH2); 77.2 (19-CH); 99.1 (24-C); 126.6 (2-CH); 152.1 (3-
CH); 170.1 (14-CO); 171.1 (18-CO); 190.1 (1-CO). 
ESMS: m/z: 485.7 [M]H+ 
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E-Cinnamon pantetheine dimethyl ketal 184179,58,137 
 
The obtained product was a white solid (0.45, 0.73 mmol, 48.8 %) 
Rf: 0.42 (EtOAc / PE, 9:1).  
1H-NMR (CDCl3, 400 MHz): 0.97 (s, 3H, 19-CH3); 1.04 (s, 3H, 20-CH3); 1.41 (s, 3H, 24-CH3); 1.46 (s, 
3H, 25-CH3); 2.42 (t, J = 5.8, 2H, 14-CH2); 3.05 (t, J = 6.7, 2H, 10-CH2); 3.27 (d, J = 11.8, 1H, 22a-CHH); 
3.39-3.62 (m, 4H, 11-15-CH2); 3.68 (d, J = 12.2, 1H, 22b-CHH); 4.07 (s, 1H, 18-CH); 6.08 (bt, J = 5.8, 
1H, 12-NH); 6.70 (d, 1H, 2-CH); 7.03 (bt, J = 5.8, 1H, 16-NH), 7.73 (dd, 3H, 5-,6-,7-CH); 7.52 (m, 2H, 4-
,8-CH); 7.59 (d, J = 15.82, 1H, 3-CH) 
13C-NMR (CDCl3, 100 MHz): δ 18.7 (19-CH3); 18.9 (20-CH3); 22.1 (24-CH3);); 28.2 (10-CH2); 29.5 (25-
CH3); 32.9 (21-C); 34.8 (14-CH2); 35.9 (15-CH2); 39.7 (11-CH2); 71.5 (22-CH2); 77.2 (18-CH); 99.1 (23-
C); 123 (2-C) 127-128.5 (4-C, 5-C, 6-C, 7-C, 8-C) 135.7 (9-C); 143 (3-C), 170.0 (13-CO); 171.1 (17-CO); 
193.7 (1-CO). 
ESMS: m/z: 449 [M]H+, 472 [M + Na]H+ 
 
E-2-Methyltetradec-2-enoyl panthetine dimethyl ketal 185179,58,137 
 
The obtained product was white solid (0.12 g, 0.22 mmol, 18.5 %) 
Rf: 0.50 (EtOAc / PE, 9:1). 
1H-NMR (CDCl3, 400 MHz): δ [ppm]: 0.88 (t, 3H, 14-CH3); 0.97 (s, 3H, 25-CH3); 1.04 (s, 3H, 26-CH3); 
1.30-1.47 (m, 18H, 5-13-CH2); 1.41 (s, 3H, 30-CH3); 1.46 (s, 3H, 31-CH3); 1.87 (s, 3H, 15-CH3); 2.21 (q, 
2H, 4-CH2); 2.42 (t, 2H, 20-CH2); 3.05 (t, J = 6.2 Hz, 2H, 16-CH2); 3.27 (d, J = 12.2 Hz, 1H, 28a-CH2); 
3.39-3.62 (m, 4H, 17-21-CH2); 3.68 (d, J = 12.2 Hz, 1H, 28b-CH2); 4.07 (s,1H, 24-CH); 6.08 (bt, J = 5.0 
Hz, 1H, 18-NH); 6.77 (t,1H, 3-CH); 7.03 (t, J = 5.5 Hz, 1H, 22-NH). 
13C-NMR (CDCl3, 100 MHz): δ[ppm]: 12.5 (14-CH3); 14.0 (15-CH3); 18.7 (25-CH3); 18.9 (26-CH3); 22.1 
(30-31-CH3 ); 22.6 (13-CH2 ); 28.5 (12-CH2); 29.1-29.9 (5-11-CH2); 31.6 (4-CH2); 34.8 (21-CH2); 39.7 (20-
CH2); 71.5 (28-CH2); 77.2 (18-CH); 99.1 (29-C); 135.7 (29-C); 142.4 (2-CH); 170.0 (23-CO); 171.1 (19-
CO); 193.7 (1-CO). 
ESMS: m/z: 541.3 [M]H+, 573 [M + Na]H+  
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8.3.4 Synthesis of panthetine substrates first method137 
 
The acyl pantetheine dimethyl ketal was stirred in a mixture of acetonitrile and water (1:1) and 
10% TFA for 20 minutes. The reaction was followed by TLC and LCMS. After that the solvents 
were liphophilized. The product was purified by preparative HPLC (acetonitrile). 
 
Tigloyl-pantethine 77179,58,137 
  
The obtained product was a colourless oil (0.167 g, 0.46 mmol, 90 %) 
Rf: 0.44 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ 0.92 (s, 3H, 17-CH3); 0.92 (s, 3H, 18-CH3); 1.82-1.87 (m, 6H, 4-5-CH3); 
2.41 (t, J = 5.9, 2H, 10-CH2); 3.01-3.10 (m, 2H, 6-CH2); 3.32-3.60 (m, 6H, 7-11-16-CH2); 3.99 (s, 1H, 14-
CH); 6.33 (bt, J = 5.8, 1H, 8-NH); 6.86 (q, J = 1.3, 6.8, 1H, 3-CH); 7.40 (bt, J = 5.6, 1H, 12-NH).  
13C-NMR (CDCl3, 100 MHz): δ 12.2 (5-CH3); 14.5 (4-CH3), 20.4 (17-CH3); 21.5 (18-CH3); 28.2 (6-CH2); 
35.2 (11-CH2); 35.6 (10-CH2); 39.3 (15-C); 39.9 (7-CH2); 70.9 (16-CH2); 77.9 (14-CH); 136.8 (3-C); 137.3 
(2-CH); 171.8 (9-CO); 173.5 (13-CO); 194.1 (1-COS). 
ESMS: m/z: 383 [M + Na]H+, 361 [M]H+, 343 [M - H2O]H+ 
 
E-2-Methylhex-2-enoylpantethine 83179,58,137 
 
The obtained product was a colourless oil (0.009 g, 0.02 mmol, 15 %) 
Rf: 0.44 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ 0.93 (q, 3H, 6-CH3); 0.95 (t, J = 7.4, 3H, 19-CH3); 1.02 (s, 3H, 20-CH3); 
1.46-1.55 (m, 2H, 5-CH2); 1.88 (d, J = 1.4, 7-CH3) 2.20 (dq, J = 1.3, J = 7.0, 2H, 4-CH2); 2.41 (t, J = 5.9, 
2H, 12-CH2); 3.00-3.13 (m, 2H, 8-CH2); 3.35-3.59 (m, 6H, 9-13-18-CH2); 3.99 (s, 1H, 16-CH); 6.23 (bt, J 
= 5.7, 1H, 10-NH); 6.77 (tq, J = 1, 4, J = 7.4, 1H, 3-CH); 7.38 (bt, J = 5.9, 1H, 14-NH).  
13C-NMR (CDCl3, 100 MHz): δ12.5 (6-CH3), 13.9 (7-CH3), 20.4 (19-CH3); 21.7 (20-CH3); 21.8 (5-CH2); 
28.3 (8-CH2); 30.8 (4-CH2); 35.1 (12-CH2); 35.5 (13-CH2); 39.4 (17-C); 39.8 (9-CH2); 70.9 (18-CH2); 77.7 
(16-CH); 135.7 (2-C); 142.5 (3-CH); 171.6 (11-CO); 173.4 (15-CO); 194.2 (1-COS).  
ESMS: m/z:411 [M + Na]H+, 389 [M]H+ 
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E-4-Methylhex-2-enoyl pantetheine 84179,58,137 
 
The obtained product was a colourless oil (0.013 g, 0.03 mmol, 21 %) 
Rf: 0.1 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 7.5, 3H, 6-CH3); 0.98 (s, 3H, 19-CH3); 1.01 (s, 3H, 20-CH3); 
1.05 (d, J = 6.9, 7-CH3); 1.38-1.47 (m, 2H, 5-CH2); 2.19-2.27 (m, 1H, 4-CH); 2.41 (t, J = 5.8, 2H, 12-CH2); 
2.94-3.15 (m, 2H, 8-CH2); 3.33-3.58 (m, 6H, 9-13-18-CH2); 4.00 (s, 1H, 16-CH); 6.08 (dd, J = 1.4, J = 
15.4, 1H, 2-CH); 6.40 (bt, J = 5.4, 1H, 10-NH); 6.83 (dd, J = 7.4, J = 15.4, 1H, 3-CH); 7.40 (bt, J = 5.4, 
1H, 14-NH).  
13C-NMR (CDCl3, 100 MHz): δ11.6 (6-CH3), 18.7 (7-CH3), 20.4 (19-CH3); 21.7 (20-CH3); 28.2 (5-CH2); 
28.8 (8-CH2); 35.1 (12-CH2); 35.8 (13-CH2); 38.2 (4-CH); 39.4 (16-C); 39.7 (9-CH2); 70.8 (18-CH2); 77.6 
(16-CH); 126.7 (2-CH); 152.1 (3-CH); 171.7 (11-CO); 173.6 (15-CO); 190.8 (1-COS).  
ESMS: m/z : 411 [M + Na]H+, 389 [M]H+ 
 
E-2-4-Dimethylhex-2-enoylpantetheine 86179,58,137 
 
The obtained product was a colourless oil (0.012 g, 0.029 mmol, 20 %) 
Rf: 0.42 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ 0.86 (t, J = 7.4, 3H, 6-CH3); 0.92 (s, 3H, 20-CH3); 1.03 (s, 3H, 21-CH3); 
1.03 (d, J = 2.3, 3H, 7-CH3); 1.30-1.51 (m, 4H, 5-CH2); 1.88 (d, J = 1.1, 8-CH3), 2.41 (t, J = 5.6, 2H, 13-
CH2); 2.40-2.49 (m, 1H, 4-CH); 2.99-3.14 (m, 2H, 9-CH2); 3.35-3.59 (m, 6H, 10-14-19-CH2); 3.99 (s, 1H, 
17-CH); 6.19 (bt, J = 5.7, 1H, 11-NH); 6.54 (dq, J = 1, 3, J = 9.8, 1H, 3-CH); 7.36 (bt, J = 5.9, 1H, 15-NH).  
13C-NMR (CDCl3, 100 MHz): δ11.9 (6-CH3), 12.7 (7-CH3), 19.5 (8-CH3), 20.4 (20-CH3); 21.7 (21-CH3); 
28.3 (9-CH2); 29.6 (5-CH); 35.1 (13-CH2); 35.6 (14-CH2); 39.4 (18-C); 39.8 (10-CH2); 71.0 (19-CH2); 77.7 
(17-CH); 134.4 (2-C); 147.8 (3-CH); 171.4 (11-CO); 173.3 (15-CO); 194.5 (1-COS).  
ESMS: m/z: 425 [M + Na]H+, 403 [M]H+, 385 [M - H2O]H+ 
 
E-2-Methyloct-2-enoylpantetheine 91179,58,137 
 
The obtained product was a colourless oil (0.01 g, 0.024 mmol, 17%) 
Rf: 0.45 (DCM / MeOH). 
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1H-NMR (CDCl3, 400 MHz): δ 0.90 (t, J = 6.9, 3H, 8-CH3); 0.91 (s, 3H, 21-CH3); 1.01 (s, 3H, 22-CH3); 
1.25-1.36 (m, 4H, 6-7-CH2); 1.41-1.50 (m, 2H, 5-CH2); 1.85 (s, 3H, 9-CH3); 2.20 (q, J = 7.5, 2H, 4-CH2); 
2.41 (t, J = 6.6, 2H, 14-CH2); 2.99-3.12 (m, 2H, 10-CH2); 3.35-3.58 (m, 6H, 11-15-20-CH2); 3.99 (s, 1H, 
18-CH); 6.37 (bt, J = 5.7, 1H, 12-NH); 6.77 (t, J = 1.3, J = 7.6, 1H, 3-CH); 7.41 (bt, J = 6.2, 1H, 16-NH).  
13C-NMR (CDCl3, 100 MHz): δ12.5 (9-CH3); 14.1 (8-CH3); 20.4 (21-CH3); 21.6 (22-CH3); 22.5 (7-CH2); 
28.1 (5-CH2); 28.2 (4-CH2); 28.8 (10-CH2); 31.6 (6-CH2); 35.1 (14-CH2); 35.6 (15-CH2); 39.4 (19-C); 39.8 
(11-CH2); 70.9 (20-CH2); 77.8 (18-CH); 135.6 (2-C); 142.7 (3-CH); 171.7 (13-CO); 173.2 (17-CO); 194.2 
(1-COS).  
ESMS: m/z: 439 [M + Na]H+, 417 [M]H+, 399 [M - H2O]H+ 
 
E-2-Methyldec-2-enoylpantetheine 95179,58,137 
 
The obtained product was a colourless oil (0.01 g, 0.02 mmol, 17 %) 
Rf: 0.48 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ 0.88 (q, J = 7.2, 3H, 10-CH3); 0.93 (s, 3H, 23-CH3); 1.04 (s, 3H, 24-CH3); 
1.28-1.31 (m, 8H, 6-9-CH2); 1.43-1.48 (m, 2H, 5-CH2); 1.87 (s, 3H, 11-CH3); 2.22 (q, J = 7.2, 2H, 4-CH2); 
2.41 (t, J = 6.2, 2H, 16-CH2); 3.00-3.14 (m, 2H, 12-CH2); 3.35-3.63 (m, 6H, 13-17-22-CH2); 3.99 (s, 1H, 
20-CH); 6.09 (bt, J = 5.6, 1H, 14-NH); 6.78 (tq, J = 1.3, J = 7.4, 1H, 3-CH); 7.38 (bt, J = 6.6, 1H, 18-NH).  
13C-NMR (CDCl3, 100 MHz): δ12.5 (11-CH3); 14.1 (10-CH3); 20.4 (23-CH3); 21.7 (24-CH3); 22.6 (9-
CH2); 28.3 (5-CH2); 28.5 (12-CH2); 29.1 (7-CH2); 29.4 (6-CH2); 31.8 (8-CH2); 35.1 (16-CH2); 35.6 (17-
CH2); 39.4 (21-C); 39.8 (13-CH2); 70.9 (22-CH2); 77.8 (19-CH); 135.6 (2-C); 142.8 (3-CH); 171.7 (15-
CO); 173.2 (19-CO); 194.2 (1-COS). 
ESMS: m/z: 467 [M + Na]H+, 445 [M]H+, 427 [M - H2O]H+ 
 
E-Cinnamon acid pantetheine 113179,58,137 
 
The obtained product was a colourless oil (0.03 g, 0.07 mmol, 26 %) 
Rf: 0.5 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): 0.97 (s, 3H, 19-CH3); 1.04 (s, 3H, 20-CH3); 2.42 (t, J = 5.8, 2H, 14-CH2); 
3.05 (t, J = 6.7, 2H, 10-CH2); 3.27 (d, J = 11.8, 1H, 21a-CHH); 3.39-3.62 (m, 4H, 11-15-CH2); 3.68 (d, J 
= 12.2, 1H, 21b-CHH); 4.07 (s, 1H, 18-CH); 6.08 (bt, J = 5.8, 1H, 12-NH); 6.70 (d, 1H, 2-CH); 7.03 (bt, J 
= 5.8, 1H, 16-NH), 7.73 (dd, 3H, 5-,6-,7-CH); 7.52 (m, 2H, 4-,8-CH); 7.59 (d, J = 15.82, 1H, 3-CH) 
13C-NMR (CDCl3, 100 MHz): δ 18.7 (19-CH3); 18.9 (20-CH3); 28.2 (10-CH2); 70.2 (21-C); 34.8 (14-CH2); 
35.9 (15-CH2); 39.7 (11-CH2); 77.2 (18-CH); 48.1 (22-C); 123 (2-C) 127-128.5 (4-C, 5-C, 6-C, 7-C, 8-C) 
135.7 (9-C); 143 (3-C), 170.0 (13-CO); 171.1 (17-CO); 193.7 (1-CO). 
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ESMS: m/z: 432 [M + Na]H+, 409 [M]H+ 
 
E-2-Methyltetradec-2-enoylpantetheine 112179,58,137 
 
The obtained product was a colourless oil (0.01 g, 0.02 mmol, 16 %) 
Rf: 0.3 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ [ppm]: 0.88 (t, 3H, 14-CH3); 0.97 (s, 3H, 25-CH3); 1.04 (s, 3H, 26-CH3); 
1.30-1.47 (m, 18H, 5-13-CH2); 1.87 (s, 3H, 15-CH3); 2.21 (q, 2H, 4-CH2); 2.42 (t, 2H, 20-CH2); 3.05 (t, J 
= 6.2 Hz, 2H, 16-CH2); 3.27 (d, J = 12.2 Hz, 1H, 28a-CH2); 3.39-3.62 (m, 4H, 17-21-CH2); 3.68 (d, J = 
12.2 Hz, 1H, 28-CH2); 4.07 (s,1H, 24-CH); 6.08 (bt, J = 5.0 Hz, 1H, 18-NH); 6.77 (t,1H, 3-CH); 7.03 (t, J 
= 5.5 Hz, 1H, 22-NH). 
13C-NMR (CDCl3, 100 MHz): δ[ppm]: 12.5 (14-CH3); 14.0 (15-CH3); 18.7 (25-CH3); 18.9 (26-CH3); 22.1 
(30-31-CH3 ); 22.6 (13-CH2 ); 28.5 (12-CH2); 29.1-29.9 (5-11-CH2); 31.6 (4-CH2); 34.8 (21-CH2); 39.7 (20-
CH2); 71.5 (28-CH2); 77.2 (18-CH); 142.4 (2-CH); 170.0 (23-CO); 171.1 (19-CO); 193.7 (1-CO). 
ESMS: m/z: 501.3 [M]H+, 523 [M + Na]H+ 
 
8.3.5 Synthesis of panthetine substrates second method 
 
The corresponding Acyl pantetheine dimethyl ketal was dissolved in 8 ml Acetonitrile. Indium 
chloride (2 eq.) and water (4 eq.) were added to the mixture. The reaction was stirred for 3 h by 
RT. After 3 h the reaction was controlled by TLC and LCMS. Afterwards was the Acetonitrile 
evaporated and purified by flash column chromatography (DCM / MeOH). 
 
E-2-Methylhex-2-enoylpantetheine 8374,190 
 
The obtained product was a colourless oil (0.2 g, 0.51 mmol, 90 %) 
Rf: 0.44 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ 0.93 (s, 3H, 1-CH3); 0.95 (t, J = 7.4, 3H, 19-CH3); 1.02 (s, 3H, 20-CH3); 
1.46-1.55 (m, 2H, 5-CH2); 1.88 (d, J = 1.4, 7-CH3) 2.20 (dq, J = 1.3, J = 7.0, 2H, 4-CH2); 2.41 (t, J = 5.9, 
2H, 12-CH2); 3.00-3.13 (m, 2H, 8-CH2); 3.35-3.59 (m, 6H, 9-13-18-CH2); 3.99 (s, 1H, 16-CH); 6.23 (bt, J 
= 5.7, 1H, 10-NH); 6.77 (t, J = 1, 4, J = 7.4, 1H, 3-CH); 7.38 (bt, J = 5.9, 1H, 14-NH).  
13C-NMR (CDCl3, 100 MHz): δ12.5 (6-CH3), 13.9 (7-CH3), 20.4 (19-CH3); 21.7 (20-CH3); 21.8 (5-CH2); 
28.3 (8-CH2); 30.8 (4-CH2); 35.1 (12-CH2); 35.5 (13-CH2); 39.4 (17-C); 39.8 (9-CH2); 70.9 (18-CH2); 77.7 
(16-CH); 135.7 (2-C); 142.5 (3-CH); 171.6 (11-CO); 173.4 (15-CO); 194.2 (1-COS). 
ESMS: m/z:411 [M + Na]H+, 389 [M]H+ 
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E-4-Methylhex-2-enoylpantetheine 8474,190 
 
The obtained product was a colourless oil (0.19 g, 0.49 mmol, 94 %) 
Rf: 0.46 (DCM / MeOH) 
1H-NMR (CDCl3, 400 MHz): δ 0.88 (t, J = 7.5, 3H, 6-CH3); 0.98 (s, 3H, 19-CH3); 1.01 (s, 3H, 20-CH3); 
1.05 (d, J = 6.9, 7-CH3); 1.38-1.47 (m, 2H, 5-CH2); 2.19-2.27 (m, 1H, 4-CH); 2.41 (t, J = 5.8, 2H, 12-CH2); 
2.94-3.15 (m, 2H, 8-CH2); 3.33-3.58 (m, 6H, 9-13-18-CH2); 4.00 (s, 1H, 16-CH); 6.08 (dd, J = 1.4, J = 
15.4, 1H, 2-CH); 6.40 (bt, J = 5.4, 1H, 10-NH); 6.83 (dd, J = 7.4, J = 15.4, 1H, 3-CH); 7.40 (bt, J = 5.4, 
1H, 14-NH).  
13C-NMR (CDCl3, 100 MHz): δ11.6 (6-CH3), 18.7 (7-CH3), 20.4 (19-CH3); 21.7 (20-CH3); 28.2 (5-CH2); 
28.8 (8-CH2); 35.1 (12-CH2); 35.8 (13-CH2); 38.2 (4-CH); 39.4 (16-C); 39.7 (9-CH2); 70.8 (18-CH2); 77.6 
(16-CH); 126.7 (2-CH); 152.1 (3-CH); 171.7 (11-CO); 173.6 (15-CO); 190.8 (1-COS).  
ESMS: m/z : 411 [M + Na]H+, 389 [M]H+ 
 
E-2-4-Dimethylhex-2-enoylpantetheine 8674,190 
 
The obtained product was a colorless oil (0.22 g, 0.54 mmol, 88 %) 
Rf: 0.42 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ 0.86 (t, J = 7.4, 3H, 6-CH3); 0.92 (s, 3H, 20-CH3); 1.03 (s, 3H, 21-CH3); 
1.03 (d, J = 2.3, 3H, 7-CH3); 1.30-1.51 (m, 4H, 5-CH2); 1.88 (d, J = 1.1, 8-CH3), 2.41 (t, J = 5.6, 2H, 13-
CH2); 2.40-2.49 (m, 1H, 4-CH); 2.99-3.14 (m, 2H, 9-CH2); 3.35-3.59 (m, 6H, 10-14-19-CH2); 3.99 (s, 1H, 
17-CH); 6.19 (bt, J = 5.7, 1H, 11-NH); 6.54 (dq, J = 1, 3, J = 9.8, 1H, 3-CH); 7.36 (bt, J = 5.9, 1H, 15-NH).  
13C-NMR (CDCl3, 100 MHz): δ11.9 (6-CH3), 12.7 (7-CH3), 19.5 (8-CH3), 20.4 (20-CH3); 21.7 (21-CH3); 
28.3 (9-CH2); 29.6 (5-CH); 35.1 (13-CH2); 35.6 (14-CH2); 39.4 (18-C); 39.8 (10-CH2); 71.0 (19-CH2); 77.7 
(17-CH); 134.4 (2-C); 147.8 (3-CH); 171.4 (11-CO); 173.3 (15-CO); 194.5 (1-COS).  
ESMS: m/z: 425 [M + Na]H+, 403 [M]H+, 385 [M - H2O]H+ 
 
E-Oct-2-enoylpantetheine 90 74,190 
 
The obtained product was a colourless oil (0.17 g, 0.42 mmol, 83 %) 
Rf: 0.45 (DCM / MeOH). 
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1H-NMR (CDCl3, 400 MHz): δ 0.91 (t, J = 6.7, 3H, 8-CH3); 0.95 (s, 3H, 20-CH3); 1.06 (s, 3H, 21-CH3); 
1.28-1.61 (m, 6H, 5-6-7-CH2); 2.21 (dq, J = 1.4, J = 7.3, 2H, 4-CH2); 2.43 (t, J = 6.0, 2H, 13-CH2); 3, 05-
3.20 (m, 2H, 9-CH2); 3.38-3.62 (m, 6H, 10-14-19-CH2); 4.01 (s, 1H, 17-CH); 6.13 (t, J= 4.07, 1H, 2-CH); 
6.17 (dt, J = 1.4, J= 15.4, 1H, 11-NH); 6.96 (dt, J = 6, 9, J = 15.4, 1H, 3-CH); 7.34 (bt, J = 5.82, 1H, 15-
NH).  
13C-NMR (CDCl3, 100 MHz): δ 13.9 (8-CH3), 20.4 (20-CH3); 21.7 (21-CH3); 22.4 (7-CH2); 27.6 (6-CH2); 
28.1 (9-CH2); 31.7 (5-CH2); 32.3 (4-CH2); 35.1 (13-CH2); 35.5 (14-CH2); 39.3 (18-C); 39.9 (10-CH2); 70.9 
(19-CH2); 77.8 (17-CH); 128.1 (2-CH); 147.3 (3-CH); 171.6 (12-CO); 173.2 (16-CO); 190.6 (1-CO). 
ESMS: m/z: 425 [M + Na]H+, 403 [M]H+ 
 
E-2-Methyloct-2-enoylpantetheine 9174,190 
 
The obtained product was a yellow oil. (0.19 g; 91.2 %) 
Rf: 0.45 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ 0.90 (t, J = 6.9, 3H, 8-CH3); 0.91 (s, 3H, 21-CH3); 1.01 (s, 3H, 22-CH3); 
1.25-1.36 (m, 4H, 6-7-CH2); 1.41-1.50 (m, 2H, 5-CH2); 1.85 (s, 3H, 9-CH3); 2.20 (q, J = 7.5, 2H, 4-CH2); 
2.41 (t, J = 6.6, 2H, 14-CH2); 2.99-3.12 (m, 2H, 10-CH2); 3.35-3.58 (m, 6H, 11-15-20-CH2); 3.99 (s, 1H, 
18-CH); 6.37 (bt, J = 5.7, 1H, 12-NH); 6.77 (t, J = 1.3, J = 7.6, 1H, 3-CH); 7.41 (bt, J = 6.2, 1H, 16-NH).  
13C-NMR (CDCl3, 100 MHz): δ12.5 (9-CH3); 14.1 (8-CH3); 20.4 (21-CH3); 21.6 (22-CH3); 22.5 (7-CH2); 
28.1 (5-CH2); 28.2 (4-CH2); 28.8 (10-CH2); 31.6 (6-CH2); 35.1 (14-CH2); 35.6 (15-CH2); 39.4 (19-C); 39.8 
(11-CH2); 70.9 (20-CH2); 77.8 (18-CH); 135.6 (2-C); 142.7 (3-CH); 171.7 (13-CO); 173.2 (17-CO); 194.2 
(1-COS).  
ESMS: m/z: 439 [M + Na]H+, 417 [M]H+, 399 [M - H2O]H+ 
 
6S,4S-2E-Dimethyloct-2-enoylpantetheine 93a74,190 
 
The obtained product was a yellow oil (0.16 g, 0.37 mmol, 73 %) 
Rf: 0.42 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ0.81-0.90 (m, 6H, 8-9-CH3), 0.92 (s, 3H, 21-CH3 ), 1.03 (s, 3H, 22-CH3), 
1.05 (m, 3H, 10-CH3 ), 1.10-1.44 (m, 6H, 5-7-CH2, 6-CH), 2.42 (t, 2H, J = 6.0, 15-CH2), 2.37-2.41 (m, 1H, 
4-CH), 3.03-3.17 (m, 2H, 11-CH2), 3.36-3.58 (m, 6H, 12-16-21-CH2), 3.99 (s, 1H, 19-CH), 6.08 (dd, 1H, 
J = 1.4, J = 15.6, 2-CH), 6.23 (bt, J = 6.0, 1H, 13-NH), 6.79 (dd, J = 7.6, 1H, 3-CH); 7.37 (bt, J = 6.0, 1H, 
17-NH).  
13C-NMR (CDCl3, 100 MHz): 11.3 (8-CH3), 18.8 (9-CH3), 20.2 (10-CH3), 20.5 (21-CH3), 21.9 (22-CH3), 
28.3 (11-CH2), 29.7 (7-CH2), 31.9 (6-CH2), 34.3 (4-CH), 35.1 (15-CH2), 35.9 (16-CH2), 39.5 (18-C), 39.8 
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(12-CH2), 43.3 (5-CH2), 71.1 (21-CH2), 77.9 (19-CH), 126.2 (2-CH), 152.5 (3-CH), 171.8 (14-CO), 173.5 
(18-CO), 190.9 (1-CO).  
ESMS: m/z: 453 [M + Na]H+, 431 [M]H+, 413 [M - H2O]H+ 
 
E-Dec-2-enoyl-pantetheine 9474,190 
 
The obtained product was a colourless oil (0.16 g, 0.37 mmol, 89 %) 
Rf: 0.48 (DCM / MeOH). 
1H-NMR (CDCl3, 400 MHz): δ 0.91 (t, J = 7.1, 3H, 10-CH3); 0.95 (s, 3H, 22-CH3); 1.06 (s, 3H, 23-CH3); 
1.28-1.33 (m, 8H, 6, 7, 8, 9-CH2); 1.45-1.53 (m, 2H, 5-CH2); 2.23 (dq, J = 1.6, J = 7.2, 2H, 4-CH2); 2.43 
(t, J = 7.2, 2H, 15-CH2); 3, 05-3.20 (m, 2H, 11-CH2); 3.37-3.62 (m, 6H, 12-16-21-CH2); 4.01 (s, 1H, 19-
CH); 6.13 (m, 1H, 2-CH); 6.17 (dt, J = 1.5, J = 15.4, 1H, 13-NH); 6.96 (dt, J = 7, 0, J = 15.5, 1H, 3-CH); 
7.34 (bt, J = 6.0, 1H, 17-NH).  
13C-NMR (CDCl3, 100 MHz): δ14.1 (10-CH3), 20.4 (22-CH3); 21.7 (23-CH3); 22.6 (9-CH2); 27.9 (5-CH2); 
28.6 (11-CH2); 29.1 (7-CH2); 29.2 (6-CH2); 31.7 (8-CH2); 32.3 (4-CH2); 35.1 (15-CH2); 35.6 (16-CH2); 
39.3 (20-C); 39.9 (12-CH2); 70.9 (21-CH2); 77.8 (19-CH); 128.1 (2-CH); 147.7 (3-CH); 171.6 (14-CO); 
173.3 (18-CO); 190.9 (1-COS). 
ESMS: m/z: 453 [M + Na]H+, 431 [M]H+ 
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8.4 SQTKS ER Domain 
 
Transformation of pET28-SQTKS-ER into E. coli Top10 
50 μl chemically competent E. coli Top10 cells were thawed on ice and incubated on ice 
for 30 min with 1 μl of the appropriate vector. Subsequently heat shock transformation 
was performed, therefore, the cells were incubated at 42 °C for 30 s, then immediately 
chilled on ice for 2 min. 250 μl SOC medium were added. The transformed cells were 
shaken (350 rpm) for 1 h at 37 °C. Positive clones were selected by plating 50 - 150 μl of 
the cells on solid LB medium containing the appropriate antibiotic. The cells were grown 
over night at 37 °C 
 
Transformation of pET28-SQTKS-ER into E. coli BL21 
50 μl chemically competent E. coli BL 21 cells were thawed on ice and incubated on ice 
for 30 min with 1 μl of the SQTKS-ER-domain. subsequently heat shock transformation 
was performed, therefore, the cells were incubated at 42 °C for 10 s, then immediately 
chilled on ice for 2 min. 800 μl SOC medium were added. The transformed cells were 
shaken (350 rpm) for 1 h at 37 °C. Positive clones were selected by plating 50 - 150 μl of 
the cells on solid LB medium containing the appropriate antibiotic. The cells were grown 
over night at 37 °C. 
 
Protein expression and purification 
A starter culture was prepared by scraping the surface of a glycerol stock of E.coli BL21 
transformed with pET28a-ER. The cells were grown in LB media with kanamycin (50 
mg/mL) and incubated at 37 °C, 180 rpm, overnight. 0.5 ml of the starter culture was 
added to 100 mL 2TY media. The cells were incubated to an OD600 of 0.6, then the flask 
was cooled down to 16 °C and induced with 50 µl 1M IPTG solution. This solution was 
incubated over night at 16 °C, 180 rpm. 
To isolate the protein, the media was centrifuged at 7000 rpm for 30 min and the 
pellet was collected. The cells could be used immediately or frozen at -20 °C. The cells 
were suspended in 50 ml of nickel column wash buffer (50 mM Tris pH 8, 150 mM NaCl, 
10 % glycerol (v/v) and 20 mM imidazole) and sonicated on ice for 6.5 minutes. Every 
30 second the sonicator was switched on and of. The rest of the solution was centrifuged 
at 8500 rpm for 30 min, filtered and purified by a nickel column*. For this a linear 
gradient of elution buffer (50 mM Tris pH 8, 150 mM NaCl, 10% glycerol (v/v) and 0.5 
M imidazole) was used. The fractions were checked by SDS gel and the fractions with 
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the correct mass were combined and concentrated. A second purification was done by a 
size exclusion column chromatography**. The protein solution was loaded onto the 
column and eluted with size exclusion elution buffer (Buffer: 50 mM Tris pH 8, 150 mM 
NaCl, 20% glycerol (v/v)). The fractions were analyzed again by SDS gel and the protein 
with the correct mass and high purity was combined and concentrated. The concentration 
of protein was estimated by a calculated absorption coefficient ε= 0.69 at 280 nm. After 
that the protein was divided into several aliquots and stored at - 4 °C. 
 
*Nickel column Protino Ni-NTA Columns 5 mL  
**Size exclusion column- HiLoad 26/600 Superdex 200pg (GE Healthcare), 320 ml). 
 
Protein expression with the Bioreactor 
A starter culture was prepared by scraping the surface of a glycerol stock of E.coli BL21 
transformed with pET28-ER. The cells were grown in LB media with kanamycin (50 mg 
/ mL) and incubated at 37 °C, 200 rpm, overnight. The reactor was filled with 8 L 2TY 
Medium and autoclaved. The pH was adjusted to pH 7 with 1 M HCl and 25 % ammonia 
solution and kept at this pH.4 ml of the starter culture was added to 8 L 2TY media. The 
air pressure was adjusted to 10 L/min and the rotational speed to 400 rpm. The cells were 
incubated to an OD600 of 0.8, then the reactor was cooled down to 20 °C and induced with 
6 ml 1M IPTG solution. This solution was incubated over night at 20°C, 400 rpm. For the 
purification of the protein the same procedure like for the non-bioreactor protein 
expression was used.  
 
8.5 Colony Polymerase-chain-reaction 
The successful transformation of BL21 cells was configured by Colony-PCR. For a 
Colony-PCR the template was added by transferring a small part of a single E.coli colony 
into the reaction mixture using a sterile toothpick. For each primer pair the specific 
annealing temperature was determined in a PCR temperature gradient. A typical Colony-
PCR contained: 
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0.2 µl  Forward Primer 
0.2 µl  Reverse Primer 
- Picked DNA 
2.5 µl  One Taq Master Mix 
7.1 µl  Water 
________________________ 
Total:  10 µl 
 
8.6 Bradford assay 
Standard solutions of bovine serum albumin (0.1-2 ml/ml) in size exclusion buffer [50 
mM Tris pH 8, 150 mM NaCl, 20 % glycerol (v/v)] were prepared by serial dilution. 100 
μl of the standards were mixed with Bradford dye reagent (1 ml) and incubated for 15 
min at RT. The absorption of each sample was measured at 595 nm against a standard 
(size exclusion buffer 100 μl, Bradford dye reagent, 1 ml) to construct a standard 
concentration curve. A sample of the protein to be quantified (20 μl) was diluted in size 
exclusion buffer (80 μl) and treated with Bradford dye reagent (1ml). This was incubated 
at room temperature for 15 mins and then the absorption was measured at 595 nm. This 
was compared to the previously prepared concentration curve to calculate the amount of 
protein that had been produced. 
 
8.7 SQTKS-ER Domain LCMS Assay 
A sample of reaction mixture (20 μl) was mixed with acetonitrile (80 μl) to precipitate 
the protein and then centrifuged (13,000 rpm, 1 min). The supernatant was analysed 
directly by LCMS using a standard LCMS profile.  
 
8.8 SQTKS-ER-Domain Enzyme Assay 
The different pantetheine assays are performed in a total volume of 400 µl. The 
concentration of NADPH (10 µL of 10 mM stock) and SQTKS-ER-domain (20 µL of 
def. 0.02 U) and the temperature at 25 °C were kept constant in all assays. The amount of 
buffer* (290-365 µL) and substrate (5-80 µL of 5 mM Stock) varied between the assays. 
The assays are performed in cuvettes under measuring the UV absorption at 340 nm. 
 
* 50 mM Tris pH 8.0, 150 mM NaCl, 20 % Glycerol. 
 
 165 
8.9 SQTKS-ER-Domain Stereochemistry Assay 
NMR assays were performed with tigloyl panthetine (2.0 mg, 10 mmol), NADPH (8 mg, 
10 mmol), buffer (50mM Tris, 150 mM NaCl, 20 % (v/v) glycerol and pH 8.0) and the 
isolated ER domain (380 μU, 100 μl of stock) in water (total volume 1 ml). The progress 
of the reaction was monitored by LCMS. After 24 h further NADPH (8 mg, 10 mmol) 
was added to the reaction. After a further 24 h the protein was precipitated with CH2Cl2 
(1 ml) and centrifuged (3000 rpm, 20 min). 
 The organic layer was removed, and the aqueous layer was further extracted with 
CH2Cl2 (2 × 1 ml). The organic fractions were combined, and the solvent was removed 
under a flow of N2 and then dried in vacuo for a further 2 h. To the dried sample was 
added water (450 μl) and aqueous NaOH (2 M, 50 μl). The sample was left for 90 min at 
RT and then acidified with aqueous HCl (2 M, 100 μl) to pH 3 and extracted with CDCl3 
(4 × 200 μl). The organics were combined, dried with MgSO4 and then filtered through 
MgSO4 directly into an NMR tube. (1R, 2R)-(+)-1, 2 diphenyl ethylenediamine was 
titrated (100 mM stock) to optimize resolution of the obtained spectra. 
 
8.10 Mutagenesis 
 
Plasmid isolation 
For the isolation of the plasmid first an overnight culture of E-coli Top10 cells with the 
desired plasmid were cultivated. The next day the cell culture was centrifuged in a 2 ml 
Eppendorf-tube at 13.000 g for 2 min and 4 °C. Afterwards the supernatant was discarded 
and the previous step was repeated with the remaining overnight culture, if necessary. 
The pellet was resuspended in 100 µl Solution (5 mM Glucose, 25 mM Tris-HCl (pH 8.0) 
and 10 mM EDTA) and 5 µl RNAse. The sample was incubated for 5 min by RT. 200 µl 
of Solution II (0.2 M NaOH and 1 % SDS) was added It was mixed carefully by inversion. 
Incubated 5 min by RT. 150 µl Solution III was added (60 ml 5M Potassium acetate, 11.5 
ml conc. acetic acid and 20.5 ml H2O) and mixed carefully by inversion. The mixture was 
centrifuged by 11 000 g for 5 min by 4°C. The supernatant was transferred to a new 1.5 
ml Eppendorf-tube. Then 800 µl EtOH (96 %, bio quality) and 45 µl 3 M Na-Acetate 
were added, inverted and to precipitate the plasmid DNA 30 min by -20 °C incubated. 
Afterwards by 11 000 g for 5 min by 4 °C centrifuged. Then the supernatant was discarded 
and the pellet was washed with 70 % EtOH (bio quality) (100 µl). Afterwards the 
suspension was centrifuged at max speed for 5 min at RT. Then the supernatant discarded 
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and pellet was dried by 37 °C for 15 min until it was clear. The pellet was resuspended in 
20 µl Water and could be stored at -20 °C for further use. 
 
Site directed mutagenesis162 
For the site directed mutagenesis, different Oligo-primers were ordered from Sigma 
Aldrich and used in different combinations. Hereby non-overlapping primer pairs were 
tested.  
As a template the vector pET28a containing the ER sequence of SQTKS was 
chosen. Two different PCR approaches with different polymerases were tested. The first 
approach contained the Q5 High-Fidelity DNA polymerase the other the Phusion High-
Fidelity DNA polymerase. 
 
Q5 High-Fidelity DNA polymerase  Phusion High-Fidelity DNA 
polymerase 
12.5 µl  Q5 Master Mix  5 µl   Phusion Buffer (5x) 
1.25 µl  Forward Primer  1.25 µl   Forward Primer 
1.25 µl  Reverse Primer  1.25 µl   Reverse Primer 
1 µl   Plasmid DNA   1 µl    Plasmid DNA 
(6.5-9 µl) Water    (9-11.25 µl)  Water  
(0-2.5 µl) MgCl2 (50 nM)  (0-2.5 µl)   MgCl2 (50 nM) 
      5 µl   dNTP Mix (1.25 mM) 
      0.25 µl  Polymerase 
_________________________  _________________________ 
Total:  25 µl     Total:  25 µl 
 
Different annealing temperatures were tested to find the best condition for the different 
primer combination. For efficient DNA amplification, 22 PCR cycles with an elongation 
time of 6.30 min were applied.  
The products of the PCR were checked on an Agarose-Gel. Afterwards the blunt 
ends of the primers were ligated through the use of the Quick Ligation Kit (New England 
BioLabs). Hereby to 10 µl of the PCR product were 10 µl of the 2 x Quick Ligation Buffer 
added and mixed. 1 µl Quick T4 DNA Ligase were added and mixed. The mixture was 
incubated by RT for 15 min. Then 0.5 µl of DpnI were added to the sample and incubated 
for 2 h. The enzyme cuts methylated DNA, therefore the parental DNA string will be cut. 
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Afterwards 1 µl of the mixture were transformed into TOP10 Cells (see 8.4). The 
transformation were checked via Colony-PCR.  
 
Sequencing  
Sequencing was done by Eurofins Genomics. Plasmids were sent to sequencing at a 
concentration of 100-200 ng / μl.  
Sequence analysis was done in Geneious (Version 7.1.9) through alignment with the 
original DNA sequence.  
 
8.11 Statistical evaluations  
First, the paired t-test was performed to test the influence of the mutation on the specifity 
constant for the different subtrates compared to non-mutated ER. Whereas a significant 
change in the specifity constant was observed after the mutation this is marked by the 
asterisk (* p < 0.05). The test for normality was performed by Shapiro-Wilk test. Groups 
with (n = 3) were examined.  
Second, the One Way ANOVA was performed test if there is a significant 
difference between the specifity constants between the mutated ER domains. Whereas a 
significant change in the specifity constant was observed after the mutation this is marked 
by the asterisk (* p < 0.05. The test for normality was performed by Shapiro-Wilk test. It 
the Test-Failed, a ANOVa on Ranks were performed. Hence the Kruskal-Wallis One Way 
Analysis of Variance on Ranks performed. Afterwards the was the multiple comparison 
procedure with the Student-Newman-Keuls method performed. Groups with (n = 3) were 
examined.  
 
8.12 Bioinformatics 
 
Sequence alignment  
The sequence of the ER, C-MeT domains SQTKS and KR and C-MeT domains from 
TENS were available in our working group. A BLAST search was done with the 
respective sequence in the NCBI database. From the possible hits, only iterative PKS 
from fungi were considered. The final sequence alignment was done in Geneious 
(Version 7.1.9) through alignment with the original sequence.  
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Investigation of the pocket volume 
For the investigation of the pocket volumes of the different mutated domains from the ER 
and the ER domain an open software program 3V web server.156 Therefore were the PDB 
Files transmitted to the Software and as search parameters an outer probe radius of 10 and 
an inner probe radius of 2 were determined.  
 
Protein modeling 
Before homology modelling for the specific domain could be done the domain boundaries 
of the specific domain of SQTKS or TENS were determined. Therefore, the sequence of 
SQTKS or TENS was examined with BLAST (basic local alignment search tool).138 
Subsequently, a conserved domain search (CD-Search) was performed to determine the 
domain boundaries.139–142 Afterwards, homology modeling was done using Swiss-
Model.83,92,95,105 Therefore was the protein sequence submitted to SwissModel.  
 
Models are computed by the SWISS-MODEL server homology modelling pipeline which 
relies on ProMod3, an in-house comparative modelling engine based on 
OpenStructure83,92,95,105. ProMod3 extracts initial structural information from the template 
structure. Insertions and deletions, as defined by the sequence alignment, are resolved by 
first searching for viable candidates in a structural database. Final candidates are then 
selected using statistical potentials of mean force scoring methods. If no candidates can 
be found, a conformational space search is performed using Monte Carlo techniques. 
Non-conserved side chains are modelled using an in-house backbone-dependent rotamer 
library. The optimal configuration of rotamers is estimated using the graph based 
TreePack algorithm by minimising the SCWRL4 energy function. As a final step, small 
structural distortions, unfavourable interactions, or clashes introduced during the 
modelling process are resolved by energy minimisation. ProMod3 uses the OpenMM 
library to perform the computations and the CHARMM27 force field for 
parameterisation.83,92,95,105 
Afterwards was the template selected and the modelling performed. Subsequently 
the model was validated. 
 
Templates: 
ER domain SQTKS (Chapter 2): CurF (PDB: 5dp2)144 
CMeT domain TENS (Chapter 5): CurJ (PDB: 5thy)171 
KR domain TENS (Chapter 5): AmphB (PDB: 3slk)180 
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Model validation via Swiss-Model 
For the first validation of the generated homolog models Swiss-Model calculates to 
parameters, which were reconsidered.  
GMQE (Global Model Quality Estimation) is a quality estimation, which combines 
properties from the target–template alignment and the template search method. The 
resulting GMQE score is expressed as a number between 0 and 1, reflecting the expected 
accuracy of a model built with that alignment and template and the coverage of the target. 
Higher numbers indicate higher reliability.  
QMEAN is a composite estimator based on different geometrical properties and provides 
both global (i.e. for the entire structure) and local (i.e. per residue) absolute quality 
estimates based on one single model. The QMEAN Z-score provides an estimate of the 
‘degree of nativeness’ of the structural features observed in the model on a global scale. 
It indicates whether the QMEAN score of the model is comparable to what one would 
expect from experimental structures of similar size. QMEAN Z-scores around zero 
indicate good agreement between the model structure and experimental structures of 
similar size. Scores of -4.0 or below are an indication of models with low quality. 
 
Integration of the Cofactor 
The respective cofactor was integrated in the specific domain through the alignment of 
the homolog model with the template in PyMOL (DeLano Scientific LLC, Version 
1.8.2.0).146,147  
 The cofactor was extracted from the template and then manually integrated into 
the structural model of the respective domain in PyMOL. Afterwards, the generated 
domain plus cofactor was minimized in YASARA, to refine the protein-cofactor 
interaction.135 Then the extracted and refined cofactor  was alignment with the cofactor 
from the template for validation. 
 
Molecular Docking 
The docking was performed by roughly manually overlaying the specific substrate in 
active site of the protein using PyMOL. Thereby, the easiest method for the identification 
of the active site was by displaying the volume of the pockets of the protein. Further, if 
the cofactor was known, this was used as an orientation point. This was done to simplify 
the docking in the next step.  
This method minimized the so-called Grid Box, which has critical role in the speed of the 
docking calculations. Molecular docking was done using Autodock Vina Vina (PyRx 
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0.8). 110,147,148 For performing the calculations with AutoDock Vina Python 3.6 was used 
as the underlaying programming language 
The protocol included the creation of the pdbqt files of the respective substrate and 
protein. Further, the degrees of freedom for the substrate were set. The degree of freedom 
as a default always were the maximum chosen. The coordinates of the Grid Box were 
customized for the specific protein-substrate complex. However, the size of the Gird Box 
that was used by default was 20 x 20 x 20 number of points. Afterwards, this information 
was saved in the corresponding configuration file. For the subsequent calculations, the 
AutoDock Vina file was used. Maximal 2 runs were performed. In addition, the used 
algorithm by Auto Dock Vina was the Broyden-Fletcher-Goldfarb-Shanno algorithm. 
 Docking results including the RMSD, the lowest binding energy and mean binding 
energy were obtained from the docking log (dlg) file. The respective, obtained docked 
substrate were then compared in the protein in PyMOL. The best docked substrates were 
chosen and separate saved in a new pdb file. Criteria for the selection was the RMSD 
value and the overall location in the active pocket. Afterwards, the specific substrates 
were integrated in the protein in PyMOL. The model was then refined by YASARA. The 
visualization of the different models, after the refinement step was always done in 
PyMOL. 
 
YASSARA Minimization Sever 
This server performs an energy minimization of your protein model with the YASARA 
force field. Or rather, YASARA, which runs molecular dynamics simulations of models 
in explicit solvent, using a new partly knowledge-based all atom force field derived from 
Amber, whose parameters have been optimized to minimize the damage done to protein 
crystal structures.135 
  
 171 
9 References 
 
1. Editorial, Nature Chemical Biology, 2007, 3, 351. 
2. G. Strobel and B. Daisy, Microbiology and Molecular Biology Reviews, 2003, 67, 491. 
3. L. Gu, B. Wang, A. Kulkarni, T. W. Geders, R. V. Grindberg, L. Gerwick, K. Håkansson, P. 
Wipf, J. L. Smith, W. H. Gerwick and D. H. Sherman, Nature, 2009, 459, 731. 
4. A. J. Dijkstra, F. D. Gunstone and J. L. Harwood, The lipid handbook, 2007. 
5. N. Murakami, W. Wang, M. Aoki, Y. Tsutsui, M. Sugimoto and M. Kobayashi, Tetrahedron 
Letters, 1998, 39, 2349. 
6. J. Beld, D. J. Lee and M. D. Burkart, Molecular BioSystems, 2015, 11, 38. 
7. A. W. Alberts, A. W. Strauss, S. Hennessy and P. R. Vagelos, Proceedings of the National 
Academy of Sciences of the United States of America, 1975, 72, 3956. 
8. S. Smith, A. Witkowski and A. K. Joshi, Progress in Lipid Research, 2003, 42, 289. 
9. K. Magnuson, S. Jackowski, C. O. Rock and J. E. Cronan, Microbiological Reviews, 1993, 57, 
522. 
10. D. M. Byers and H. Gong, Biochemistry and Cell Biology, 2007, 85, 649. 
11. J. G. Olsen, A. Kadziola, P. von Wettstein-Knowles, M. Siggaard-Andersen and S. Larsen, 
Structure, 2001, 9, 233. 
12. C. Davies, R. J. Heath, S. W. White and C. O. Rock, Structure, 2000, 8, 185. 
13. W. Huang, J. Jia, P. Edwards, K. Dehesh, G. Schneider and Y. Lindqvist, The EMBO journal, 
1998, 17, 1183. 
14. J. M. Crawford, B. C. R. Dancy, E. A. Hill, D. W. Udwary and C. A. Townsend, Proceedings of 
the National Academy of Sciences of the United States of America, 2006, 103, 16728. 
15. A. T. Keatinge-Clay, Natural Product Reports, 2012, 29, 1050. 
16. M. Leesong, B. S. Henderson, J. R. Gillig, J. M. Schwab and J. L. Smith, Structure, 1996, 4, 
253. 
17. D. Kostrewa, F. K. Winkler, G. Folkers, L. Scapozza and R. Perozzo, Protein Science, 2005, 
14, 1570. 
18. D. H. Kwan and F. Schulz, Molecules, 2011, 16, 6092. 
19. D. H. Kwan, Y. Sun, F. Schulz, H. Hong, B. Popovic, J. C. C. Sim-Stark, S. F. Haydock and P. F. 
Leadlay, Chemistry & Biology, 2008, 15, 1231. 
20. K. Finzel, D. J. Lee and M. D. Burkart, ChemBioChem, 2015, 16, 528. 
21. D. L. Ollis, E. Cheah, M. Cygler, B. Dijkstra, F. Frolow, S. M. Franken, M. Harel, S. J. 
Remington, I. Silman and J. Schrag, Protein Engineering, 1992, 5, 197. 
22. Z. Zhuang, F. Song, H. Zhao, L. Li, J. Cao, E. Eisenstein, O. Herzberg and D. Dunaway-
Mariano, Biochemistry, 2008, 47, 2789. 
23. T. Maier, M. Leibundgut and N. Ban, Science, 2008, 321, 1315. 
 172 
24. D. A. Herbst, C. A. Townsend and T. Maier, Natural Product Reports, 2018, 35, 1046. 
25. T. Maier, S. Jenni and N. Ban, Science, 2006, 311, 1258. 
26. M. Leibundgut, S. Jenni, C. Frick and N. Ban, Science, 2007, 316, 288. 
27. M. Leesong, B.S. Henderson, J.F Gillig, J.M. Schwab, J.L. Smith, Structure, 1996, 4, 253-64. 
28. A. C. Price, Y.-M. Zhang, C. O. Rock and S. M. White, Structure, 2004, 12, 417-428. 
29. C. Baldock, J. B. Rafferty and D. W. Rice, J. Mol. Biol., 1998, 284, 1529-46. 
30. G. Pappenberger, T. Schulz-Gasch, J. Bailly and M. Hennig, Acta Crystallorg., 2007, 63, 
1208. 
31. K. J. Weissman, Nature Chemical Biology, 2015, 11, 660. 
32. A. Hagen, S. Poust, T. d. Rond, J. L. Fortman, L. Katz, C. J. Petzold and J. D. Keasling, ACS 
Synthetic Biology, 2016, 5, 21. 
33. T. Dingermann, R. Hänsel and I. Zündorf, Pharmazeutische Biologie: Molekulare 
Grundlagen und klinische Anwendung, Springer, 2002. 
34. S.-C. Tsai, H. Lu, D. E. Cane, C. Khosla and R. M. Stroud, Biochemistry, 2002, 41, 12598. 
35. C. Hertweck, Angewandte Chemie, 2009, 48, 4688. 
36. T. P. Nicholson, B. A. Rudd, M. Dawson, C. M. Lazarus, T. J. Simpson and R. J. Cox, 
Chemistry & Biology, 2001, 8, 157. 
37. M. E. Hillenmeyer, G. A. Vandova, E. E. Berlew and L. K. Charkoudian, Proceedings of the 
National Academy of Sciences of the United States of America, 2015, 112, 13952. 
38. J. Schümann and C. Hertweck, Journal of Biotechnology, 2006, 124, 690. 
39. R. J. Cox, Organic & Biomolecular Chemistry, 2007, 5, 2010. 
40. J. Staunton and K. J. Weissman, Nat. Prod. Rep., 2001, 18, 380. 
41. Z. Chang, N. Sitachitta, J. V. Rossi, M. A. Roberts, P. M. Flatt, J. Jia, D. H. Sherman and W. 
H. Gerwick, Journal of Natural Products, 2004, 67, 1356. 
42. L. Gu, T. W. Geders, B. Wang, W. H. Gerwick, K. Håkansson, J. L. Smith and D. H. Sherman, 
Science, 2007, 318, 970. 
43. L. Gu, E. B. Eisman, S. Dutta, T. M. Franzmann, S. Walter, W. H. Gerwick, G. Skiniotis and 
D. H. Sherman, Angewandte Chemie, 2011, 50, 2795. 
44. J. M. Crawford, A. L. Vagstad, K. P. Whitworth, C. A. Townsend and K. C. Ehrlich, 
ChemBioChem, 2008, 9, 1019. 
45. I. Soehano, L. Yang, F. Ding, H. Sun, Z. J. Low, X. Liu and Z.-X. Liang, Organic & 
Biomolecular Chemistry, 2014, 12, 8542. 
46. J. Beck, S. Ripka, A. Siegner, E. Schiltz and E. Schweizer, European Journal of Biochemistry, 
1990, 192, 487. 
47. T. Shimizu, H. Kinoshita, S. Ishihara, K. Sakai, S. Nagai and T. Nihira, Applied and 
Environmental Microbiology, 2005, 71, 3453. 
 173 
48. K. L. Eley, L. M. Halo, Z. Song, H. Powles, R. J. Cox, A. M. Bailey, C. M. Lazarus and T. J. 
Simpson, ChemBioChem, 2007, 8, 289. 
49. T. Ugai, A. Minami, R. Fujii, M. Tanaka, H. Oguri, K. Gomi and H. Oikawa, Chemical 
Communications, 2015, 51, 1878. 
50. J. L. Smith, G. Skiniotis and D. H. Sherman, Current Opinion in Structural Biology, 2015, 31, 
9. 
51. S. S. Chirala, A. Jayakumar, Z. W. Gu and S. J. Wakil, Proceedings of the National Academy 
of Sciences of the United States of America, 2001, 98, 3104. 
52. S. Smith, FASEB, 1994, 8, 1248. 
53. J. S. Parascandolo, J. Havemann, H. K. Potter, F. Huang, E. Riva, J. Connolly, I. Wilkening, L. 
Song, P. F. Leadlay and M. Tosin, Angewandte Chemie, 2016, 128, 3524. 
54. S. M. Ma and Y. Tang, The FEBS Journal, 2007, 274, 2854. 
55. M. Sato, F. Yagishita, T. Mino, N. Uchiyama, A. Patel, Y.-H. Chooi, Y. Goda, W. Xu, H. 
Noguchi, T. Yamamoto, K. Hotta, K. N. Houk, Y. Tang and K. Watanabe, ChemBioChem, 
2015, 16, 2294. 
56. H. Yao, In Vitro Investigation of Multi-Domain Fragments of Squalestatin Tetraketide 
Synthase, PhD-Thesis, Hannover, 2018. 
57. E. Liddle, A. Scott, L.-C. Han, D. Ivison, T. J. Simpson, C. L. Willis and R. J. Cox, Chemical 
Communications, 2017, 53, 1727. 
58. D. M. Roberts, C. Bartel, A. Scott, D. Ivison, T. J. Simpson and R. J. Cox, Chem. Sci., 2017, 8, 
1116. 
59. J. Zheng and A. T. Keatinge-Clay, Med. Chem. Commun., 2013, 4, 34. 
60. R. Reid, M. Piagentini, E. Rodriguez, G. Ashley, N. Viswanathan, J. Carney, D. V. Santi, C. R. 
Hutchinson and R. McDaniel, Biochemistry, 2003, 42, 72. 
61. A. T. Keatinge-Clay, Chemistry & Biology, 2007, 14, 898. 
62. A. T. Keatinge-Clay, Nat. Prod. Rep., 2016, 33, 141. 
63. B. Bonsch, V. Belt, C. Bartel, N. Duensing, M. Koziol, C. M. Lazarus, A. M. Bailey, T. J. 
Simpson and R. J. Cox, Chemical Communications, 2016, 52, 6777. 
64. R. J. Cox, F. Glod, D. Hurley, C. M. Lazarus, T. P. Nicholson, B. A. M. Rudd, T. J. Simpson, B. 
Wilkinson and Y. Zhang, Chemical Communications, 2004, 20, 2260. 
65. M. N. Heneghan, A. A. Yakasai, K. Williams, K. A. Kadir, Z. Wasil, W. Bakeer, K. M. Fisch, A. 
M. Bailey, T. J. Simpson, R. J. Cox and C. M. Lazarus, Chem. Sci., 2011, 2, 972. 
66. J. Kennedy, Natural Product Reports, 2008, 25, 25. 
67. Y. Shimizu, H. Ogata and S. Goto, ChemBioChem, 2017, 18, 1048. 
68. K. J. Weissman, Natural Product Reports, 2016, 33, 203. 
69. W. Zhang and J. Liu, F1000Research, 2016, 5. 
70. J. F. Barajas, J. M. Blake-Hedges, C. B. Bailey, S. Curran and J. D. Keasling, Synthetic and 
Systems Biotechnology, 2017, 2, 147. 
 174 
71. J.-H. Yong and W.-H. Byeon, Journal of microbiology, 2005, 43, 277. 
72. C. J. Dutton, S. P. Gibson, A. C. Goudie, K. S. Holdom, M. S. Pacey, J. C. Ruddock, J. D. 
Bu'Lock and M. K. Richards, The Journal of Antibiotics, 1991, 44, 357. 
73. H. Mehlhorn, H. L. Jones, A. J. Weatherley and B. Schumacher, Parasitol Res, 1993, 79, 
603. 
74. E. J. Skellam, D. Hurley, J. Davison, C. M. Lazarus, T. J. Simpson and R. J. Cox, Molecular 
BioSystems, 2010, 6, 680. 
75. L. M. Halo, J. W. Marshall, A. A. Yakasai, Z. Song, C. P. Butts, M. P. Crump, M. Heneghan, 
A. M. Bailey, T. J. Simpson, C. M. Lazarus and R. J. Cox, ChemBioChem, 2008, 9, 585. 
76. K. M. Fisch, W. Bakeer, A. A. Yakasai, Z. Song, J. Pedrick, Z. Wasil, A. M. Bailey, C. M. 
Lazarus, T. J. Simpson and R. J. Cox, ACS, 2011, 133, 16635. 
77. A. A. Yakasai, J. Davison, Z. Wasil, L. M. Halo, C. P. Butts, C. M. Lazarus, A. M. Bailey, T. J. 
Simpson and R. J. Cox, ACS, 2011, 133, 10990. 
78. B. Busch and C. Hertweck, Phytochemistry, 2009, 70, 1833. 
79. X.-L. Yang, S. Friedrich, S. Yin, O. Piech, K. Williams, T. J. Simpson and R. J. Cox, Chem. Sci., 
2019, 10, 8478-8489. 
80. R. A. Cacho, J. Thuss, W. Xu, R. Sanichar, Z. Gao, A. Nguyen, J. C. Vederas and Y. Tang, ACS, 
2015, 137, 15688. 
81. C. M. Kao, M. McPherson, R. N. McDaniel, H. Fu, D. E. Cane and C. Khosla, ACS, 1998, 120, 
2478. 
82. M. Klaus and M. Grininger, Nat. Prod. Rep., 2018, 35, 1070. 
83. T. Schwede, Nucleic Acids Research, 2003, 31, 3381. 
84. S. Kaczanowski and P. Zielenkiewicz, Theor Chem Acc, 2010, 125, 643. 
85. D. Baker and A. Sali, Science, 2001, 294, 93. 
86. A. Tramontano, R. Leplae and V. Morea, Proteins, 2001, Suppl 5, 22. 
87. M. A. Martí-Renom, A. C. Stuart, A. Fiser, R. Sánchez, F. Melo and A. Sali, Annual Review of 
Biophysics and Biomolecular Structure, 2000, 29, 291. 
88. T. J. Chuan and S. Ranganathan, eds., Computer-Aided Baccine Design, Witney, 2011. 
89. O. Sensoy, J. G. Almeida, J. Shabbir, I. S. Moreira and G. Morra, Methods in Cell Biology, 
2017, 142, 205. 
90. L. Bordoli, F. Kiefer, K. Arnold, P. Benkert, J. Battey and T. Schwede, Nature Protocols, 
2009, 4, 1. 
91. A. Waterhouse, M. Bertoni, S. Bienert, G. Studer, G. Tauriello, R. Gumienny, F. T. Heer, T. 
A. P. de Beer, C. Rempfer, L. Bordoli, R. Lepore and T. Schwede, Nucleic Acids Research, 
2018, 46, W296-W303. 
92. S. Bienert, A. Waterhouse, T. A. P. de Beer, G. Tauriello, G. Studer, L. Bordoli and T. 
Schwede, Nucleic Acids Research, 2017, 45, D313-D319. 
93. N. Guex, M. C. Peitsch and T. Schwede, Electrophoresis, 2009, 30 Suppl 1, S162-73. 
 175 
94. P. Benkert, M. Biasini and T. Schwede, Bioinformatics, 2011, 27, 343. 
95. M. Bertoni, F. Kiefer, M. Biasini, L. Bordoli and T. Schwede, Scientific Reports, 2017, 7, 
10480. 
96. A. Sali and T. L. Blundell, Journal of Molecular Biology, 1993, 234, 779. 
97. A. Fiser, R. K. Do and A. Sali, Protein Science, 2000, 9, 1753. 
98. C. A. Rohl, C. E. M. Strauss, D. Chivian and D. Baker, Proteins, 2004, 55, 656. 
99. C. S. Soto, M. Fasnacht, J. Zhu, L. Forrest and B. Honig, Proteins, 2008, 70, 834. 
100. B. Rost, Protein Engineering, 1999, 12, 85. 
101. K. Ginalski, Current Opinion in Structural Biology, 2006, 16, 172. 
102. S. Ovchinnikov, H. Park, D. E. Kim, F. DiMaio and D. Baker, Proteins, 2018, 86 Suppl 1, 113. 
103. A. Fiser and A. Šali, Macromolecular Crystallography, Elsevier, 2003, p 461. 
104. F. Kiefer, K. Arnold, M. Künzli, L. Bordoli and T. Schwede, Nucleic Acids Research, 2009, 37, 
D387-92. 
105. M. Biasini, S. Bienert, A. Waterhouse, K. Arnold, G. Studer, T. Schmidt, F. Kiefer, T. Gallo 
Cassarino, M. Bertoni, L. Bordoli and T. Schwede, Nucleic Acids Research, 2014, 42, 252-8. 
106. M. Remmert, A. Biegert, A. Hauser and J. Söding, Nature Methods, 2011, 9, 173. 
107. P. Benkert, S. C. E. Tosatto and D. Schomburg, Proteins, 2008, 71, 261. 
108. J. Biesiada, A. Porollo, P. Velayutham, M. Kouril and J. Meller, Hum Genomics, 2011, 5, 
497. 
109. D. S. Goodsell, G. M. Morris and A. J. Olson, J. Mol. Recognit., 1996, 9, 1. 
110. O. Trott and A. J. Olson, Journal of Computational Chemistry, 2010, 31, 455. 
111. P. T. Lang, S. R. Brozell, S. Mukherjee, E. F. Pettersen, E. C. Meng, V. Thomas, R. C. Rizzo, 
D. A. Case, T. L. James and I. D. Kuntz, RNA, 2009, 15, 1219. 
112. B. K. Shoichet, I. D. Kuntz and D. L. Bodian, J. Comput. Chem., 1992, 13, 380. 
113. H. Claussen, C. Buning, M. Rarey and T. Lengauer, JMB, 2001, 308, 377. 
114. R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. 
Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis and P. S. Shenkin, 
Journal of Medicinal Chemistry, 2004, 47, 1739. 
115. M. L. Verdonk, J. C. Cole, M. J. Hartshorn, C. W. Murray and R. D. Taylor, Proteins, 2003, 
52, 609. 
116. I. W. Davis and D. Baker, JMB, 2009, 385, 381. 
117. M. I. Zavodszky, A. Rohatgi, J. R. van Voorst, H. Yan and L. A. Kuhn, JMR, 2009, 22, 280. 
118. A. N. Jain, Journal of Medicinal Chemistry, 2003, 46, 499. 
119. S. F. Sousa, P. A. Fernandes and M. J. Ramos, Proteins, 2006, 65, 15. 
120. I. D. Kuntz, J. M. Blaney, S. J. Oatley, R. Langridge and T. E. Ferrin, JMB, 1982, 161, 269. 
 176 
121. I. Muegge and M. Rarey in Reviews in Computational Chemistry, Volume 17, 2001, p 1. 
122. G. M. Morris and M. Lim-Wilby, Methods in Molecular Biology, 2008, 443, 365. 
123. G. M. Morris, D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew and A. J. Olson, 
J. Comput. Chem., 1998, 19, 1639. 
124. D. B. Kitchen, H. Decornez, J. R. Furr and J. Bajorath, Nature Reviews, 2004, 3, 935. 
125. B. Kramer, M. Rarey and T. Lengauer, Proteins, 1999, 37, 228. 
126. P. K. Weiner and P. A. Kollman, J. Comput. Chem., 1981, 2, 287. 
127. S. J. Weiner, P. A. Kollman, D. A. Case, U. C. Singh, C. Ghio, G. Alagona, S. Profeta and P. 
Weiner, ACS, 1984, 106, 765. 
128. T. Gaillard, Journal of Chemical Information and Modeling, 2018, 58, 1697. 
129. R. Huey, G. M. Morris, A. J. Olson and D. S. Goodsell, J. Comput. Chem., 2007, 28, 1145. 
130. W. D. Cornell, P. Cieplak, C. I. Bayly, I. R. Gould, K. M. Merz, D. M. Ferguson, D. C. 
Spellmeyer, T. Fox, J. W. Caldwell and P. A. Kollman, ACS, 1995, 117, 5179. 
131. J. R. Schames, R. H. Henchman, J. S. Siegel, C. A. Sotriffer, H. Ni and J. A. McCammon, 
Journal of Medicinal Chemistry, 2004, 47, 1879. 
132. R. E. Amaro, A. Schnaufer, H. Interthal, W. Hol, K. D. Stuart and J. A. McCammon, 
Proceedings of the National Academy of Sciences of the United States of America, 2008, 
105, 17278. 
133. Y.-C. Chen, Trends in Pharmacological Sciences, 2015, 36, 78. 
134. X.-Y. Meng, H.-X. Zhang, M. Mezei and M. Cui, Current Computer-Aided Drug Design, 
2011, 7, 146. 
135. E. Krieger, K. Joo, J. Lee, J. Lee, S. Raman, J. Thompson, M. Tyka, D. Baker and K. Karplus, 
Proteins, 2009, 77, 114. 
136. E. Krieger, G. Koraimann and G. Vriend, Proteins, 2002, 47, 393. 
137. C. Bartel, Enzymology of Isolated functional Domains from Iterative Fungal Polyketide 
Synthases, PhD-Thesis, Hannover, 2017. 
138. S. F. Altschul, T. L. Madden, A. A. Schäffer, J. Zhang, Z. Zhang, W. Miller and D. J. Lipman, 
Nucleic Acids Research, 1997, 25, 3389. 
139. A. Marchler-Bauer and S. H. Bryant, Nucleic Acids Research, 2004, 32, W327-31. 
140. A. Marchler-Bauer, S. Lu, J. B. Anderson, F. Chitsaz, M. K. Derbyshire, C. DeWeese-Scott, J. H. Fong, 
L. Y. Geer, R. C. Geer, N. R. Gonzales, M. Gwadz, D. I. Hurwitz, J. D. Jackson, Z. Ke, C. J. Lanczycki, F. 
Lu, G. H. Marchler, M. Mullokandov, M. V. Omelchenko, C. L. Robertson, J. S. Song, N. Thanki, R. A. 
Yamashita, D. Zhang, N. Zhang, C. Zheng and S. H. Bryant, Nucleic Acids Research, 2011, 39, 225-9. 
141. A. Marchler-Bauer, M. K. Derbyshire, N. R. Gonzales, S. Lu, F. Chitsaz, L. Y. Geer, R. C. Geer, J. He, 
M. Gwadz, D. I. Hurwitz, C. J. Lanczycki, F. Lu, G. H. Marchler, J. S. Song, N. Thanki, Z. Wang, R. A. 
Yamashita, D. Zhang, C. Zheng and S. H. Bryant, Nucleic Acids Research, 2015, 43, 222-6. 
142. A. Marchler-Bauer, Y. Bo, L. Han, J. He, C. J. Lanczycki, S. Lu, F. Chitsaz, M. K. Derbyshire, R. C. Geer, 
N. R. Gonzales, M. Gwadz, D. I. Hurwitz, F. Lu, G. H. Marchler, J. S. Song, N. Thanki, Z. Wang, R. A. 
 177 
Yamashita, D. Zhang, C. Zheng, L. Y. Geer and S. H. Bryant, Nucleic Acids Research, 2017, 45, 200-
D203. 
143. D. A. Herbst, R. P. Jakob, F. Zähringer and T. Maier, Nature, 2016, 531, 533 EP -. 
144. D. Khare, W. A. Hale, A. Tripathi, L. Gu, D. H. Sherman, W. H. Gerwick, K. Håkansson and J. 
L. Smith, Structure, 2015, 23, 2213. 
145. W. D. Fiers, G. J. Dodge, D. H. Sherman, J. L. Smith and C. C. Aldrich ,ACS, 2016, 138, 
16024. 
146. G. Janson, C. Zhang, M. G. Prado and A. Paiardini, Bioinformatics, 2017, 33, 444. 
147. S. Forli, R. Huey, M. E. Pique, M. F. Sanner, D. S. Goodsell and A. J. Olson, Nature 
Protocols, 2016, 11, 905. 
148. D. Seeliger and B. L. de Groot, Journal of Computer-Aided Molecular Design, 2010, 24, 
417. 
149. H. B. B:urgi, J. D. Dunitz, J. M. Lehn and G. Wipff, Tetrahedron, 1974, 30, 1563. 
150. H.‐B. Bürgi and J. D. Dunitz, Structure Correlation, Wiley, 1994. 
151. S. H. Light, G. Minasov, M.-E. Duban and W. F. Anderson, Acta crystall., 2014, 70, 544. 
152. E. D. Caldas, K. Sadilkova, B. L. Ward, A. D. Jones, C. K. Winter and D. G. Gilchrist, J. Agric. 
Food Chem., 1998, 46, 4734. 
153. I. Gaffoor and F. Trail, Applied and Environmental Microbiology, 2006, 72, 1793. 
154. I. Fujii, N. Yoshida, S. Shimomaki, H. Oikawa and Y. Ebizuka, Chemistry & Biology, 2005, 
12, 1301. 
155. Y.-M. Chiang, E. Szewczyk, A. D. Davidson, N. Keller, B. R. Oakley and C. C. C. Wang, ACS, 
2009, 131, 2965. 
156. N. R. Voss and M. Gerstein, Nucleic Acids Research, 2010, 38, 555-62. 
157. A. C. Murphy, H. Hong, S. Vance, R. W. Broadhurst and P. F. Leadlay, Chemical 
Communications, 2016, 52, 8373. 
158. F. Wang, Y. Wang, J. Ji, Z. Zhou, J. Yu, H. Zhu, Z. Su, L. Zhang and J. Zheng, ACS Chem. Biol., 
2015, 10, 1017. 
159. D. H. Kwan and P. F. Leadlay, ACS Chem. Biol., 2010, 5, 829. 
160. A. G. Newman, A. L. Vagstad, P. A. Storm and C. A. Townsend, ACS, 2014, 136, 7348. 
161. D. M. Roberts, Investigating the Programming of Type I highly Reducing Iterative 
Polyketide Synthases, PhD-Thesis, Bristol, 2014. 
162. L. Zheng, U. Baumann and J.-L. Reymond, Nucleic Acids Research, 2004, 32, 115. 
163. David Ivison, Investigating the Programming of Type I Iterative Polyketide Synthase 
Enzymes, PhD-Thesis, Bristol, 2013. 
164. D. Voet, J. G. Voet and C. W. Pratt, Principles of Biochemistry, 2008. 
165. H. A. David and J. L. Gunnink, The American Statistician, 1997, 51, 9. 
166. S. S. Shapiro and M. B. Wilk, Biometrika, 1965, 52, 591. 
 178 
167. J. Chiu, P. E. March, R. Lee and D. Tillett, Nucleic Acids Research, 2004, 32, 174. 
168. J. Chiu, D. Tillett, I. W. Dawes and P. E. March, Journal of Microbiological Methods, 2008, 
73, 195. 
169. R. M. Q. Shanks, N. C. Caiazza, S. M. Hinsa, C. M. Toutain and G. A. O'Toole, Applied and 
Environmental Microbiology, 2006, 72, 5027. 
170. S. B. Hua, M. Qiu, E. Chan, L. Zhu and Y. Luo, Plasmid, 1997, 38, 91. 
171. M. A. Skiba, A. P. Sikkema, W. D. Fiers, W. H. Gerwick, D. H. Sherman, C. C. Aldrich and J. 
L. Smith, ACS Chemical Biology, 2016, 11, 3319. 
172. P. A. Storm, D. A. Herbst, T. Maier and C. A. Townsend, Cell Chemical Biology, 2017, 24, 
316. 
173. M. A. Skiba, A. P. Sikkema, N. A. Moss, A. N. Lowell, M. Su, R. M. Sturgis, L. Gerwick, W. H. 
Gerwick, D. H. Sherman and J. L. Smith, ACS Chem. Biol., 2018, 13, 1640. 
174. J. L. Meinke, M. R. Mehaffey, D. T. Wagner, N. Sun, Z. Zhang, J. S. Brodbelt and A. T. 
Keatinge-Clay, ACS Chem. Biol., 2018, 13, 3306. 
175. A. Jansson, H. Koskiniemi, A. Erola, J. Wang, P. Mäntsälä, G. Schneider and J. Niemi, The 
Journal of Biological Chemistry, 2005, 280, 3636. 
176. S. Kishimoto, Y. Tsunematsu, T. Matsushita, K. Hara, H. Hashimoto, Y. Tang and K. 
Watanabe, Biochemistry, 2019, 58, 3933. 
177. S. Horowitz, L. M. A. Dirk, J. D. Yesselman, J. S. Nimtz, U. Adhikari, R. A. Mehl, S. Scheiner, 
R. L. Houtz, H. M. Al-Hashimi and R. C. Trievel, ACS, 2013, 135, 15536. 
178. P. Z. Kozbial and A. R. Mushegian, BMC Structural Biology, 2005, 5, 19. 
179. A. C. Legon and D. J. Millen, Chem. Soc. Rev., 1987, 16, 467. 
180. J. Zheng, D. C. Gay, B. Demeler, M. A. White and A. T. Keatinge-Clay, Nature Chemical 
Biology, 2012, 8, 615. 
181. J. Zheng, C. A. Taylor, S. K. Piasecki and A. T. Keatinge-Clay, Structure, 2010, 18, 913. 
182. S. A. Bonnett, J. R. Whicher, K. Papireddy, G. Florova, J. L. Smith and K. A. Reynolds, 
Chemistry & Biology, 2013, 20, 772. 
183. S. K. Piasecki, J. Zheng, A. J. Axelrod, M. E. Detelich and A. T. Keatinge-Clay, Proteins, 
2014, 82, 2067. 
184. P. Caffrey, ChemBioChem, 2003, 4, 654. 
185. A. T. Keatinge-Clay and R. M. Stroud, Structure, 2006, 14, 737. 
186. C. Schubert, C. M. Milligan, K. Vo and B. Grasberger, To be published, 2016. 
187. H. E. Gottlieb, V. Kotlyar and A. Nudelman, J. Org. Chem., 1997, 62, 7512. 
188. N. M. Gaudelli and C. A. Townsend, J. Org. Chem., 2013, 78, 6412. 
189. A. L. Vagstad, A. G. Newman, P. A. Storm, K. Belecki, J. M. Crawford and C. A. Townsend, 
Angewandte Chemie, 2013, 52, 1718. 
190. F. Pfrengle, V. Dekaris, L. Schefzig, R. Zimmer and H.-U. Reissig, Synlett, 2008, 2008, 2965. 
 179 
10 Appendix 
 
10.1 Protein pdb Data File List (attached CD) 
 
Number Name (pdb file) Content/Docked Substrated 
1 SQTKS-ER-Apo ER (w/o) NADPH 
2 SQTKS-ER-Holo ER with NADPH 
3 SQTKS-ER-Tetra-S-S Tetraketide 93a 
4 SQTKS-ER-Tetra-S-R Tetraketide 93b 
5 SQTKS-ER-Tetra-R-S Tetraketide 93c 
6 SQTKS-ER-Tetra-R-R Tetraketide 93d 
7 SQTKS-ER-Tigloyl Tigloyl 77 
8 SQTKS-ER-Triketide Triketide 85 
9 SQTKS-ER-Penta Pentaketide 94 
10 SQTKS-ER-I1938A Tetraketide 93a 
11 SQTKS-ER-F1941A Tetraketide 93aa 
12 SQTKS-ER-L2146A Triketide 85 
13 SQTKS-ER-L2146A Pentaketide 94 
14 SQTKS-ER-L2146V Triketide 85 
15 SQTKS-ER-L2146V Pentaketide 94 
16 SQTKS-ER-I2147A Triketide 85 
17 SQTKS-ER-I2147A Pentaketide 94 
18 SQTKS-ER-F2157A Triketide 85 
19 SQTKS-ER-F2157A Pentaketide 94 
20 SQTKS-ER-L2146A/I2147A Triketide 85 
21 SQTKS-ER L2146A/I2147A Pentaketide 94 
22 SQTKS-ER-I2147A/F2157A Triketide 85 
23 SQTKS-ER-I2147A/F2157A Pentaketide 94 
24 SQTKS-ER-F1941A/F2157A Triketide 85 
25 SQTKS-ER-F1941A/F2157A Pentaketide 94 
26 
SQTKS-ER-
F1941/I2147A/F2157V 
Triketide 85 
27 
SQTKS-ER-
F1941/I2147A/F2157V 
Pentaketide 94 
28 TENS-CMeT-Apo C-MeT (w/o) SAM 
29 TENS-CMeT-Holo C-MeT with SAM 
30 TENS-CMeT-Sub Substrate 128 
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31 TENS-CMeT-Sub Substrate 129 
32 TENS-CMeT-Sub Substrate 130 
33 TENS-KR-Apo KR (w/o) NADPH 
34 TENS-KR-Holo KR with NADPH 
35 TENS-KR-Sub Substrate 135a 
36 TENS/mFAS-Hybrid 
Chimeric structure of TENS KR, C-
MET domain and mFAS DH, ER and 
ψKR 
37 DMBS-KR KR (w/o) NADPH 
38 MILS-KR KR (w/o) NADPH 
39 TENS-KR*(MILS) Mutated KR domain of TENS to MILS 
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10.2 Multiple Alignment of β-Processing Domains of TENS, DMBS, mFAS pig and 
mFAS rat 
 
                 1                                               50 
.                              KS                                KS 
TENS         (1) MSPMKQNESESHSVSEPIAIIGSAYRFPGGCNTPSKLWDLLRQPRDILKE 
DMBS         (1) MSPMKQNESESHCVSEPIAIVGSAYRFPGGCNTPSKLWDLLRQPRDILKE 
SQTKS        (1) MVPYYQPASCGSN-SEPIAIIGMSCRFPGNATSPEKLWELCAQGRSAWSS 
mFAS pig     (1) --------------MEEVVIAGMSGKLPESENLEEFWANLIG-------- 
mFAS rat     (1) --------------MEEVVIAGMSGKLPESENLQEFWANLIG-------- 
 
                 51                                             100 
.                KS                                              KS 
TENS        (51) IDPERLNLRRYYHPDGETHGSTDVANKAYTLEEDISRFDASFFGISPLEA 
DMBS        (51) IDPERLNLRRYYHPDGETHGSTDVSNRAYTLEEDISRFDASFFGISPLEA 
SQTKS       (65) IPKSRFRQEGFYNPNAERVG-TSHVVGGHFLEEDPSLFDASFFNLSAEAA 
mFAS pig    (29) ------GVDMVTADDRRWKAGLYGLPRRMGKLKDLSRFDASFFGVHSKQA 
mFAS rat    (29) ------GVDMVTDDDRRWKAGLYGLPKRSGKLKDLSKFDASFFGVHPKQA 
 
                 101                                            150 
.                KS                                              KS 
TENS       (101) ASMDPQQRTLLEVVYESTETAGIPLDKLRGSLTSVHVGVMTTDWAQMQRR 
DMBS       (101) AGMDPQQRTLLEVVYESTETAGIPLDKLRGSLTSVHVGVMTTDWAQMQRR 
SQTKS      (114) KTMDPQFRLQLESVYEAMESAGITLEHIAGSDTSVYAGACFRDYHDSLVR 
mFAS pig    (73) NTMDPQLRMLLEVTYEAIVDGGINPASLRGTSTGVWVGVSSSDASEALSR 
mFAS rat    (73) HTMDPQLRLLLEVSYEAIVDGGINPASLRGTNTGVWVGVSGSEASEALSR 
 
                 151                                            200 
.                KS                               *************  KS 
TENS       (151) DPETMPQYTATGIASSIISNRISYIFDLKGASETIDTACSSSLVALHNAA 
DMBS       (151) DPETMPQYTATGIASSIISNRISYIFDLKGASETIDTACSSSLVALHNAA 
SQTKS      (165) DPDLVPRFLLTGNGAAMSSNRVSHFYDLRGASMTVDTGCSTTLTALHLAC 
mFAS pig   (123) DPETLVGYSMIGCQRAMMANRLSFFFDFKGPSITIDTACSSSLLALQSAY 
mFAS rat   (123) DPETLLGYSMVGCQRAMMANRLSFFFDFKGPSIALDTACSSSLLALQNAY 
 
                 201                                            250 
.                KS                                              KS 
TENS       (201) RALQSGDCEKAIVAGVNLILDPDPFIYESKLHMLSPDARSRMWDAAANGY 
DMBS       (201) RALQSGDSEKAIVAGVNLILDPDPFIFESKLHMLSPDSRSRMWDAAANGY 
SQTKS      (215) QGLRNRESKTSIVTGANVILNPDMFVTMSSLGLLGPEGKSHTFDARANGY 
mFAS pig   (173) QAIRGGECSAAVVGGLNVLLKPNSSLQFMKLGMLSQDGTCRSFDAEGTGY 
mFAS rat   (173) QAIRSGECPAATVGGINLLLKPNTSVQFMKLGMLSPDGTCRSFDDSGNGY 
 
                 251                                            300 
.                KS                                              KS 
TENS       (251) ARGEGAAAVVLKTLGHALRDGDRIEGVIRSTFVNSDGLSSGLTMPSSAAQ 
DMBS       (251) ARGEGAAAVVLKTLGHALRDGDQIEGVIRSTYVNSDGLSSGLTMPSSAAQ 
SQTKS      (265) GRGEGIATVIIKRLDDALRAQDPIRCIIRGTALNQDGRTATLTSPSQTAQ 
mFAS pig   (223) CRAEAVVAVLLTKKSLARRVYATILNAGTNTDGSKE---QGVTFPSGDVQ 
mFAS rat   (223) CRAEAVVAVLLTKKSLARRVYATILNAGTNTDGCKE---QGVTFPSGEAQ 
 
                 301                                            350 
.                KS                                              KS 
TENS       (301) TALIRQTYRKAGLDPVRDRPQFFECHGTGTKAGDPVEARAISDAFLPPSH 
DMBS       (301) TALIRQTYRKAGLDPVKDRPQFFECHGTGTKAGDPVEARAISDAFLPNHK 
SQTKS      (315) SDLIRACYRAAALDPNDTAFLAAHGTGTRTGDAVEIAAAAD-DKRSPERP 
mFAS pig   (270) EQLIRSLYAPA--GPDPESLEYIEAHGTGTKVGDPQELNGIVNALCATRR 
mFAS rat   (270) EQLIRSLYQPG--GVAPESLEYIEAHGTGTKVGDPQELNGITRSLCAFRQ 
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                 351                                            400 
.                KS                                              KS 
TENS       (351) RTNGAATTVDAPLYVGSIKTVVGHLEGCAGLAGLVKVLLSLKHGIIPPNL 
DMBS       (351) TKG--AATVDAPLYVGSIKTVVGHLEGCAGLAGVIKVLLSLKHGIIPPNL 
SQTKS      (367) LWIGSVKTNIGHSEATSGLASVIQAALALEKGLIPPNINFKEPNEKLGQV 
mFAS pig   (318) EPL----------LIGSTKSNMGHPEPASGVAALIKVLLSLEHGVWAPNL 
mFAS rat   (318) SPL----------LIGSTKSNMGHPEPASGLAALTKVLLSLENGVWAPNL 
 
                 401                                            450 
.                KS                                              KS 
TENS       (401) WFDKLNPEIARYYGPLQIPTKAIPWPKLAPGTPLRASVNSFGFGGTNAHA 
DMBS       (399) WFNKLNPEIARYYGPLQIPTTAIPWPELAPGTPFRASVNSFGFGGTNAHA 
SQTKS      (417) SAAVRVPSNLQKWPSVSGVRRASVNNFGYGGANAHVILESGIPGHTPIAN 
mFAS pig   (358) HYHTPNPEIPALQDGRLQVVDRPLPIRGGN-----VGINSFGFGGSNVHV 
mFAS rat   (358) HFHNPNPEIPALLDGRLQVVDRPLPVRGGI-----VGINSFGFGGANVHV 
 
                 451                                            500 
.                KS    KS 
TENS       (451) IIERYDASQSYCSQWRRNMTEEKTIARTQNNESIEIPVPLVLTAKTGRAL 
DMBS       (449) IIERYDANQSYCSQWRRDMTEQKTIVRPQDEGNTNIPVPLLLTAKTGGAL 
SQTKS      (467) GSGRSNGTGNGHNGANGTTNGHNGTNGT-NGHFDATQATNGHYGTDETPD 
mFAS pig   (403) ILQ------------------PNSRPAPPPAQHAALPRLLQASGRTLEAV 
mFAS rat   (403) ILQ------------------PNTQQAPAPAPHAALPHLLHASGRTMEAV 
 
                 501                                            550 
TENS       (501) WRTVDAYAQHLRQHPKLRVTNLSQFMHSRRSTHRVRASFSGASREELVEN 
DMBS       (499) WRTVDAYAQHLRQNPELGLANLSKFMHSRRATHRVRASFSGASREELLEN 
SQTKS      (517) YAPLDSFVISISAKEEASARSMVTNLADYLRTLQVQDETKHFKSIAHTLG 
mFAS pig   (435) QTLLEQGLRHSRDLAFVGMLNEIAAVSPVAMPFRGYAVLGGEAGS----- 
mFAS rat   (435) QGLLEQGRQHSQDLAFVSMLNDIAATPTAAMPFRGYTVLGVEGHV----- 
 
                 551                                            600 
.                                                  AT            AT 
TENS       (551) MAKFVQAHAADAKSPASQNRIGYSPLHIDPKEAPGILGVFTGQGAQWPAM 
DMBS       (549) MAKFVQAHAADAKSPASQNRIGYSPLLIDPKEVPGILGVFTGQGAQWPAM 
SQTKS      (567) SHRSMFKWTAAKSITGPEELIAAAEGGQFQASRALERTRLGFVFTGQGAQ 
mFAS pig   (480) -----------------------QEVQQVPGSKRPVWFICSGMGAQWQGM 
mFAS rat   (480) -----------------------QEVQQVPASQRPLWFICSGMGTQWRGM 
 
                 601                                            650 
.                AT                                              AT 
TENS       (601) GRDMMHQSPLFRKTIADCESVLQALPAKDAPVWSLSEELKKDASTSRLGE 
DMBS       (599) GRDMMHQSPLFRKTIADCESVLQALPSKDVPSWSLSEELKKDASTSRLGE 
SQTKS      (617) WFAMGRELINTYPVFRQSLDRADRYLKEFGCEWSIIDELSRDAENSNVND 
mFAS pig   (507) GLSLMRLDRFRDSILRSDQALKPLGLRVSDLLLSTDEAVLDDIVSS---- 
mFAS rat   (507) GLSLMRLDSFRESILRSDEALKPLGVKVSDLLLSTDEHTFDDIVHS---- 
 
                 651                                            700 
.                AT                            **************    AT 
TENS       (651) AEISQPLCTAVQLALVNVLLASGVHFDAVVGHSSGEIAATYASGIINLEA 
DMBS       (649) AEISQPLCTAVQLALVNVLTASGVHFDAVVGHSSGEIAATYASGIISLKG 
SQTKS      (667) MTLSPPLCTAVQISLVQLLESWGIVPTAVTGHSSGEIAAAYAAGLDFKSA 
mFAS pig   (553) ----FVSLTSIQIALIDLLTSLGLQPDGIIGHSLGEVACGYADGCLTQEE 
mFAS rat   (553) ----FVSLTAIQIALIDLLTSMGLKPDGIIGHSLGEVACGYADGCLSQRE 
 
                 701                                            750 
.                AT                                              AT 
TENS       (701) AMQIAYYRGLYAKLARGETDAAGGMMAAGLSMNDAVKLCRLPEFEGRIHV 
DMBS       (699) AMQIAYYRGLYAKLARGKSDESGGMMAAGLSMNEAVKLCRLPEFEGRIQV 
SQTKS      (717) AMAVTYFRGEVGLACQDKIVGKGGMIAVGLGPEDAE-DRIARVQSGKIVV 
mFAS pig   (599) AVLSSYWRGYCIKEAN---VLPGAMAAVGLSWEECKQRCPPGIVP----- 
mFAS rat   (599) AVLAAYWRGQCIKDAN---LPAGSMAAVGLSWEECKQRCPPGVVP----- 
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                 751                                            800 
.                AT                                              AT 
TENS       (751) AASNAPQSVTLSGDKEAIKAAKAKLDADGVFARELKVDTAYHSHHMLPCA 
DMBS       (749) AASNAPQSVTLSGDKEAIKAAKAMLDSDGVFARELKVDTAYHSHHMLPCA 
SQTKS      (767) ACINSQSSVTVSGDLSGIVELEDLLKAEGVFARRVKVQAAYHSHHMQVIA 
mFAS pig   (641) ACHNSKDTVTISGPQAAMSEFLQQLKREDVFVKEVRTGGIAFHSYFMESI 
mFAS rat   (641) ACHNSEDTVTISGPQAAVNEFVEQLKQEGVFAKEVRTGGLAFHSYFMEGI 
 
                 801                                            850 
.                AT                                              AT 
TENS       (801) EPYLKALLACDIQVSAPTTTPGRKCMWSSSVRGDAELLRHDRNLDSLKGP 
DMBS       (799) EPYLESLLACDIQVSAPTPG---KCMWSSSVRGDAELLRGDRNLDSLKGP 
SQTKS      (817) NGYLTSLKDMLKPTKKFGKIIYSSPTTGRRETNAKLMASAQHWVNNMLSP 
mFAS pig   (691) APTLLRQLRKVILDPKPRSK-----------RWLSTSIPEAQWQGSLART 
mFAS rat   (691) APTLLQALKKVIREPRPRSA-----------RWLSTSIPEAQWQSSLART 
 
                 851                                            900 
.                AT                                              AT 
TENS       (851) YWVANMVQTVLFSRAVQSTIWHGGPFDLAVEVGPHPALKGPTEQTLKAVY 
DMBS       (846) YWVANMVQTVLFSRAVQSTIWHGGPFDLAIEVGPHPALKGPTEQTLKAVY 
SQTKS      (867) VRFAESFQNMCFSNRNSSQSEEIFQDVDIVLEVGPHGMLQGPIQQMMSLP 
mFAS pig   (730) FSAEYSVNNLVSPVLFQEALQHVPAHAVVVEIAPHALLQAVLKRSLESSC 
mFAS rat   (730) SSAEYNVNNLVSPVLFQEALWHVPEHAVVLEIAPHALLQAVLKRGVKPSC 
 
                 901                                            950 
.                AT                          AT 
TENS       (901) GSAPLYTGVLSRGANDAVAFSTAIGNIWSHLGPAFVDITGYQSIFSSTCE 
DMBS       (896) GSTPLYTGVLRRGANDAVAFSTAIGNIWSHLGPAFVDMTGCQSIFSGASE 
SQTKS      (917) IFERARLPYISCLLRGQSAVHT-------MQTVAAGLMGWGYRVDMVAVN 
mFAS pig   (780) TIIPLMKKDHRDNLEFFLSNVGRLHLAGVSVNPNGLFPPVEFPAPRGTPL 
mFAS rat   (780) TIIPLMKRDHKDNLEFFLTNLGKVHLTGIDINPNALFPPVEFPVPRGTPL 
 
                 951                                           1000 
.                                                          DH    DH 
TENS       (951) GHGGGSAAPFISDLPLYPWDHDEEYWRESRISRRHRTGKDESHELLGRRT 
DMBS       (946) GHGG-SAAPFISDLPLYPWDHDEEYWRESRISRRYRTGKDESHELLGRRT 
SQTKS      (967) FPQGTYGVKILHDLPSYPWNHDNSYWWEPRLNKAHRQRVHPPHELLGSLI 
mFAS pig   (830) ISPH------------IKWDHSQAWDVPSAADFPSGSSCSSVAVYKFDVS 
mFAS rat   (830) ISPH------------IKWDHSQTWDIPVAEDFPNGSSSSSATVYNIDAS 
 
                 1001                                          1050 
.                DH                      **************          DH 
TENS      (1001) PDDNEREIRWRNLLKVSELPWTQGHRVLGEVLLPGAAYISMAIEAGRRLA 
DMBS       (995) PDDNEREIRWRNLLKVSELPWTQGHRVLGEVLLPGAAYISMAIEAGRRLA 
SQTKS     (1016) VGRDLREPTWRHFIRVQDIPWIRDHVVQSALVYPGAGFICMAMEAMVQLH 
mFAS pig   (868) PESP--------------DHYLVDHCIDGRVLFPGTGYLWLTWKTLARAL 
mFAS rat   (868) SESS--------------DHYLVDHCIDGRVLFPGTGYLYLVWKTLARSL 
 
                 1051                                          1100 
.                DH                                              DH 
TENS      (1051) LDQGREARLLEVSDVDILRPVVVADNKEGTETLFTVRLLDEYASTGKKSD 
DMBS      (1045) LDQGRQVCLLEVFDVDILRPVVVADNKEGTETLFTVRLLDEHTVSAKKLD 
SQTKS     (1067) ELRDSQSRKVAGYRLAEVDILRAMLIPDTSEGLEAHISLRPCSTKLLLTN 
mFAS pig   (904) SQN-----------------------LEETPVVFEDVTLHQATILPKTGT 
mFAS rat   (904) SLS-----------------------LEETPVVFENVTFHQATILPRTGT 
 
                 1101                                          1150 
.                DH                                              DH 
TENS      (1101) ELITASFSFYIYNSPASTSIVHTCEGRIAVQLGAKLGSEAGANSMPQLPH 
DMBS      (1095) EIITASFSFYIHNSSASTSVVHTCEGRMAVHLGAKLGSGVGANSMPQLPQ 
SQTKS     (1117) EWYDFCVSSVGDDDKFVDHCRGTITIEFDTSGSADTPRTLRERSRSTGLM 
mFAS pig   (931) VSLEVRLLEASHAFEVSDSNGSLIASGKVYQWESPDPKLFDTRAAVDPAD 
mFAS rat   (931) VPLEVRLLEASHAFEVSDS-GNLIVSGKVYQWEDPDSKLFDHPEVPIPAE 
                 1151                                          1200 
 184 
.                DH                                              DH 
TENS      (1151) REPSISNLQQLDCEKLYSVFETIGLEYSGAFRRIVSSSRCLGHATATASW 
DMBS      (1145) RELSVSNLQPIDCEKLYSLFETIGLEYSGAFRAINSSSRRLGHATASASW 
SQTKS     (1181) RSVDPSNLYSFLRAQGIYHGPIFQNLKTISSRKDHSESSFVVANTASVMP 
mFAS pig   (981) STAEFRLSQGDVYKDLRLRGYDYGPFFQLVLESDLEGNR----------- 
mFAS rat   (980) SESVSRLTQGEVYKELRLRGYDYGPHFQGVYEATLEGEQ----------- 
 
                 1201                                          1250 
.                DH                                              DH 
TENS      (1201) PTTDLNDCYLIHPAILDVAFQTIFVARAHPDSGQLSSALLPSRIERVRVV 
DMBS      (1195) ASLDLNNCYLIHPAILDVAFQTMFVARAHPDSGQLNSALLPSRIERVRVI 
SQTKS     (1218) NGFQSPHVIHPTTLDSIFQGAYTALPGAGLDQNTAMIPRSIQELYLSSAL 
mFAS pig  (1020) -------------------------------------------------- 
mFAS rat  (1019) -------------------------------------------------- 
 
                 1251                                          1300 
.                DH                 *                            DH 
.                                           1A1                 1A1 
                                            .                     . 
TENS      (1251) PSLAMGSKLQNNENFNAAIDSWALNQTASSLTGNINVYDAESGRALIQVE 
DMBS      (1245) PSSAMESKLQSNENINAEIDSWVLNQTVSSLTGDLNVYDTDTGIPLLQVE 
SQTKS     (1268) TSDVGQCLVSDTSLIRYDGQSFTVNVDVSSKADSEHTPVLEIKGLRNQSV 
mFAS pig  (1020) ------GRLQWNDSWVSFLDAMLHMSILAPGQLGLYLPTRFTSIRIDPVT 
mFAS rat  (1019) ------GKLLWKDNWVTFMDTMLQISILGFSKQSLQLPTRVTAIYIDPAT 
 
                 1301                                          1350 
.                DH                                          DHCmeT 
.                1A1                                            1A1 
.                                                                 B 
TENS      (1301) GFEVRAVGEPDASKDRLLFYETVWGRDISIMGLSDPIRDETSDAMVHNLS 
DMBS      (1295) GFEVRAVGEPDASKDRLLFSETVWGRDISIMGLSDPIRNETTDAAVQSLAD 
MILS      (1341)                                               QSLA 
5thz      (64)                                                 EELS 
SQTKS     (1318) GQMAPQPGDSSNNDLCFKLDWAPDISSVKQERLKEKFGFPLDPTEADIIM 
mFAS pig  (1064) HRQKLYTLQDTTQAADVVVDRNLNTVVAGGALFLGAHSSVAPRRPQEHLK 
mFAS rat  (1063) HLQKVYMLEGDTQVADVTTSRCLGVTVSGGVYISRLQTTATSRRQQEQLV 
 
                 1351                                          1400 
.                CMeT                                          CmeT 
.                1A1  1A11A2                                    1A2 
.                                                                 . 
TENS      (1351) EAIERVSLFYVRQLMGELSTADRRQANWYHTRMLAAFDYHLAKVHEETHL 
DMBS      (1345) EAIERVSLFYVRQLMSELSTKDRREANWYHSRMLTAFEHHLARIHEDTHL 
MILS      (1345) EAGERVSLFYVRRLMSELTAEDRDQANWYHTRMLQAFDHHLTEVKNDTHL 
5thz      (68)   VDYIVQGLLQMGWSYQPTESFDLD-CLGVVPTQVRLFERLLQILAEVGIL 
SQTKS     (1381) GLRQACIHFIHRSLQSLTAPDRDQLDWHOKRFYDWMVLQIQLAEEDRLSA 
mFAS pig  (1114) PILEKFCFTPHVESGCLAGNTALQEELQLCRGLAQALQTKVAQQGLKMVV 
mFAS rat  (1113) PTLEKFVFTPHVEPECLSESAILQKELQLCKGLAKALQTKATQQGLKMTV 
 
                 1401                                          1450 
.                CMeT                                          CmeT 
.                1A2                1A21B1                      1B1 
.                                                B   B            . 
TENS      (1401) HLRPEWLADDWAVIQTIDEAYPDAVELQMLHAVGQNVADVIRGKKHLLEV 
DMBS      (1395) HVRQEWLSDDWSVIQIIDEAYPDTVELQMLHAIGQNMANVIRGEKHMLEV 
MILS      (1394) HLRREWLSDDWAAIHAIDEAYPDTVELQMLHAVGKNMVSVIKGEQHMLEV 
5thz      (123)  -NQQQWQVQKT-QSQSLLSQYPDE-TLTLLERCASQLSGVLRGEIDPVQL 
SQTKS     (1418) NSSAWLQCSSSDEQKLLENVRASSVNGQMVVHVGKSMLAILRHEIAPLEL 
mFAS pig  (1164) PGLDGAQAPREAPQQSLPRLLAAACQLQLNGNLQLELGQVLAQE------ 
mFAS rat  (1163) PGLE------DLPQHGLPRLLAAACQLQLNGNLQLELGEVLARE------ 
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                 1451                                          1500 
.                CMeT                                  ********CmeT 
.                1B1      1B11B2                                1B2 
.                SC    CC  S                           CCCCCCCC CCC 
TENS      (1451) LRVDNLLDRLYTEDKGMHMANLFLANALEEITFKFPRCKILEIGAGTGAT 
DMBS      (1445) MRVNNLLDRLYTEDKGMQQGNHFLANALKEITFKFPRCKILEIGAGTGAT 
MILS      (1444) MRVDDMLDRFYADDKGMQQVNHFLAGALNEITFKFPRCNILEIGAGTGAT 
5thz      (180   VFPQGDL-QLYKDSAVAKVMNTIVEKVIMKAMEKLPPS-LLEIGAGTGGT 
SQTKS     (1468) MLQDKLLYRYYTDAIKWDRSYQQIDQLVKLHAHKCPTAKIIEIGAGTGGC 
mFAS pig  (1208) ---RPLLCDDPLLSGLLDAPALKACVDTALENMASPKMKVVEVLAGDGQL 
mFAS rat  (1201) ---RLLLPEDPLISGLLNSQALKACIDTALENLSTLKMKVVEVLAGEGHL 
 
                 1501                                          1550 
.                CMeT                                          CmeT 
.                1B2            1B22A1                          2A1 
.                1B2B              CCC  C                   CCCS  . 
TENS      (1501) TWAALSAIGEAFDTYTYTDLSVGFFENAVERFSAFRHRMVFRALDIEKDP 
DMBS      (1495) TWAVLSAIDETFDTYTYTDLSVGFFETAVERFSAFRHKMIFKALDIEKSP 
MILS      (1494) TSAVLNALDDAFDTYTYTDLSVGFFETAMERFSSFRHKMIFKALDVEKDV 
5thz      (236)  TSYILPHLNPNQTEYIFTDLGALFTSKAQEKFQDYRF-LGYQTLDIEVDP 
SQTKS     (1518) TRAVLDA-IARCAQYDFTDVSSGFFEAAQQKFAAFDDVIRFQKLDIEKDI 
mFAS pig  (1255) YSRIPALLNTQPVMDLDYTATDRNPQALEAAQAKLEQLHVTQGQWDPAN- 
mFAS rat  (1248) YSHISALLNTQPMLQLEYTATDRHPQALKDVQTKLQQHDVAQGQWDPSG- 
 
                 1551                                          1600 
.                CMeT                                          CmeT 
.                2A2                                            2A2   
.                               CCC SSS                        S  . 
TENS      (1551) ASQSFDLNSYDIIIATNVLHATRNLGVTLGNVRALLKPGGYLLLNEKTGP 
DMBS      (1545) AAQSFDLGSYDIIIATNVLHATRNLDITLGNVRSLLKPGGYLLLNEKTGP 
MILS      (1544) ATQGFDLGSYDIIIAANVLHATRSLEVTLGNVRSLLKAGGYLLLNEKTGA 
SQTKS     (1572) EMQGFECGSYDLVIASQVLHATGKMEHTMANVRKLLKPGGKLLLVETTRD 
5thz      (285)  SSQGFESHRYDVIIAANVLHATTSLKQTLSHVRQLLAPGGILVLYEAT-T 
mFAS pig  (1304) -PAPGSLGKADLLVCNCALATLGDPAVAVGNMAATLKEGGFLLLHTLLAG 
mFAS rat  (1297) –PAPTNLGALDLVVCNCALATLGDPALALDNMVAALKDGGFLLMHTVLKG 
 
                 1601                                          1650 
.                                                              CmeT 
.                2B1                                  2B12B2    2B2 
.                    S   S  SSSS S          SS                    . 
TENS      (1601) ESLRATFNFGGLEGWWLAEEKER-QLSPLMSPDGWDAQLQKASFSGVDHI 
DMBS      (1595) ESLRATFNFGGLEGWWLAEEEER-QLSPLLSPDGWDSQLQKTQFSGVDHV 
MILS      (1594) ESLRATFNFGGLQGWWLAEEEDR-QLSPLMSPGGWDAQLQRARFSGIDHV 
5thz      (334)  RSRWVDLIFGLLEGWW-TDYELR-PDYPLLNREQWKKVLSETGFTQVV-T 
SQTKS     (1622) E-MDLQLVFGLLPGWWLSSEEERQMSPSLSTNSWEKVLKKTGFDGLDIEL 
mFAS pig  (1353) HPLGEMVGFLTSPEQGGRHLLSQDQWESLFAGASLHLVALKRSFYGSVLF 
mFAS rat  (1346) HALGETLACLPSEVQPGPSFLSQEEWESLFSRKALHLVGLKKSFYGTALF 
 
                 1651                                          1700 
.                CMeT            CMeTYKR                        YKR 
                 2B2              2B2YKR1                      YKR1 
.                                                                 . 
TENS      (1650) VHDVQEDQQDKQQNSMIMSQAVDDTFYARLSPLSEMANLLPMNEPLLIIG 
DMBS      (1644) VHDVQEEGKQ—-QNSMIMSQAVDDAFYARLSPLSEMASLLPTQEPLLLIG 
MILS      (1643) VHDIPEE—PKQQ                             
5thz      (383)  LPEVEGMAEALSQQTVIVAQAAS                   
SQTKS     (1672) LRDCDSDEFYSFSVMMATASSTIASSSMAFAIVYGEVPLPDQFLDDMKTA 
mFAS pig  (1403) LCRQQTPQDSP------VFLSVEDTSFRWVDSLKDILADASSRPVWLMAV 
mFAS rat  (1396) LCRRLSPQDKP------IFLPVEDTSFQWVDSLKSILATSSSQPVWLTAM 
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                 1701                                          1750 
                 YKR                                            YKR 
                 YKR1                   YKR1YKR2               YKR2 
                 .                                                . 
TENS      (1700) GQTTATLKMIKEIQKLLPRQWRHKVRLIASVDHVEAEGLPAHSDVICLQE 
DMBS      (1692) GQTNTTLRIIKEIQKQLPRKWRHKIRLIASVDQLEDEDLPAHSDVICVQE 
SQTKS     (1721) ISSSAVSDPVVGHLDSIDATGKFCIFIEDPETDILSSPDEKSYASIQKLV 
mFAS pig  (1447) GCSTSGVVGMVNCLRKEPGGHRIRCVLVSNLSSTSPAPEMHPSSSELQKV 
mFAS rat  (1440) NCPTSGVVGLVNCLRKEPGGHRIRCILLSNLSSTSHVPKLDPGSSELQKV 
 
                 1751                                          1800 
                 YKR                           YKRER             ER 
                 YKR2                         YKR2             
                 .                               .             
TENS      (1750) LDRGLFTTAMTSKCLDALKTLFINTRNLLWVTNAQNSSSMTPRASMFRGI 
DMBS      (1742) LDRGLFTTAMTSKRLNALKSLFMNTKNLLWVTNAQNSSSMTPRASMFRGI 
SQTKS     (1771) TRCKGLIWVSRGGAMHGTRPNSSLKTGLLRTLRLEYTEKRFISLDLDSAR 
mFAS pig  (1497) LQGDLVMNVYRDGAWGAFRHFPLEQDRPEKQTEHAFVN----------VL 
mFAS rat  (1490) LESDLVMNVYRDGAWGAFRHFQLEQDKPEEQTAHAFVN----------VL 
 
 
                 1801                                          1850 
.                ER                                              ER 
TENS      (1800) TRVLDGEVPHIRTQVLGIEPRETPSATARTLLEAFLRLRSDDGRHAGNVD 
DMBS      (1792) TRVMDGEVPHIRTQILGIEPIGAPSTIARNLLEAFLRLRFDDTYQAATID 
SQTKS     (1821) PQWNHDSITTINEVLCGALAQNADSSIKDSEFAEQDGQLFVPRISCDIAR 
mFAS pig  (1537) SRGDLSSIRWVCSPLHYALP---ASCQDRLCSVYYTSLNFRDVMLATGKL 
mFAS rat  (1530) TRGDLASIRWVSSPLKHMQPP--SSSGAQLCTVYYASLNFRDIMLATGKL 
 
                 1851                                          1900 
.                ER                                              ER 
TENS      (1850) EDGADGSSQQVLWLHEPEAELLSNGTMMVPRVKARKSLNDTYLASTRAIS 
DMBS      (1842) GDGADGGSQQVLWSHEPEVDLLSSGTMMIPRVKLRKSLNDTYLASTRAIS 
SQTKS     (1871) NEDLSSDSNSPAQMEPFHQPGKLLQMGIKTPGLIDTLQFSKTDATDNLPN 
mFAS pig  (1584) SPDSIPG------------------------------------------- 
mFAS rat  (1578) SPDAIPG------------------------------------------- 
 
                 1901                                          1950 
.                ER                                              ER 
TENS      (1900) TTVDARCVSVQAVAGPAKMLLRPVEDFAGEHAISNQTSDSKVHIQVESTL 
DMBS      (1892) TTVDARCVPVQAVAGPAKIMLRPVEDIAVDHEISSQTSDPKVHIQVEVTL 
SQTKS     (1921) DYIEIEPKAFGLNFRDVMVAMGQLEESIMGFECAGVVRRVGPSSAGHNIK 
mFAS pig  (1591) KWLTRDCMLGMEFSGRDASGRRVMGMVPAEGLATSVLLLQHATWEVPSTW 
mFAS rat  (1585) KWASRDCMLGMEFSGRDKCGRRVMGLVPAEGLATSVLLSPDFLWDVPSSW 
 
                 1951                                          2000 
.                ER                                              ER 
TENS      (1950) HIPEALDGTCLYLVCGWTRTAET----SVPVIALSANNASMVAVESKAVA 
DMBS      (1942) HIPEALDGTCLYLVCGWTRPAEASDTSSVPVMALSTSNASIIAVEPKAVA 
SQTKS     (1971) VGDRVCALLGGQWTNTVRVHWHS----VAPIPQAMDWETAASIPIVFAVA 
mFAS pig  (1641) TLEEAASVPIVYTTAYYSLVVRGRMQ------------------PGESVL 
mFAS rat  (1635) TLEEAASVPVVYTTAYYSLVVRGRIQ------------------HGETVL 
 
                 2001                                          2050 
.                ER                                              ER 
TENS      (1996) MIDEVDVKPETLLRVFQHMAMQALDSAVKRHGQGQSTALIYGADEELAKL 
DMBS      (1992) MIDEVDLKPEALLRVFQHMAMQAVDSAVRRHGQRQRTALIYGADEELAEL 
SQTKS     (2018) YISLVKIARMQAGETVLIHAASGGVGQAAIILAKHVGAEIFATVGTDEKR 
mFAS pig  (1673) IHSGSGGVGQAAIAIALSRGCRVFTTVGSAEKRAYLQARFPQLDETCFAN 
mFAS rat  (1667) IHSGSGGVGQAAISIALSLGCRVFTTVGSAEKRAYLQARFPQLDDTSFAN 
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                 2051                                          2100 
.                ER                                              ER 
TENS      (2046) TSERFAVRESKVYFASSRTFAPGDWLKVQPLLSKFALSQMIPADVEVFID 
DMBS      (2042) TSKRCAVRESKIYFASSHSAAPGDWLKVHRLSSKFAMSQMVPSGVQVFID 
SQTKS     (2067) DLLIKEYKIPDDHIFSSRNALFAKSIRQRTNGKGVDVVLNCLAGGLLQES 
mFAS pig  (1723) SRDTSFEQHVLRHTAGKGVDLVLNSLAEEKLQASVRCLAQHGRFLEIGKF 
mFAS rat  (1717) SRDTSFEQHVLLHTGGKGVDLVLNSLAEEKLQASVRCLAQHGRFLEIGKF 
 
                 2101                                          2150 
.                ER                                              ER 
TENS      (2096) CLGDTESFDACRTLQSCLSTTRTVQHRLDACLLSQMSRCSPDALVDAYSY 
DMBS      (2092) CLGGTESFDACRTLQSCLPTTCTVHR-LDACLLSEMSQCSPDFLLDAYSY 
SQTKS     (2117) FDCLADFGRFIEIGKRDIELNHCLNMGMFARSATFTAVDLIAIGRDRSYM 
mFAS pig  (1773) DLSNNHALGMAVFLKNVTFHGILLDSLFEEGGATWQEVSELLKAGIQEGV 
mFAS rat  (1767) DLSNNHPLGMAIFLKNVTFHGILLDALFEGANDSWREVAELLKAGIRDGV 
 
                 2151                                          2200 
.                ER                                              ER 
TENS      (2146) AKTQSNAEFSWNGYVKTFTAAELAGKLSHSLIHSVYMTNWQKKDSILVTV 
DMBS      (2141) AQTQSNAGFSRSDNIKTFTAAELAGKLSHSLINSMYITDWQKQDAILVTV 
SQTKS     (2166) FAEALPKIMTLLQEKAIRPVTPISIYKIGDIETAFRLMQAGKHMGKIVIT 
mFAS pig  (1823) VQPLKCTVFPRTKVEAAFRYMAQGKHIGKVVIQVREEEQGPAPRGLPPIA 
mFAS rat  (1817) VKPLKCTVFPKAQVEDAFRYMAQGKHIGKVLVQVREEEPEAMLPGAQPTL 
 
                 2201                                          2250 
.                ER     KR     ***********                       KR 
.                       4A                                       3A 
.                                 CCCCCCCC  B               CCC  CC 
TENS      (2196) PPLQTRGLFKSDRTYLMVGAAGGLGTSICRWMVRNGARHVVVTSRN--PK 
DMBS      (2191) PPLQTRGLFKSDRTYLMVGAAGGLGTSLCRWMVRNGARHVVVTSRN—-PK 
MILS      (2196)        LFQSDRTYLMVGAAGGVGTSLCRWMVRHGARHVIVTSRN--PK 
3mjv      (235)  -------RPPVHGSVLVTGGTGGIGGRVARRLAEQGAAHLVLTSRRGAD- 
SQTKS     (2118) APEDAMVPVITRPPKLQLRPDASYLIVGGLGGIGRSLCKNFVENGA--RS 
mFAS pig  (1873) LTGLSKTFCPPHKSYVITGGLGGFGLQLAQWLRLRGAQKLVLTSRSGIRT 
mFAS rat  (1867) ISAISKTFCPEHKSYIITGGLGGFGLELARWLVLRGAQRLVLTSRSGIRT 
 
                 2251                                          2300 
.                KR                                              KR 
.                4A                         4A4B                 3B 
.                C                   CCCC                        CC 
TENS      (2244) ADPEMLNEAERYGAAVQVVPMDACSKDSVQTVVDMIRATMPPIAGVCNAA 
DMBS      (2239) ADPEMLNEAERYGAIVRVVPMDACNKDSVQTVVDTIRATMPPIAGVCNAA 
MILS      (2237) GDPTMLSEAKQYGATVRVVSMDVCDRRSVEAVVGMIRATMPPIACVCNAA 
3mjv      (279)  GAAELRAELEQLGVRVTIAACDAADREALAALLAEL-PEDAPLTAVFHSA 
SQTKS     (2265) LVLLSRNANVSQQSGEFLDELRSTGCIVGVVDCDISSKTQVEATMLRLKK 
mFAS pig  (1923) GYQARQVREWRRQGVQVLVSTSNASSLDGARSLITEATQLGPVGGVFNLA 
mFAS rat  (1917) GYQAKHVREWRRQGIHVLVSTSNVSSLEGARALIAEATKLGPVGGVFNLA 
 
                 2301                                          2350 
.                KR                                              KR 
.                4B                                              4B 
.                CCS                  CC                     B CBCS 
TENS      (2294) MVLRDKLFLDMNVDHMKDVLGPKMQGTEHLDSIFAQEP--LDFFVLLSSS 
DMBS      (2289) MVLCDKLFLDMDVDQMNNTLGPKVDGTEYLDSIFAHEP--LDFFILLGSA 
MILS      (2287) MVLCDKLFLDMDVDILNNTLGPKVDGTEILDSIFSEEA--LDFFILLGST 
3mjv      (328)  GVAHDD-PVDLTLGQLDALMRAKLTAARHLHELTADL--DLDAFVLFSSG 
SQTKS     (2317) PIRGIVHAGMVLQDSVFERMSLDDYNTAIRPKV-------SWNLHSGLSD 
mFAS pig  (1973) MVLRDAVLENQTPEFFQDVSKPKYSGTANLDRVTREACPELDYFVIFSSV 
mFAS rat  (1967) MVLRDAMLENQTPELFQDVNKPKYNGTLNLDRATREACPELDYFVAFSSV 
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                 2351                                          2400 
.                KR                                              KR 
.                 5A                                             5A 
.                S  SSS  S  C                         CCCC  CCCS  C 
TENS      (2342) AAILNNTGQSNYHCANLYMDSLVTNRRSRGLAASIIHVGHVCDTGYVARL 
DMBS      (2337) AAILNNMGQSNYHCANLYMDSLVKHRRSRGLAASIIHIGHVCDTGYVARM 
MILS      (2235) ATIANNIGQSNYHCANLYMDSLVAQRRSRGLAASIIHIGYICDTGYVARL 
3mjv             AAVFGSGGQPGYAAANAYLDALAEHRRSLGLTASSVAWGTWGEVGMATDP 
SQTKS     (2363) CDLDFFIMLSSLAGVSGSASQANYTAGGAYQDALAKYRRAQGLSAVSIDL 
mFAS pig  (2023) SCGRGNAGQANYGFANSAMERICEKRRHDGLPGLAVQWGAIGDVGVVLET 
mFAS rat  (2017) SCGRGNAGQSNYGFANSTMERICEQRRHDGLPGLAVQWGAIGDVGIILEA 
 
                 2401                                          2450 
.                KR                                              KR 
.                5A                5A5B                          5B 
.                C    S  SSB  S S                                 . 
TENS      (2392) VDDTKVQMSLGTTRVMSVSETDVHHAFAEAVRGGQPDSRSGSHNIIMGIE 
DMBS      (2387) VDDNRIQSNIATMRAMRLSETDVHHAFAQAVRGGQLDSRSGSYNIIMGIE 
MILS      (2385) GDDAKVHSNRDVMRATTLSETDVHHAFAEAVRGGSPGSPIGSYNIIMGID 
3mjv      (337)  EVHDRLVRQGVLAMEPPEHALGALDQMLNDDTAAAPITMDWEMFAPAFTN 
SQTKS     (2413) GMVQSVGYVAETKGVAERLVRMGYSPISEMEVLKIVEHAITNPPPEASSA 
mFAS pig  (2073) MGTNDTVIGGTLPQRIASCLEVLDLFLSQPHPVLS--------------- 
mFAS rat  (2067) MGTNDTVVGGTLPQRISSCMEVLDLFLNQPHAVLS--------------- 
 
                 2451                                          2500 
.                KR                                    KR 
.                5B                                    5B 
.                .                                      . 
TENS      (2442) PPTKPLDLTKRKPVWISDPRLGPCLPFSTLENQMMASEQAAAASAVDSLA 
DMBS      (2437) PPTKPLDLTRRQAVWLSDPRLGHMLPYSTLENQMIASGQAAAS—ADSLA- 
MILS      (2435) PPTKSLDSSRRKALWLSDPRLGHMVPYSASADQAVTSEQA 
3mjv      (478)  RPSALLSTVPEAVSALSDE-------------------- 
SQTKS     (2463) QIITGISTKPGRHWTESSWLQDARFATLRERARDVKELSNSQGAQ-DKQL 
mFAS pig  (2108) -------------------------SFVLAEKKAAAPRDGSSQK------ 
mFAS rat  (2102) -------------------------SFVLVEKKAVAHGDGEAQR------ 
 
                 2501                                          2550 
.                           ACP                               ***** 
TENS      (2492) QQVSEATTDEEAAVAALKGFATKLEGILLLPLGSIGEDSAGRPVTDLGID 
DMBS      (2485) QQVSEATTDEEATAAVLKGFATKLEGILLLPPGSIGEDSAGRPVTDLGID 
SQTKS     (2512) AAGQELSMATSLVEAIDVVGRAITAKLATMFLIAAESIIASKSLSEYGVD 
mFAS pig  (2127) --------------------DLVKAVAHILGIRDVASINPDSTLVDLGLD 
mFAS rat  (2121) --------------------DLVKAVAHILGIRDLAGINLDSSLADLGLD 
 
                 2551                                          2600 
.                ********                                       ACP 
TENS      (2542) SLVAVEIRTWFLKQLRVDVPVMKILGGSTVGQLSALAAKLARQDAKKRAQ 
DMBS      (2535) SLVAVEIRTWFLKQLRVDVPVMKILGGSTVGQLSALAAKLARQDAKKQAQ 
SQTKS     (2563) SLVAVELRNWLAAQLSSDVSVF-TQSQSLTALATTVATKSSRIDKSLLVA 
mFAS pig  (2157) SLMGVEVRQILEREHDLVLSMREVRQLSLRKLQELSSKTSTDADPATPTS 
mFAS rat  (2151) SLMGVEVRQILEREHDLVLPIREVRQLTLRKLQEMSSKAGSDTELAAPK- 
 
                 2601                                          2650 
TENS      (2592) LEEPSGNQPVALPSPPPKDKAGGLNKNGKSPKLPEIAQVDTVVERMEPLV 
DMBS      (2585) VEEASGNQHVALP--PPKDKVG-PNTNGKAQDSPETAQVGTLIERMEPLV 
SQTKS     (----) -------------------------------------------------- 
mFAS pig  (2207) HEDSPVRQQATLN----------LSTLLVNPEGPTLTRLNSVQSAERPLF 
mFAS rat  (2200) SKNDTSLKQAQLN----------LSILLVNPEGPTLTRLNSVQSSERPLF 
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Alignment colour coding 
 
 Foreground Background 
Non-similar black white 
Conservative dark blue cyan 
Block of Similar black light green 
Identical red yellow 
Weakly Similar dark green white 
 
C = Cofactor binding   **** = 'active site'  S = Substrate binding 
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